WEBVTT

NOTE duration:"01:06:43"

NOTE recognizability:0.752

NOTE language:en-us

NOTE Confidence: 0.593006248333333

00:00:00.000 --> 00:00:03.776 Much for joining us today for another

NOTE Confidence: 0.593006248333333

00:00:03.776 --> 00:00:05.612 edition of the highlights of the

NOTE Confidence: 0.593006248333333

00:00:05.612 --> 00:00:07.205 American State of Hematology meeting

NOTE Confidence: 0.593006248333333

00:00:07.205 --> 00:00:10.010 that was held in December 2021.

NOTE Confidence: 0.593006248333333

00:00:10.010 --> 00:00:13.150 My name is Ammar.

NOTE Confidence: 0.593006248333333

00:00:13.150 --> 00:00:16.389 I'm joined today by Doctor Nicola and

NOTE Confidence: 0.593006248333333

00:00:16.389 --> 00:00:20.461 Doctor Rory Chalice and we will be together

NOTE Confidence: 0.593006248333333

00:00:20.461 --> 00:00:22.180 presenting on myeloid malignancies.

NOTE Confidence: 0.593006248333333

00:00:22.180 --> 00:00:25.000 I will start by talking about

NOTE Confidence: 0.593006248333333

00:00:25.000 --> 00:00:27.080 MD's for around 15 minutes.

NOTE Confidence: 0.593006248333333

00:00:27.080 --> 00:00:28.832 Doctor Cialis will follow

NOTE Confidence: 0.593006248333333

00:00:28.832 --> 00:00:30.584 with highlights of XAML.

NOTE Confidence: 0.593006248333333

00:00:30.590 --> 00:00:32.180 For another 15 minutes and

NOTE Confidence: 0.593006248333333

00:00:32.180 --> 00:00:33.452 then Doctor will finish.

NOTE Confidence: 0.593006248333333

00:00:33.460 --> 00:00:35.740 Will highlights of Milo

NOTE Confidence: 0.593006248333333

00:00:35.740 --> 00:00:36.915 proliferative neoplasms?

NOTE Confidence: 0.593006248333333

00:00:36.915 --> 00:00:42.410 Feel free to post your questions in the chat.

NOTE Confidence: 0.593006248333333

00:00:42.410 --> 00:00:42.989 At the end,

NOTE Confidence: 0.593006248333333

00:00:42.989 --> 00:00:44.949 we are going to have 10 to 15 minutes.

NOTE Confidence: 0.593006248333333

00:00:44.950 --> 00:00:48.250 We'll try to finish around 12:50 so that

NOTE Confidence: 0.593006248333333

00:00:48.250 --> 00:00:49.810 you can ask your questions directly.

NOTE Confidence: 0.593006248333333

00:00:49.810 --> 00:00:50.918 Or if you want,

NOTE Confidence: 0.593006248333333

00:00:50.918 --> 00:00:51.749 if you prefer,

NOTE Confidence: 0.593006248333333

00:00:51.750 --> 00:00:55.264 you can type them during the presentations

NOTE Confidence: 0.593006248333333

00:00:55.270 --> 00:00:59.919 so that we can also tackle them at the end.

NOTE Confidence: 0.593006248333333

00:00:59.920 --> 00:01:01.342 Thank you so much for joining

NOTE Confidence: 0.593006248333333

00:01:01.342 --> 00:01:02.970 and I'm going to get started.

NOTE Confidence: 0.5379125446

00:01:07.310 --> 00:01:09.990 So for MTS, basically, UM,

NOTE Confidence: 0.5379125446

00:01:09.990 --> 00:01:12.678 this has been a very exciting field.

NOTE Confidence: 0.5379125446

00:01:12.680 --> 00:01:13.784 These are my disclosures.

NOTE Confidence: 0.5379125446

00:01:13.784 --> 00:01:16.124 There has been a lot of new developments

NOTE Confidence: 0.5379125446

00:01:16.124 --> 00:01:18.604 in MD's over the last couple of years,

NOTE Confidence: 0.5379125446

00:01:18.610 --> 00:01:21.139 and I think this is an area where we

NOTE Confidence: 0.5379125446

00:01:21.139 --> 00:01:22.972 continue to have new drugs approved.

NOTE Confidence: 0.5379125446

00:01:22.972 --> 00:01:26.770 So one of the drugs that has been recently

NOTE Confidence: 0.5379125446

00:01:26.857 --> 00:01:29.617 approved is a combination of oral.

NOTE Confidence: 0.5379125446

00:01:29.620 --> 00:01:31.915 Put in so the site being is a standard

NOTE Confidence: 0.5379125446

00:01:31.915 --> 00:01:34.098 of care treatment for higher risk

NOTE Confidence: 0.5379125446

00:01:34.100 --> 00:01:35.860 MD's that's given intravenously.

NOTE Confidence: 0.5379125446

00:01:35.860 --> 00:01:38.966 The problem is that this drug cannot

NOTE Confidence: 0.5379125446

00:01:38.966 --> 00:01:41.335 be given orally because it undergoes

NOTE Confidence: 0.5379125446

00:01:41.335 --> 00:01:44.655 first passed in the liver and the gut

NOTE Confidence: 0.5379125446

00:01:44.655 --> 00:01:48.002 and therefore has not been able to do

NOTE Confidence: 0.5379125446

00:01:48.002 --> 00:01:49.763 orally subsequently which inhibits

NOTE Confidence: 0.5379125446

00:01:49.763 --> 00:01:52.018 the enzyme cytidine dominates as

NOTE Confidence: 0.5379125446

00:01:52.018 --> 00:01:54.684 you can see in this slide basically

NOTE Confidence: 0.5379125446

00:01:54.684 --> 00:01:57.565 allows the desire to be in to be given

NOTE Confidence: 0.5379125446

00:01:57.565 --> 00:01:59.676 orally and in a phase three trial.

NOTE Confidence: 0.5379125446

00:01:59.676 --> 00:02:01.856 All that certain trial that

NOTE Confidence: 0.5379125446

00:02:01.856 --> 00:02:04.310 we participated in at at Yale.

NOTE Confidence: 0.5379125446

00:02:04.310 --> 00:02:06.272 It was shown to have the

NOTE Confidence: 0.5379125446

00:02:06.272 --> 00:02:06.926 same pharmacokinetics,

NOTE Confidence: 0.5379125446

00:02:06.930 --> 00:02:08.786 which is the primary endpoint of the study,

NOTE Confidence: 0.5379125446

00:02:08.790 --> 00:02:10.502 such as intravenous decided

NOTE Confidence: 0.5379125446

00:02:10.502 --> 00:02:12.642 and based on this data,

NOTE Confidence: 0.5379125446

00:02:12.650 --> 00:02:15.826 the drug was approved in the year 2020.

NOTE Confidence: 0.5379125446

00:02:15.830 --> 00:02:17.134 The clinical results have

NOTE Confidence: 0.5379125446

00:02:17.134 --> 00:02:18.764 been presented more than once,

NOTE Confidence: 0.5379125446

00:02:18.770 --> 00:02:23.578 but the paper has not been published yet,

NOTE Confidence: 0.5379125446

00:02:23.580 --> 00:02:26.534 so this is the presentation of the

NOTE Confidence: 0.5379125446

00:02:26.534 --> 00:02:29.177 overall data from 2020 where the

NOTE Confidence: 0.5379125446

00:02:29.177 --> 00:02:31.327 complete response rate was shown

NOTE Confidence: 0.5379125446

00:02:31.327 --> 00:02:33.170 to be around 20%.

NOTE Confidence: 0.5379125446

00:02:33.170 --> 00:02:35.672 And many patients achieved as you

NOTE Confidence: 0.5379125446

00:02:35.672 --> 00:02:38.410 can see platelets and erythrocytes.

NOTE Confidence: 0.5379125446

00:02:38.410 --> 00:02:40.405 Transition independence around

NOTE Confidence: 0.5379125446

00:02:40.405 --> 00:02:42.400 50% of patients.

NOTE Confidence: 0.5379125446

00:02:42.400 --> 00:02:44.626 And you can see the CR was

NOTE Confidence: 0.5379125446

00:02:44.626 --> 00:02:46.160 durable around 14 months.

NOTE Confidence: 0.5379125446

00:02:46.160 --> 00:02:49.065 The patients are still being followed for.

NOTE Confidence: 0.5379125446

00:02:49.070 --> 00:02:53.060 Long term survival I think.

NOTE Confidence: 0.5379125446

00:02:53.060 --> 00:02:55.900 Important update that was presented

NOTE Confidence: 0.5379125446

00:02:55.900 --> 00:02:58.580 in in this ASH in December was

NOTE Confidence: 0.5379125446

00:02:58.580 --> 00:03:00.500 the activity in the lower risk.

NOTE Confidence: 0.5379125446

00:03:00.500 --> 00:03:01.356 Andy Ashby,

NOTE Confidence: 0.5379125446

00:03:01.356 --> 00:03:03.517 'cause some patients had intermediate

NOTE Confidence: 0.5379125446

00:03:03.517 --> 00:03:07.093 1 tips and as you can see the

NOTE Confidence: 0.5379125446

00:03:07.093 --> 00:03:09.663 complete response rate was also

NOTE Confidence: 0.5379125446

00:03:09.663 --> 00:03:12.573 seen in those patients around 23%.

NOTE Confidence: 0.5379125446

00:03:12.573 --> 00:03:15.184 So it seems that even for lower

NOTE Confidence: 0.5379125446

00:03:15.184 --> 00:03:17.061 risk MD SIDEK has activity,

NOTE Confidence: 0.5379125446

00:03:17.061 --> 00:03:18.946 which is something we see.

NOTE Confidence: 0.5379125446

00:03:18.950 --> 00:03:22.138 Also the intravenous decide.

NOTE Confidence: 0.5379125446

00:03:22.140 --> 00:03:22.414 However,

NOTE Confidence: 0.5379125446

00:03:22.414 --> 00:03:24.332 it's not clear if this is the

NOTE Confidence: 0.5379125446

00:03:24.332 --> 00:03:25.999 right dose for these patients,

NOTE Confidence: 0.5379125446

00:03:26.000 --> 00:03:28.285 because we certainly see neutropenia

NOTE Confidence: 0.5379125446

00:03:28.285 --> 00:03:29.880 and thrombocytopenia and therefore

NOTE Confidence: 0.5379125446

00:03:29.880 --> 00:03:31.920 a phase two study randomized phase.

NOTE Confidence: 0.5379125446

00:03:31.920 --> 00:03:34.080 Two study was initiated where

NOTE Confidence: 0.5379125446

00:03:34.080 --> 00:03:37.180 the Sidik is given in two doses,

NOTE Confidence: 0.5379125446

00:03:37.180 --> 00:03:39.250 lower doses than the approved dose

NOTE Confidence: 0.5379125446

00:03:39.250 --> 00:03:41.361 in patients with lower risk MD's

NOTE Confidence: 0.5379125446

00:03:41.361 --> 00:03:43.887 who are not responding to her

NOTE Confidence: 0.5379125446

00:03:43.887 --> 00:03:45.150 therapist stimulating agents.

NOTE Confidence: 0.5379125446

00:03:45.150 --> 00:03:46.866 So this study is open currently

NOTE Confidence: 0.5379125446

00:03:46.866 --> 00:03:49.045 at the main campus for any lower

NOTE Confidence: 0.5379125446

00:03:49.045 --> 00:03:50.080 risk MD's patient,

NOTE Confidence: 0.5379125446

00:03:50.080 --> 00:03:52.162 feel free to discuss any patients

NOTE Confidence: 0.5379125446

00:03:52.162 --> 00:03:55.109 who might have. For this study.

NOTE Confidence: 0.5379125446

00:03:55.110 --> 00:03:57.336 Another drug that has been also approved

NOTE Confidence: 0.5379125446

00:03:57.336 --> 00:03:59.709 in the year 2020 as Los Patterson,

NOTE Confidence: 0.5379125446

00:03:59.710 --> 00:04:01.165 solo spatter said,

NOTE Confidence: 0.5379125446

00:04:01.165 --> 00:04:03.105 basically is a transforming

NOTE Confidence: 0.5379125446

00:04:03.105 --> 00:04:05.376 growth factor pathway inhibitor.

NOTE Confidence: 0.5379125446

00:04:05.376 --> 00:04:07.968 So these transforming growth

NOTE Confidence: 0.5379125446

00:04:07.968 --> 00:04:10.935 factor pathway proteins have been

NOTE Confidence: 0.5379125446

00:04:10.935 --> 00:04:13.155 shown to interfere with.

NOTE Confidence: 0.5379125446

00:04:13.160 --> 00:04:15.533 Luis is and what does low specific

NOTE Confidence: 0.5379125446

00:04:15.533 --> 00:04:18.180 do its ligand trap so it removes it,

NOTE Confidence: 0.5379125446

00:04:18.180 --> 00:04:20.784 removes the inhibitory effect

NOTE Confidence: 0.5379125446

00:04:20.784 --> 00:04:23.388 on erythropoiesis and therefore

NOTE Confidence: 0.5379125446

00:04:23.388 --> 00:04:25.496 stimulating red blood cell production?

NOTE Confidence: 0.5379125446

00:04:25.496 --> 00:04:28.427 The drug has been shown to improve

NOTE Confidence: 0.5379125446

00:04:28.427 --> 00:04:30.440 transfusion independence rates.

NOTE Confidence: 0.5379125446

00:04:30.440 --> 00:04:32.246 You can see here the pivotal

NOTE Confidence: 0.726456156363636

00:04:32.250 --> 00:04:34.340 trial results from the MIDDLE'S

NOTE Confidence: 0.726456156363636

00:04:34.340 --> 00:04:36.780 trial which was published in 2020

NOTE Confidence: 0.726456156363636

00:04:36.780 --> 00:04:39.857 yet participated in that around

NOTE Confidence: 0.726456156363636

00:04:39.857 --> 00:04:42.042 1/3 of the patients achieved

NOTE Confidence: 0.726456156363636

00:04:42.042 --> 00:04:44.252 transfusion independence, so this was.

NOTE Confidence: 0.726456156363636

00:04:44.252 --> 00:04:46.900 Refractory setting after yes, a failure.

NOTE Confidence: 0.726456156363636

00:04:46.900 --> 00:04:49.510 We currently have the commands trial

NOTE Confidence: 0.726456156363636

00:04:49.510 --> 00:04:51.550 which is in the frontline setting,

NOTE Confidence: 0.726456156363636

00:04:51.550 --> 00:04:53.674 so this is open actually in

NOTE Confidence: 0.726456156363636

00:04:53.674 --> 00:04:57.840 several of the Cancer Center.

NOTE Confidence: 0.726456156363636

00:04:57.840 --> 00:04:59.780 Satellite centers basically this

NOTE Confidence: 0.726456156363636

00:04:59.780 --> 00:05:02.690 is available for a front drawing.

NOTE Confidence: 0.726456156363636

00:05:02.690 --> 00:05:04.142 Randomization against erythropoiesis,

NOTE Confidence: 0.726456156363636

00:05:04.142 --> 00:05:06.562 stimulating agents and this is

NOTE Confidence: 0.726456156363636

00:05:06.562 --> 00:05:08.376 regardless whether you have the

NOTE Confidence: 0.726456156363636

00:05:08.376 --> 00:05:10.490 patient has rings to drop class or not,

NOTE Confidence: 0.726456156363636

00:05:10.490 --> 00:05:13.642 so please feel free to refer patients

NOTE Confidence: 0.726456156363636

00:05:13.642 --> 00:05:16.846 for this or again it's open in many of

NOTE Confidence: 0.726456156363636

00:05:16.846 --> 00:05:19.204 the care centers so the patients can

NOTE Confidence: 0.726456156363636

00:05:19.204 --> 00:05:21.675 be treated on the trial right there.

NOTE Confidence: 0.726456156363636

00:05:21.680 --> 00:05:25.600 That is another drug first in class

NOTE Confidence: 0.726456156363636

00:05:25.600 --> 00:05:28.230 TELOMERS inhibitor that has shown

NOTE Confidence: 0.726456156363636

00:05:28.230 --> 00:05:30.925 also good data in the refractory labs.

NOTE Confidence: 0.726456156363636

00:05:30.930 --> 00:05:32.310 Lower risk MD.

NOTE Confidence: 0.726456156363636

00:05:32.310 --> 00:05:35.419 As you can see here the presentation

NOTE Confidence: 0.726456156363636

00:05:35.419 --> 00:05:37.862 from the phase two part of the

NOTE Confidence: 0.726456156363636

00:05:37.862 --> 00:05:40.605 emerge study which showed a rate of

NOTE Confidence: 0.726456156363636

00:05:40.605 --> 00:05:42.581 transfusion independence of around 42%.

NOTE Confidence: 0.726456156363636

00:05:42.581 --> 00:05:45.709 So a good number of patients are achieving

NOTE Confidence: 0.726456156363636

00:05:45.709 --> 00:05:48.029 transfusion independence with this drug.

NOTE Confidence: 0.726456156363636

00:05:48.029 --> 00:05:50.423 So this trial has a phase

NOTE Confidence: 0.726456156363636

00:05:50.423 --> 00:05:51.620 three component called.

NOTE Confidence: 0.726456156363636

00:05:51.620 --> 00:05:54.945 Also the emerge which has been open

NOTE Confidence: 0.726456156363636

00:05:54.945 --> 00:05:57.660 at the main part of the study has

NOTE Confidence: 0.726456156363636

00:05:57.660 --> 00:05:59.899 actually been fully accrued and closed.

NOTE Confidence: 0.726456156363636

00:05:59.900 --> 00:06:01.796 But there is an extension of this study.

NOTE Confidence: 0.726456156363636

00:06:01.800 --> 00:06:04.248 So currently if you have patients

NOTE Confidence: 0.726456156363636

00:06:04.248 --> 00:06:08.058 who have lower risk MD's who are.

NOTE Confidence: 0.726456156363636

00:06:08.060 --> 00:06:08.692 First line,

NOTE Confidence: 0.726456156363636

00:06:08.692 --> 00:06:10.588 they can be considered for the

NOTE Confidence: 0.726456156363636

00:06:10.588 --> 00:06:12.564 commands trial if they have received

NOTE Confidence: 0.726456156363636

00:06:12.564 --> 00:06:14.580 essays and they are not responding.

NOTE Confidence: 0.726456156363636

00:06:14.580 --> 00:06:15.948 We have two options.

NOTE Confidence: 0.726456156363636

00:06:15.948 --> 00:06:18.696 I merge trial with that as well as

NOTE Confidence: 0.726456156363636

00:06:18.696 --> 00:06:21.608 the lower dose of the oral disability

NOTE Confidence: 0.726456156363636

00:06:21.608 --> 00:06:24.900 being available for these patients.

NOTE Confidence: 0.726456156363636

00:06:24.900 --> 00:06:27.392 How about higher risk MD's so many

NOTE Confidence: 0.726456156363636

00:06:27.392 --> 00:06:30.524 of you are aware of any talk lacks

NOTE Confidence: 0.726456156363636

00:06:30.524 --> 00:06:33.940 having very good activity in XAML.

NOTE Confidence: 0.726456156363636

00:06:33.940 --> 00:06:35.720 It's a standard approved drug.

NOTE Confidence: 0.726456156363636

00:06:35.720 --> 00:06:38.800 Now it's an oral pill that's given for

NOTE Confidence: 0.726456156363636

00:06:38.800 --> 00:06:41.335 older patients with acute myeloid leukemia,

NOTE Confidence: 0.726456156363636

00:06:41.335 --> 00:06:43.210 and we've been using it

NOTE Confidence: 0.726456156363636

00:06:43.210 --> 00:06:44.710 for several years now,

NOTE Confidence: 0.726456156363636

00:06:44.710 --> 00:06:47.725 so there has been a lot of interest in

NOTE Confidence: 0.726456156363636

00:06:47.725 --> 00:06:50.348 exploring that in patients who have higher

NOTE Confidence: 0.726456156363636

00:06:50.348 --> 00:06:52.598 risk MD's as well with excess players,

NOTE Confidence: 0.726456156363636

00:06:52.600 --> 00:06:54.310 and we have preclinical data

NOTE Confidence: 0.726456156363636

00:06:54.310 --> 00:06:55.336 suggesting synergy with.

NOTE Confidence: 0.726456156363636

00:06:55.340 --> 00:06:57.612 There's a side to Dean because one of

NOTE Confidence: 0.726456156363636

00:06:57.612 --> 00:07:01.390 the common resistance mechanisms to.

NOTE Confidence: 0.726456156363636

00:07:01.390 --> 00:07:03.376 Cited in is actually up regulation

NOTE Confidence: 0.726456156363636

00:07:03.376 --> 00:07:04.369 of PCL two,

NOTE Confidence: 0.726456156363636

00:07:04.370 --> 00:07:06.476 so trial was two trials were

NOTE Confidence: 0.726456156363636

00:07:06.476 --> 00:07:08.239 designed basically as early phase

NOTE Confidence: 0.726456156363636

00:07:08.239 --> 00:07:10.297 trials in the frontline as well as

NOTE Confidence: 0.726456156363636

00:07:10.297 --> 00:07:12.648 in the relapse refractory setting.

NOTE Confidence: 0.726456156363636

00:07:12.650 --> 00:07:14.810 After HMA failure,

NOTE Confidence: 0.726456156363636

00:07:14.810 --> 00:07:17.367 combining venetoclax with you

NOTE Confidence: 0.726456156363636

00:07:17.367 --> 00:07:20.146 can see in this slide that those

NOTE Confidence: 0.726456156363636

00:07:20.146 --> 00:07:22.820 escalation design of that study that

NOTE Confidence: 0.726456156363636

00:07:22.820 --> 00:07:25.070 subsequently went to those expansion

NOTE Confidence: 0.726456156363636

00:07:25.070 --> 00:07:27.905 and this is in the frontline setting.

NOTE Confidence: 0.726456156363636

00:07:27.910 --> 00:07:30.016 Very important to note that venetoclax

NOTE Confidence: 0.726456156363636

00:07:30.016 --> 00:07:31.979 here was given for 14 days.

NOTE Confidence: 0.726456156363636

00:07:31.980 --> 00:07:33.655 So it's not continuously given

NOTE Confidence: 0.726456156363636

00:07:33.655 --> 00:07:36.880 like it is in AML only 14 days and

NOTE Confidence: 0.726456156363636

00:07:36.880 --> 00:07:37.987 doses 400 milligram,

NOTE Confidence: 0.726456156363636

00:07:37.990 --> 00:07:39.754 which is the same dose that

NOTE Confidence: 0.726456156363636

00:07:39.754 --> 00:07:41.589 we do in patients with AML.

NOTE Confidence: 0.726456156363636

00:07:41.590 --> 00:07:44.250 However has a lot of drug interactions

NOTE Confidence: 0.726456156363636

00:07:44.250 --> 00:07:46.718 and it's important to adjust those

NOTE Confidence: 0.726456156363636

00:07:46.718 --> 00:07:48.818 accordingly and monitor the patient

NOTE Confidence: 0.726456156363636

00:07:48.818 --> 00:07:51.124 closely for infections which are

NOTE Confidence: 0.726456156363636

00:07:51.124 --> 00:07:53.454 common because you get neutropenia,

NOTE Confidence: 0.726456156363636

00:07:53.460 --> 00:07:55.504 those patients should be

NOTE Confidence: 0.726456156363636

00:07:55.504 --> 00:07:57.037 on prophylactic antibiotics

NOTE Confidence: 0.805172283636364

00:07:57.040 --> 00:07:58.465 and should be treated very

NOTE Confidence: 0.805172283636364

00:07:58.465 --> 00:08:00.460 aggressively if they have an infection.

NOTE Confidence: 0.805172283636364

00:08:00.460 --> 00:08:03.142 They need a lot of transfusion care as well.

NOTE Confidence: 0.805172283636364

00:08:03.150 --> 00:08:04.173 Especially during the

NOTE Confidence: 0.805172283636364

00:08:04.173 --> 00:08:05.878 first one to two cycles.

NOTE Confidence: 0.805172283636364

00:08:05.880 --> 00:08:08.440 So the patient should be seen at least

NOTE Confidence: 0.805172283636364

00:08:08.440 --> 00:08:11.727 twice a week and given transitions as needed.

NOTE Confidence: 0.805172283636364

00:08:11.730 --> 00:08:13.206 With all of that being said,

NOTE Confidence: 0.805172283636364

00:08:13.210 --> 00:08:15.910 basically we are seeing early

NOTE Confidence: 0.805172283636364

00:08:15.910 --> 00:08:18.610 activity in with this combination,

NOTE Confidence: 0.805172283636364

00:08:18.610 --> 00:08:21.660 so the complete response rate is around 35%,

NOTE Confidence: 0.805172283636364

00:08:21.660 --> 00:08:23.510 which is similar to what

NOTE Confidence: 0.805172283636364

00:08:23.510 --> 00:08:24.990 was observed in XAML.

NOTE Confidence: 0.805172283636364

00:08:24.990 --> 00:08:26.784 However, many of the other patients

NOTE Confidence: 0.805172283636364

00:08:26.784 --> 00:08:28.735 are achieving also more OCR where the

NOTE Confidence: 0.805172283636364

00:08:28.735 --> 00:08:31.554 plants are less than 5% and they are

NOTE Confidence: 0.805172283636364

00:08:31.554 --> 00:08:33.198 achieving hematologic improvement.

NOTE Confidence: 0.805172283636364

00:08:33.200 --> 00:08:35.798 You can see that the response

NOTE Confidence: 0.805172283636364

00:08:35.798 --> 00:08:37.530 is achieved relatively quickly.

NOTE Confidence: 0.805172283636364

00:08:37.530 --> 00:08:39.672 The first response is seen within one

NOTE Confidence: 0.805172283636364

00:08:39.672 --> 00:08:41.918 month and those responses are durable.

NOTE Confidence: 0.805172283636364

00:08:41.920 --> 00:08:44.608 12 months you can see also that

NOTE Confidence: 0.805172283636364

00:08:44.608 --> 00:08:46.922 there is and this is the main update

NOTE Confidence: 0.805172283636364

00:08:46.922 --> 00:08:48.592 that was presented in ASH 2021.

NOTE Confidence: 0.805172283636364

00:08:48.592 --> 00:08:51.616 You can see that many patients achieve

NOTE Confidence: 0.805172283636364

00:08:51.616 --> 00:08:54.637 no molecular clearance where the TP 53

NOTE Confidence: 0.805172283636364

00:08:54.637 --> 00:08:57.560 for example molecular load is decreased.

NOTE Confidence: 0.805172283636364

00:08:57.560 --> 00:08:57.942 However,

NOTE Confidence: 0.805172283636364

00:08:57.942 --> 00:09:00.998 the question in TP 53 in particular is

NOTE Confidence: 0.805172283636364

00:09:00.998 --> 00:09:03.958 whether overall survival is improved or not.

NOTE Confidence: 0.805172283636364

00:09:03.960 --> 00:09:06.578 So I think this data is encouraging.

NOTE Confidence: 0.805172283636364

00:09:06.580 --> 00:09:07.270 Clearly, however,

NOTE Confidence: 0.805172283636364

00:09:07.270 --> 00:09:09.340 this is a single ARM study.

NOTE Confidence: 0.805172283636364

00:09:09.340 --> 00:09:10.585 It's not randomized.

NOTE Confidence: 0.805172283636364

00:09:10.585 --> 00:09:13.490 Study less than 70 patients were enrolled.

NOTE Confidence: 0.805172283636364

00:09:13.490 --> 00:09:16.406 And therefore we have an ongoing

NOTE Confidence: 0.805172283636364

00:09:16.410 --> 00:09:18.214 registration study called DEVARONA.

NOTE Confidence: 0.805172283636364

00:09:18.214 --> 00:09:20.920 Which is also open at Yale.

NOTE Confidence: 0.805172283636364

00:09:20.920 --> 00:09:22.606 This is a randomized phase three

NOTE Confidence: 0.805172283636364

00:09:22.606 --> 00:09:24.059 study in which patients are

NOTE Confidence: 0.805172283636364

00:09:24.059 --> 00:09:25.439 randomized in a double blind,

NOTE Confidence: 0.805172283636364

00:09:25.440 --> 00:09:28.000 placebo controlled fashion to receive.

NOTE Confidence: 0.805172283636364

00:09:28.000 --> 00:09:30.564 Either as a sighted in with venetoclax

NOTE Confidence: 0.805172283636364

00:09:30.564 --> 00:09:33.300 or azacitidine with placebo,

NOTE Confidence: 0.805172283636364

00:09:33.300 --> 00:09:35.532 and we have presented the schema

NOTE Confidence: 0.805172283636364

00:09:35.532 --> 00:09:37.825 of this study in ASCO 2021.

NOTE Confidence: 0.805172283636364

00:09:37.825 --> 00:09:41.225 You can see here 500 patients will be

NOTE Confidence: 0.805172283636364

00:09:41.225 --> 00:09:43.070 enrolled and this study continues to

NOTE Confidence: 0.805172283636364

00:09:43.070 --> 00:09:45.403 be open and we encourage you to refer

NOTE Confidence: 0.805172283636364

00:09:45.403 --> 00:09:48.040 patients who have higher risk MD's.

NOTE Confidence: 0.805172283636364

00:09:48.040 --> 00:09:51.760 I currently discourage people from using.

NOTE Confidence: 0.805172283636364

00:09:51.760 --> 00:09:54.196 Plaques off label in the frontline

NOTE Confidence: 0.805172283636364

00:09:54.196 --> 00:09:56.273 setting because we still don't

NOTE Confidence: 0.805172283636364

00:09:56.273 --> 00:09:58.547 fully understand if it actually is

NOTE Confidence: 0.805172283636364

00:09:58.547 --> 00:10:01.199 better than is cited in monotherapy.

NOTE Confidence: 0.805172283636364

00:10:01.200 --> 00:10:03.489 And that's I think another reason to

NOTE Confidence: 0.805172283636364

00:10:03.489 --> 00:10:05.238 consider enrolling patients on this study,

NOTE Confidence: 0.805172283636364

00:10:05.240 --> 00:10:06.890 which is open at yet.

NOTE Confidence: 0.805172283636364

00:10:06.890 --> 00:10:09.650 In the refractory relapse setting,

NOTE Confidence: 0.805172283636364

00:10:09.650 --> 00:10:12.362 Yale has participated in a study

NOTE Confidence: 0.805172283636364

00:10:12.362 --> 00:10:14.170 that was led by.

NOTE Confidence: 0.805172283636364

00:10:14.170 --> 00:10:17.537 The sponsor or organized by the sponsor,

NOTE Confidence: 0.805172283636364

00:10:17.540 --> 00:10:18.480 similar design,

NOTE Confidence: 0.805172283636364

00:10:18.480 --> 00:10:20.830 those escalation followed by those

NOTE Confidence: 0.805172283636364

00:10:20.830 --> 00:10:22.685 expansion and this was a smaller

NOTE Confidence: 0.805172283636364

00:10:22.685 --> 00:10:24.070 study than the frontline study.

NOTE Confidence: 0.805172283636364

00:10:24.070 --> 00:10:26.746 44 patients were treated same dosing,

NOTE Confidence: 0.805172283636364

00:10:26.750 --> 00:10:29.242 400 milligram of Veneto class given for

NOTE Confidence: 0.805172283636364

00:10:29.242 --> 00:10:31.758 two weeks and venetoclax was added to

NOTE Confidence: 0.805172283636364

00:10:31.758 --> 00:10:34.829 a society in so the patient had a failure.

NOTE Confidence: 0.805172283636364

00:10:34.830 --> 00:10:37.150 But the patient continued in the MA so it is.

NOTE Confidence: 0.8713487

00:10:39.420 --> 00:10:41.658 And you can see here that

NOTE Confidence: 0.8713487

00:10:41.660 --> 00:10:43.673 response rate was seen in 39%.

NOTE Confidence: 0.8713487

00:10:43.673 --> 00:10:46.004 However, many of those were more hours.

NOTE Confidence: 0.8713487

00:10:46.010 --> 00:10:47.730 The CRA was 7%,

NOTE Confidence: 0.8713487

00:10:47.730 --> 00:10:49.880 but those responses were durable.

NOTE Confidence: 0.8713487

00:10:49.880 --> 00:10:52.776 As you can see, the duration was nine

NOTE Confidence: 0.8713487

00:10:52.776 --> 00:10:56.140 months of the CR or the more OCR.

NOTE Confidence: 0.8713487

00:10:56.140 --> 00:10:57.364 But most importantly,

NOTE Confidence: 0.8713487

00:10:57.364 --> 00:10:58.996 we are actually seeing.

NOTE Confidence: 0.8713487

00:10:59.000 --> 00:11:02.306 I think mean clinically meaningful responses.

NOTE Confidence: 0.8713487

00:11:02.310 --> 00:11:05.094 You can see that platelets and red blood

NOTE Confidence: 0.8713487

00:11:05.094 --> 00:11:06.889 cell transfusion independence among

NOTE Confidence: 0.8713487

00:11:06.889 --> 00:11:09.464 patients who were transfusion dependent.

NOTE Confidence: 0.8713487

00:11:09.470 --> 00:11:11.990 OK fine, so the patient was needing

NOTE Confidence: 0.8713487

00:11:11.990 --> 00:11:14.073 blood or platelets around 1/3

NOTE Confidence: 0.8713487

00:11:14.073 --> 00:11:16.408 of those patients are becoming

NOTE Confidence: 0.8713487

00:11:16.408 --> 00:11:18.302 transfusion independent with by

NOTE Confidence: 0.8713487

00:11:18.302 --> 00:11:20.886 adding venetoclax to exercise and you

NOTE Confidence: 0.8713487

00:11:20.886 --> 00:11:23.514 can see that many patients achieve

NOTE Confidence: 0.8713487

00:11:23.514 --> 00:11:24.989 hematologic improvement as well,

NOTE Confidence: 0.8713487

00:11:24.990 --> 00:11:26.990 43% and the median overall

NOTE Confidence: 0.8713487

00:11:26.990 --> 00:11:28.590 survival was 12 months.

NOTE Confidence: 0.8713487

00:11:28.590 --> 00:11:30.995 We know historically that median

NOTE Confidence: 0.8713487

00:11:30.995 --> 00:11:33.400 overall survival after a jammy

NOTE Confidence: 0.8713487

00:11:33.483 --> 00:11:35.698 failure is around six months,

NOTE Confidence: 0.8713487

00:11:35.700 --> 00:11:37.510 so it does seem that.

NOTE Confidence: 0.8713487

00:11:37.510 --> 00:11:41.731 We are seeing promising activity with this

NOTE Confidence: 0.8713487

00:11:41.731 --> 00:11:46.018 combination in the refractory labs setting.

NOTE Confidence: 0.8713487

00:11:46.020 --> 00:11:48.290 I think another important study

NOTE Confidence: 0.8713487

00:11:48.290 --> 00:11:51.076 from this hash meeting was the

NOTE Confidence: 0.8713487

00:11:51.076 --> 00:11:53.031 phase three update using that,

NOTE Confidence: 0.8713487

00:11:53.031 --> 00:11:54.036 so people need this stat.

NOTE Confidence: 0.8713487

00:11:54.040 --> 00:11:56.360 Is it activating enzyme inhibitor?

NOTE Confidence: 0.8713487

00:11:56.360 --> 00:11:58.208 It works upstream of the protein zone so

NOTE Confidence: 0.8713487

00:11:58.208 --> 00:12:00.117 this is a negative phase three study.

NOTE Confidence: 0.8713487

00:12:00.120 --> 00:12:03.168 The reason why I think this is an

NOTE Confidence: 0.8713487

00:12:03.168 --> 00:12:04.917 important presentation is because there

NOTE Confidence: 0.8713487

00:12:04.917 --> 00:12:07.470 has been a lot of early data with.

NOTE Confidence: 0.8713487

00:12:07.470 --> 00:12:09.582 That we had a randomized phase

NOTE Confidence: 0.8713487

00:12:09.582 --> 00:12:11.736 two study with people instead that

NOTE Confidence: 0.8713487

00:12:11.736 --> 00:12:14.981 showed the CR rate was 50% more than

NOTE Confidence: 0.8713487

00:12:14.981 --> 00:12:17.566 double death of his immunotherapy,

NOTE Confidence: 0.8713487

00:12:17.570 --> 00:12:20.730 and we had durable responses.

NOTE Confidence: 0.8713487

00:12:20.730 --> 00:12:22.942 So there was a lot of excitement

NOTE Confidence: 0.8713487

00:12:22.942 --> 00:12:25.203 about this drug and we did participate

NOTE Confidence: 0.8713487

00:12:25.203 --> 00:12:27.460 in the phase two part of this.

NOTE Confidence: 0.8713487

00:12:27.460 --> 00:12:29.546 Evaluation, but not in the phase three.

NOTE Confidence: 0.8713487

00:12:29.550 --> 00:12:29.833 However,

NOTE Confidence: 0.8713487

00:12:29.833 --> 00:12:31.814 you can see here in the phase

NOTE Confidence: 0.8713487

00:12:31.814 --> 00:12:33.020 three that there was.

NOTE Confidence: 0.8713487

00:12:33.020 --> 00:12:35.190 No difference in the event free survival,

NOTE Confidence: 0.8713487

00:12:35.190 --> 00:12:37.010 which was the primary endpoint.

NOTE Confidence: 0.8713487

00:12:37.010 --> 00:12:39.920 No difference in the overall survival.

NOTE Confidence: 0.8713487

00:12:39.920 --> 00:12:42.069 And even in the CRA there was

NOTE Confidence: 0.8713487

00:12:42.069 --> 00:12:43.690 no improvement with the combo.

NOTE Confidence: 0.8713487

00:12:43.690 --> 00:12:46.301 So that I think highlights why it's

NOTE Confidence: 0.8713487

00:12:46.301 --> 00:12:48.298 very important we enroll patients

NOTE Confidence: 0.8713487

00:12:48.298 --> 00:12:51.105 in phase three trials and not just

NOTE Confidence: 0.8713487

00:12:51.105 --> 00:12:54.049 assume activity based on phase two trials.

NOTE Confidence: 0.8713487

00:12:54.050 --> 00:12:55.650 How about immune checkpoint inhibition?

NOTE Confidence: 0.8713487

00:12:55.650 --> 00:12:56.690 As I'm sure you know,

NOTE Confidence: 0.8713487

00:12:56.690 --> 00:12:59.305 in solar tumors immune checkpoint

NOTE Confidence: 0.8713487

00:12:59.305 --> 00:13:02.890 inhibition has led to very important.

NOTE Confidence: 0.8713487

00:13:02.890 --> 00:13:05.476 Progress in very difficult to treat

NOTE Confidence: 0.8713487

00:13:05.476 --> 00:13:08.449 tumors such as Melanoma and lung cancer.

NOTE Confidence: 0.8713487

00:13:08.450 --> 00:13:10.820 Early data with immune checkpoint

NOTE Confidence: 0.8713487

00:13:10.820 --> 00:13:13.658 inhibitors in MD's has not been

NOTE Confidence: 0.8713487

00:13:13.658 --> 00:13:15.546 so far particularly great.

NOTE Confidence: 0.8713487

00:13:15.550 --> 00:13:18.798 With this is an example of this study

NOTE Confidence: 0.8713487

00:13:18.798 --> 00:13:21.530 that was conducted at several centers,

NOTE Confidence: 0.8713487

00:13:21.530 --> 00:13:22.236 including Yale,

NOTE Confidence: 0.8713487

00:13:22.236 --> 00:13:24.707 where we showed that there was no

NOTE Confidence: 0.8713487

00:13:24.707 --> 00:13:26.650 difference by adding door volume app,

NOTE Confidence: 0.8713487

00:13:26.650 --> 00:13:29.200 which is an approved PDL 1

NOTE Confidence: 0.8713487

00:13:29.200 --> 00:13:30.900 inhibitor that already has.

NOTE Confidence: 0.8713487

00:13:30.900 --> 00:13:33.280 Meaningful clinical activity and solid

NOTE Confidence: 0.8713487

00:13:33.280 --> 00:13:36.519 tumors by adding it to a society.

NOTE Confidence: 0.8713487

00:13:36.520 --> 00:13:38.440 However, there are novel.

NOTE Confidence: 0.8713487

00:13:38.440 --> 00:13:40.360 I think immune checkpoint

NOTE Confidence: 0.8713487

00:13:40.360 --> 00:13:42.262 inhibitors that seem to.

NOTE Confidence: 0.8713487

00:13:42.262 --> 00:13:45.106 Early and early results seem to

NOTE Confidence: 0.8713487

00:13:45.106 --> 00:13:47.232 have a promising clinical activity.

NOTE Confidence: 0.8713487

00:13:47.232 --> 00:13:50.518 One of them is about so sabatelli map

NOTE Confidence: 0.8713487

00:13:50.518 --> 00:13:53.360 works on a receptor called Team Three.

NOTE Confidence: 0.8713487

00:13:53.360 --> 00:13:56.449 So term 3 basically is an inhibitory

NOTE Confidence: 0.8713487

00:13:56.449 --> 00:13:59.023 receptor that is not only expressed

NOTE Confidence: 0.8713487

00:13:59.023 --> 00:14:00.800 on the adaptive cells,

NOTE Confidence: 0.8713487

00:14:00.800 --> 00:14:01.920 such as the T cells,

NOTE Confidence: 0.777102485555556

00:14:01.920 --> 00:14:03.955 but also it's expressed in

NOTE Confidence: 0.777102485555556

00:14:03.955 --> 00:14:05.583 the innate immune cells,

NOTE Confidence: 0.777102485555556

00:14:05.590 --> 00:14:07.240 including the macrophages,

NOTE Confidence: 0.777102485555556

00:14:07.240 --> 00:14:10.540 but also importantly on the leukemia

NOTE Confidence: 0.777102485555556

00:14:10.540 --> 00:14:13.984 stem cells. So this is being.

NOTE Confidence: 0.777102485555556

00:14:13.984 --> 00:14:17.350 Presented as as an immuno myeloid agent?

NOTE Confidence: 0.777102485555556

00:14:17.350 --> 00:14:19.696 Because it leads to activation of

NOTE Confidence: 0.777102485555556

00:14:19.696 --> 00:14:23.604 the T cells and then it immune system

NOTE Confidence: 0.777102485555556

00:14:23.604 --> 00:14:27.864 but also it directly inhibits.

NOTE Confidence: 0.777102485555556

00:14:27.870 --> 00:14:31.202 A loop of self renewal within the

NOTE Confidence: 0.777102485555556

00:14:31.202 --> 00:14:33.983 leukemia stem cells by interfering with

NOTE Confidence: 0.777102485555556

00:14:33.983 --> 00:14:37.011 the ligand called galectin 9 that binds

NOTE Confidence: 0.777102485555556

00:14:37.011 --> 00:14:39.258 to team three on leukemia stem cells.

NOTE Confidence: 0.777102485555556

00:14:39.260 --> 00:14:41.573 So this drug was combined with Dean

NOTE Confidence: 0.777102485555556

00:14:41.573 --> 00:14:43.904 and Decitabine in a phase one trial.

NOTE Confidence: 0.777102485555556

00:14:43.910 --> 00:14:46.164 You can see here the early data

NOTE Confidence: 0.777102485555556

00:14:46.164 --> 00:14:47.898 that was presented in actually

NOTE Confidence: 0.777102485555556

00:14:47.898 --> 00:14:50.504 in more than one ASH meeting.

NOTE Confidence: 0.777102485555556

00:14:50.504 --> 00:14:54.969 And, uh, the CR rate was not very

NOTE Confidence: 0.777102485555556

00:14:54.969 --> 00:14:57.659 high compared to a similar therapy.

NOTE Confidence: 0.777102485555556

00:14:57.659 --> 00:14:59.674 However, in certain subsets like

NOTE Confidence: 0.777102485555556

00:14:59.674 --> 00:15:03.969 TP 53 for example, the CR rate.

NOTE Confidence: 0.777102485555556

00:15:03.970 --> 00:15:05.250 The CR was durable.

NOTE Confidence: 0.777102485555556

00:15:05.250 --> 00:15:06.850 The median duration of response

NOTE Confidence: 0.777102485555556

00:15:06.850 --> 00:15:07.819 was 21 months,

NOTE Confidence: 0.777102485555556

00:15:07.820 --> 00:15:10.880 which again in a very difficult

NOTE Confidence: 0.777102485555556

00:15:10.880 --> 00:15:12.656 field such as CP3, I think,

NOTE Confidence: 0.777102485555556

00:15:12.660 --> 00:15:13.491 is very exciting,

NOTE Confidence: 0.777102485555556

00:15:13.491 --> 00:15:15.430 but we are also seeing hints of

NOTE Confidence: 0.777102485555556

00:15:15.495 --> 00:15:17.139 durability and other subsets,

NOTE Confidence: 0.777102485555556

00:15:17.140 --> 00:15:20.560 so clearly there is also excitement

NOTE Confidence: 0.777102485555556

00:15:20.560 --> 00:15:22.037 about this agent.

NOTE Confidence: 0.777102485555556

00:15:22.037 --> 00:15:24.059 There is actually a randomized phase

NOTE Confidence: 0.777102485555556

00:15:24.059 --> 00:15:26.990 two and a randomized phase three trial.

NOTE Confidence: 0.777102485555556

00:15:26.990 --> 00:15:28.718 Both of them were open at Yale and

NOTE Confidence: 0.777102485555556

00:15:28.718 --> 00:15:30.558 they are fully enrolled and we have

NOTE Confidence: 0.777102485555556

00:15:30.558 --> 00:15:32.220 two other studies with this drug,

NOTE Confidence: 0.777102485555556

00:15:32.220 --> 00:15:33.950 one in combination with oral.

NOTE Confidence: 0.777102485555556

00:15:33.950 --> 00:15:34.988 Typo methylating agents.

NOTE Confidence: 0.777102485555556

00:15:34.988 --> 00:15:37.410 So you can give the sidik the

NOTE Confidence: 0.777102485555556

00:15:37.474 --> 00:15:39.459 oral decitabine with this drug,

NOTE Confidence: 0.777102485555556

00:15:39.460 --> 00:15:42.622 and another study of a triplet

NOTE Confidence: 0.777102485555556

00:15:42.622 --> 00:15:46.800 where is cited in with venetoclax

NOTE Confidence: 0.777102485555556

00:15:46.800 --> 00:15:48.755 and will be given for patients

NOTE Confidence: 0.777102485555556

00:15:48.755 --> 00:15:50.499 with high risk MD's and both of

NOTE Confidence: 0.777102485555556

00:15:50.499 --> 00:15:52.137 those studies will open at the end.

NOTE Confidence: 0.777102485555556

00:15:52.140 --> 00:15:52.740 Lastly,

NOTE Confidence: 0.777102485555556

00:15:52.740 --> 00:15:56.940 the idea inhibitors this is dawn of

NOTE Confidence: 0.777102485555556

00:15:56.940 --> 00:16:00.548 the precision era in MD's like other.

NOTE Confidence: 0.765714246666667

00:16:11.690 --> 00:16:13.916 Malignancies in leukemia, where we do

NOTE Confidence: 0.765714246666667

00:16:13.916 --> 00:16:16.742 it more so approved clearly and MD's,

NOTE Confidence: 0.765714246666667

00:16:16.742 --> 00:16:19.310 but we have seen 2 presentations

NOTE Confidence: 0.765714246666667

00:16:19.388 --> 00:16:21.929 from the French group and ash where

NOTE Confidence: 0.765714246666667

00:16:21.930 --> 00:16:24.780 we are seeing basically activity and

NOTE Confidence: 0.765714246666667

00:16:24.780 --> 00:16:27.743 responses within a signal for IDH 2

NOTE Confidence: 0.765714246666667

00:16:27.743 --> 00:16:30.038 mutated MD's and I was sitting there

NOTE Confidence: 0.765714246666667

00:16:30.038 --> 00:16:32.658 for IDH 1 mutated MD's so I think

NOTE Confidence: 0.765714246666667

00:16:32.658 --> 00:16:34.909 this is an option clearly off label.

NOTE Confidence: 0.765714246666667

00:16:34.909 --> 00:16:37.540 But in the absence of a clinical trial,

NOTE Confidence: 0.765714246666667

00:16:37.540 --> 00:16:39.916 I do check for IDH mutations for patients

NOTE Confidence: 0.765714246666667

00:16:39.916 --> 00:16:42.806 with MD's and consider using these drugs.

NOTE Confidence: 0.765714246666667

00:16:42.810 --> 00:16:46.200 Lastly, CPX 351 or liposomal

NOTE Confidence: 0.765714246666667

00:16:46.200 --> 00:16:48.720 daunorubicin was approved for secondary,

NOTE Confidence: 0.765714246666667

00:16:48.720 --> 00:16:52.045 AML is also being studied in high

NOTE Confidence: 0.765714246666667

00:16:52.045 --> 00:16:53.915 risk patients who have access plus

NOTE Confidence: 0.765714246666667

00:16:53.915 --> 00:16:55.852 in particular and we are seeing

NOTE Confidence: 0.765714246666667

00:16:55.852 --> 00:16:56.818 encouraging activity.

NOTE Confidence: 0.765714246666667

00:16:56.820 --> 00:16:59.016 Again this is single ARM study.

NOTE Confidence: 0.765714246666667

00:16:59.020 --> 00:17:00.352 Small number of patients.

NOTE Confidence: 0.765714246666667

00:17:00.352 --> 00:17:02.574 Those are not your typical MD's patients.

NOTE Confidence: 0.765714246666667

00:17:02.574 --> 00:17:03.959 Those are younger fit patients

NOTE Confidence: 0.765714246666667

00:17:03.959 --> 00:17:05.400 who go to transplant.

NOTE Confidence: 0.765714246666667

00:17:05.400 --> 00:17:06.675 So this probably does not

NOTE Confidence: 0.765714246666667

00:17:06.675 --> 00:17:07.695 apply to most patients,

NOTE Confidence: 0.765714246666667

00:17:07.700 --> 00:17:09.400 and this is intensive chemo,

NOTE Confidence: 0.765714246666667

00:17:09.400 --> 00:17:11.094 so there is high risk of toxicity.

NOTE Confidence: 0.765714246666667

00:17:11.100 --> 00:17:12.955 Those patients should be monitored

NOTE Confidence: 0.765714246666667

00:17:12.955 --> 00:17:15.191 the same way you would consider

NOTE Confidence: 0.765714246666667

00:17:15.191 --> 00:17:17.354 someone who is getting 7 + 3.

NOTE Confidence: 0.765714246666667

00:17:17.360 --> 00:17:20.566 So in summary, a lot of active.

NOTE Confidence: 0.765714246666667

00:17:20.570 --> 00:17:23.053 Instigation for new agents in MD's,

NOTE Confidence: 0.765714246666667

00:17:23.053 --> 00:17:25.116 I think the field is clearly

NOTE Confidence: 0.765714246666667

00:17:25.116 --> 00:17:28.846 very exciting with looking like

NOTE Confidence: 0.765714246666667

00:17:28.850 --> 00:17:30.230 a therapeutic revolution similar

NOTE Confidence: 0.765714246666667

00:17:30.230 --> 00:17:31.955 to what's happening in XAML,

NOTE Confidence: 0.765714246666667

00:17:31.960 --> 00:17:33.759 and I think to continue with that

NOTE Confidence: 0.765714246666667

00:17:33.759 --> 00:17:35.730 we need to continue to refer

NOTE Confidence: 0.765714246666667

00:17:35.730 --> 00:17:37.236 patients for clinical trials.

NOTE Confidence: 0.765714246666667

00:17:37.236 --> 00:17:39.066 So thank you so much.

NOTE Confidence: 0.765714246666667

00:17:39.070 --> 00:17:41.578 This is my email.

NOTE Confidence: 0.765714246666667

00:17:41.580 --> 00:17:43.820 Many of you have my cell as well

NOTE Confidence: 0.765714246666667

00:17:43.820 --> 00:17:46.204 and feel free to reach out for

NOTE Confidence: 0.765714246666667

00:17:46.204 --> 00:17:48.283 any questions about MD's or any

NOTE Confidence: 0.765714246666667

00:17:48.283 --> 00:17:49.988 other questions you might have.

NOTE Confidence: 0.765714246666667

00:17:49.990 --> 00:17:53.221 Thank you so much and I will move

NOTE Confidence: 0.765714246666667

00:17:53.221 --> 00:17:55.363 to Doctor Challace who will talk

NOTE Confidence: 0.765714246666667

00:17:55.363 --> 00:17:58.017 about acute myeloid leukemia updates.

NOTE Confidence: 0.79296975

00:18:01.500 --> 00:18:02.538 I have to confirm it's just

NOTE Confidence: 0.79296975

00:18:02.538 --> 00:18:03.769 presenter view or the standard view.

NOTE Confidence: 0.47510125125

00:18:08.570 --> 00:18:10.635 It's a present, sorry it's

NOTE Confidence: 0.47510125125

00:18:10.635 --> 00:18:12.140 your for you. You need

NOTE Confidence: 0.6405133912

00:18:12.150 --> 00:18:17.590 to. Such. How's that look good? Yeah, but.

NOTE Confidence: 0.814054174

00:18:18.980 --> 00:18:21.156 So alright thanks Doctor

NOTE Confidence: 0.814054174

00:18:21.156 --> 00:18:23.130 Sadanand all of you for joining.

NOTE Confidence: 0.814054174

00:18:23.130 --> 00:18:24.684 I'll be reviewing some of the

NOTE Confidence: 0.814054174

00:18:24.684 --> 00:18:26.002 highlights from this past meeting

NOTE Confidence: 0.814054174

00:18:26.002 --> 00:18:27.716 as it relates to similar disease.

NOTE Confidence: 0.814054174

00:18:27.716 --> 00:18:30.537 Akuma leukemia touching on a few that

NOTE Confidence: 0.814054174

00:18:30.540 --> 00:18:33.180 caught our attention as a community we

NOTE Confidence: 0.814054174

00:18:33.180 --> 00:18:35.460 can start with a retrospective analysis.

NOTE Confidence: 0.814054174

00:18:35.460 --> 00:18:38.764 First, liposomal done rubison sutera

NOTE Confidence: 0.814054174

00:18:38.764 --> 00:18:42.176 been or CPX 351 and hypomethylating

NOTE Confidence: 0.814054174

00:18:42.176 --> 00:18:45.340 agent plus band have shown vantage

NOTE Confidence: 0.814054174

00:18:45.340 --> 00:18:47.840 as frontline therapies for older

NOTE Confidence: 0.814054174

00:18:47.923 --> 00:18:50.299 and we call adverse risk AML.

NOTE Confidence: 0.814054174

00:18:50.300 --> 00:18:53.462 Although HMA van is approved for

NOTE Confidence: 0.814054174

00:18:53.462 --> 00:18:55.430 ineligible patients who are ineligible

NOTE Confidence: 0.814054174

00:18:55.430 --> 00:18:56.870 to receive intensive therapy,

NOTE Confidence: 0.814054174

00:18:56.870 --> 00:18:58.784 there's an increased use of this

NOTE Confidence: 0.814054174

00:18:58.784 --> 00:19:00.570 combo in older intensive therapy.

NOTE Confidence: 0.814054174

00:19:00.570 --> 00:19:01.965 Eligible patients including

NOTE Confidence: 0.814054174

00:19:01.965 --> 00:19:03.360 adverse risk disease.

NOTE Confidence: 0.814054174

00:19:03.360 --> 00:19:05.064 Furthermore, there's no getting around the

NOTE Confidence: 0.814054174

00:19:05.064 --> 00:19:07.557 fact that CPX is just pretty darn expensive,

NOTE Confidence: 0.814054174

00:19:07.560 --> 00:19:09.597 and we also recently published data on

NOTE Confidence: 0.814054174

00:19:09.597 --> 00:19:11.558 this and listen to classical 7 + 3,

NOTE Confidence: 0.814054174

00:19:11.560 --> 00:19:13.712 but getting back to CPX and ban there

NOTE Confidence: 0.814054174

00:19:13.712 --> 00:19:15.508 have been no randomized trials.

NOTE Confidence: 0.814054174

00:19:15.510 --> 00:19:17.868 So the two treatments have not

NOTE Confidence: 0.814054174

00:19:17.868 --> 00:19:19.047 been appropriately compared.

NOTE Confidence: 0.814054174

00:19:19.050 --> 00:19:20.088 There have been a number of.

NOTE Confidence: 0.814054174

00:19:20.090 --> 00:19:21.482 Retrospective analysis comparing them.

NOTE Confidence: 0.814054174

00:19:21.482 --> 00:19:23.222 But as upfront therapy for

NOTE Confidence: 0.814054174

00:19:23.222 --> 00:19:24.309 newly diagnosed AML.

NOTE Confidence: 0.814054174

00:19:24.310 --> 00:19:27.470 But this would be the largest thus far,

NOTE Confidence: 0.814054174

00:19:27.470 --> 00:19:29.936 so this was a multicenter retrospective

NOTE Confidence: 0.814054174

00:19:29.936 --> 00:19:32.550 study from 4 centers northwestern,

NOTE Confidence: 0.814054174

00:19:32.550 --> 00:19:33.766 Moffitt, Cornell.

NOTE Confidence: 0.814054174

00:19:33.766 --> 00:19:34.982 And yeah,

NOTE Confidence: 0.814054174

00:19:34.982 --> 00:19:36.806 I think Sloane,

NOTE Confidence: 0.814054174

00:19:36.810 --> 00:19:39.486 presented by Pinkel Desai and included

NOTE Confidence: 0.814054174

00:19:39.486 --> 00:19:42.521 211 patients treated with CPX 351 and

NOTE Confidence: 0.814054174

00:19:42.521 --> 00:19:45.120 server 220 that got then you could

NOTE Confidence: 0.814054174

00:19:45.120 --> 00:19:46.980 see here the overall population on

NOTE Confidence: 0.814054174

00:19:46.980 --> 00:19:49.108 the left baseline characteristics.

NOTE Confidence: 0.814054174

00:19:49.110 --> 00:19:50.850 The meeting ages were different between.

NOTE Confidence: 0.814054174

00:19:50.850 --> 00:19:51.741 Groups as expected,

NOTE Confidence: 0.814054174

00:19:51.741 --> 00:19:53.523 more adverse risk disease in the

NOTE Confidence: 0.814054174

00:19:53.523 --> 00:19:54.529 HM Event group.

NOTE Confidence: 0.814054174

00:19:54.530 --> 00:19:55.445 Like I mentioned,

NOTE Confidence: 0.814054174

00:19:55.445 --> 00:19:57.580 there's also a trend towards being a

NOTE Confidence: 0.814054174

00:19:57.639 --> 00:19:59.491 more enriched for P53 mutated disease,

NOTE Confidence: 0.814054174

00:19:59.491 --> 00:20:01.570 but the CPX group was more likely

NOTE Confidence: 0.814054174

00:20:01.629 --> 00:20:03.939 to have received prior HMA relevant

NOTE Confidence: 0.814054174

00:20:03.939 --> 00:20:05.479 consideration given these patients

NOTE Confidence: 0.814054174

00:20:05.539 --> 00:20:07.012 probably progressed from MD's.

NOTE Confidence: 0.814054174

00:20:07.012 --> 00:20:09.076 The study team is also interested

NOTE Confidence: 0.814054174

00:20:09.076 --> 00:20:10.368 on the right here.

NOTE Confidence: 0.814054174

00:20:10.370 --> 00:20:11.990 You could see in patients aged

NOTE Confidence: 0.814054174

00:20:11.990 --> 00:20:13.070 60 or 75 years,

NOTE Confidence: 0.814054174

00:20:13.070 --> 00:20:14.638 which was the original

NOTE Confidence: 0.814054174

00:20:14.638 --> 00:20:16.549 age group studied for CPX.

NOTE Confidence: 0.814054174

00:20:16.549 --> 00:20:18.583 351 on the randomized phase three

NOTE Confidence: 0.814054174

00:20:18.583 --> 00:20:20.172 and differences between groups were

NOTE Confidence: 0.814054174

00:20:20.172 --> 00:20:22.228 about the same as you can see here.

NOTE Confidence: 0.814054174

00:20:22.230 --> 00:20:23.654 With regards to outcomes,

NOTE Confidence: 0.814054174

00:20:23.654 --> 00:20:26.470 more patients achieved CR in the CPX group,

NOTE Confidence: 0.814054174

00:20:26.470 --> 00:20:28.422 but more CRI in the HMA Venn Group

NOTE Confidence: 0.814054174

00:20:28.422 --> 00:20:30.664 as you would expect given the

NOTE Confidence: 0.814054174

00:20:30.664 --> 00:20:32.356 continual the cyclic continuous

NOTE Confidence: 0.814054174

00:20:32.356 --> 00:20:34.274 mouse oppression that's encountered

NOTE Confidence: 0.814054174

00:20:34.274 --> 00:20:36.298 with phonetic lack specifically.

NOTE Confidence: 0.814054174

00:20:36.300 --> 00:20:36.737 However,

NOTE Confidence: 0.814054174

00:20:36.737 --> 00:20:39.359 these differences appear to offset when

NOTE Confidence: 0.814054174

00:20:39.359 --> 00:20:42.200 looking at the overall or composite.

NOTE Confidence: 0.814054174

00:20:42.200 --> 00:20:44.090 Rate.

NOTE Confidence: 0.814054174

00:20:44.090 --> 00:20:47.446 And there was a trend towards better

NOTE Confidence: 0.814054174

00:20:47.446 --> 00:20:50.229 CR CR I in the TPP related subgroup.

NOTE Confidence: 0.814054174

00:20:50.230 --> 00:20:51.054 And interestingly,

NOTE Confidence: 0.814054174

00:20:51.054 --> 00:20:53.526 no differences in response rates for

NOTE Confidence: 0.814054174

00:20:53.526 --> 00:20:55.950 patients with prior looking to the right.

NOTE Confidence: 0.814054174

00:20:55.950 --> 00:20:58.244 You can see that real free survival

NOTE Confidence: 0.814054174

00:20:58.244 --> 00:21:00.404 RFS was longer than CPX group,

NOTE Confidence: 0.814054174

00:21:00.410 --> 00:21:02.186 actually more than doubled but did

NOTE Confidence: 0.814054174

00:21:02.186 --> 00:21:03.370 not meet statistical significance.

NOTE Confidence: 0.814054174

00:21:03.370 --> 00:21:03.823 However,

NOTE Confidence: 0.814054174

00:21:03.823 --> 00:21:06.541 meeting OS was better in the

NOTE Confidence: 0.814054174

00:21:06.541 --> 00:21:09.630 arm at 17.3 months.

NOTE Confidence: 0.814054174

00:21:09.630 --> 00:21:12.094 Among patients aged 60 to 75 years,

NOTE Confidence: 0.814054174

00:21:12.100 --> 00:21:13.650 similar to the overall cohort

NOTE Confidence: 0.814054174

00:21:13.650 --> 00:21:15.200 or FS was no different,

NOTE Confidence: 0.814054174

00:21:15.200 --> 00:21:17.132 but neither in this case was

NOTE Confidence: 0.814054174

00:21:17.132 --> 00:21:18.825 OS in multivariable analysis.

NOTE Confidence: 0.814054174

00:21:18.825 --> 00:21:21.555 After adjusting for things like age,

NOTE Confidence: 0.814054174

00:21:21.560 --> 00:21:22.622 Ellen Risk,

NOTE Confidence: 0.814054174

00:21:22.622 --> 00:21:24.746 history of permanency and

NOTE Confidence: 0.814054174

00:21:24.746 --> 00:21:27.280 importantly prior receipt of HMA,

NOTE Confidence: 0.814054174

00:21:27.280 --> 00:21:29.410 there was an advantage favoring

NOTE Confidence: 0.814054174

00:21:29.410 --> 00:21:31.540 CPX for with regards to

NOTE Confidence: 0.619771994

00:21:31.620 --> 00:21:35.138 S in the P53. Sorry TP. 50 mutated cohort.

NOTE Confidence: 0.619771994

00:21:35.140 --> 00:21:37.597 However, it should be noted that among

NOTE Confidence: 0.619771994

00:21:37.597 --> 00:21:39.628 this population age 60 or 75 years.

NOTE Confidence: 0.619771994

00:21:39.630 --> 00:21:42.321 The shy 50% of patients in the CPX arm

NOTE Confidence: 0.619771994

00:21:42.321 --> 00:21:45.129 went to transplant compared to just 520.

NOTE Confidence: 0.619771994

00:21:45.130 --> 00:21:47.614 In the ACE event or sorry HM Event group.

NOTE Confidence: 0.619771994

00:21:47.620 --> 00:21:49.741 So more than double in this is

NOTE Confidence: 0.619771994

00:21:49.741 --> 00:21:51.010 important because you know,

NOTE Confidence: 0.619771994

00:21:51.010 --> 00:21:52.718 transplant was a significant

NOTE Confidence: 0.619771994

00:21:52.718 --> 00:21:54.853 predictor of RFS and OS.

NOTE Confidence: 0.619771994

00:21:54.860 --> 00:21:57.562 They conducted another MVA in patients that

NOTE Confidence: 0.619771994

00:21:57.562 --> 00:22:00.209 were aged 65 years who did not receive a

NOTE Confidence: 0.619771994

00:22:00.209 --> 00:22:02.280 transplant and found no difference in OS.

NOTE Confidence: 0.619771994

00:22:02.280 --> 00:22:05.108 So, in conclusion, this there was a

NOTE Confidence: 0.619771994

00:22:05.108 --> 00:22:07.427 significant difference favoring CPS and the

NOTE Confidence: 0.619771994

00:22:07.427 --> 00:22:09.515 overall cohort and in several subgroups,

NOTE Confidence: 0.619771994

00:22:09.520 --> 00:22:12.136 although in no difference in C.

NOTE Confidence: 0.619771994

00:22:12.140 --> 00:22:13.586 However, this is very likely related

NOTE Confidence: 0.619771994

00:22:13.586 --> 00:22:15.321 to a better rate of outlook transplant

NOTE Confidence: 0.619771994

00:22:15.321 --> 00:22:17.008 in the CPX group or likely had.

NOTE Confidence: 0.619771994

00:22:17.010 --> 00:22:17.850 As you'd imagine,

NOTE Confidence: 0.619771994

00:22:17.850 --> 00:22:19.530 if you were morbidities and thus

NOTE Confidence: 0.619771994

00:22:19.530 --> 00:22:21.479 you know CPX could still be the

NOTE Confidence: 0.619771994

00:22:21.479 --> 00:22:23.289 standard for for younger fit patients,

NOTE Confidence: 0.619771994

00:22:23.290 --> 00:22:26.428 even with at risk risk disease.

NOTE Confidence: 0.619771994

00:22:26.430 --> 00:22:28.398 Switching gears to some clinical trial

NOTE Confidence: 0.619771994

00:22:28.398 --> 00:22:30.090 updates starting with targeted agents.

NOTE Confidence: 0.619771994

00:22:30.090 --> 00:22:32.026 Given the the dawn of a new era,

NOTE Confidence: 0.619771994

00:22:32.030 --> 00:22:34.230 that Doctor Zaidan had appropriately

NOTE Confidence: 0.619771994

00:22:34.230 --> 00:22:35.759 mentioned and specifically starting

NOTE Confidence: 0.619771994

00:22:35.759 --> 00:22:36.848 with frontline trials,

NOTE Confidence: 0.619771994

00:22:36.850 --> 00:22:39.346 we could talk about each one mutated disease,

NOTE Confidence: 0.619771994

00:22:39.350 --> 00:22:41.884 which are found so mutations in IDH

NOTE Confidence: 0.619771994

00:22:41.884 --> 00:22:44.133 1 mutations are found at about 5

NOTE Confidence: 0.619771994

00:22:44.133 --> 00:22:46.210 to 10% really diagnose patients.

NOTE Confidence: 0.619771994

00:22:46.210 --> 00:22:49.546 Ibis Sydney is an oral IDH 1 inhibitor

NOTE Confidence: 0.619771994

00:22:49.546 --> 00:22:52.021 that's FDA approved for two population,

NOTE Confidence: 0.619771994

00:22:52.021 --> 00:22:53.769 specifically adults with factory

NOTE Confidence: 0.619771994

00:22:53.769 --> 00:22:56.419 mutated disease and those with newly

NOTE Confidence: 0.619771994

00:22:56.419 --> 00:22:58.290 diagnosed disease, but are just.

NOTE Confidence: 0.619771994

00:22:58.290 --> 00:22:59.650 Older 75 years plus,

NOTE Confidence: 0.619771994

00:22:59.650 --> 00:23:01.750 or if commodities that quote UN quote

NOTE Confidence: 0.619771994

00:23:01.750 --> 00:23:03.818 preclude the use of intensive therapy

NOTE Confidence: 0.619771994

00:23:03.820 --> 00:23:05.266 there already data from a phase.

NOTE Confidence: 0.619771994

00:23:05.270 --> 00:23:08.326 One study of think it was 2425 patients

NOTE Confidence: 0.619771994

00:23:08.326 --> 00:23:10.166 with newly diagnosed disease that

NOTE Confidence: 0.619771994

00:23:10.166 --> 00:23:11.994 showed a favorable safety profile

NOTE Confidence: 0.619771994

00:23:11.994 --> 00:23:13.641 and pretty encouraging clinical

NOTE Confidence: 0.619771994

00:23:13.641 --> 00:23:15.826 activity for the combination of

NOTE Confidence: 0.619771994

00:23:15.826 --> 00:23:18.384 either sitting in a society and for

NOTE Confidence: 0.619771994

00:23:18.384 --> 00:23:21.101 that reason and also for the fact

NOTE Confidence: 0.619771994

00:23:21.101 --> 00:23:23.406 that this trial started enrolling.

NOTE Confidence: 0.619771994

00:23:23.410 --> 00:23:26.434 I think I wanna say March or April 2018,

NOTE Confidence: 0.619771994

00:23:26.440 --> 00:23:28.820 before we had the valley a data.

NOTE Confidence: 0.619771994

00:23:28.820 --> 00:23:30.698 This prompted a double blind randomized,

NOTE Confidence: 0.619771994

00:23:30.700 --> 00:23:32.725 placebo controlled phase three study

NOTE Confidence: 0.619771994

00:23:32.725 --> 00:23:35.078 where patients were randomized 1 to

NOTE Confidence: 0.619771994

00:23:35.078 --> 00:23:37.190 one to receive Asia or Asia plus I've

NOTE Confidence: 0.619771994

00:23:37.190 --> 00:23:39.277 acid nip with the primary endpoint.

NOTE Confidence: 0.619771994

00:23:39.280 --> 00:23:40.648 As you can see in the right here

NOTE Confidence: 0.619771994

00:23:40.648 --> 00:23:41.619 of event free survival,

NOTE Confidence: 0.619771994

00:23:41.620 --> 00:23:44.070 which was defined as a time frame

NOTE Confidence: 0.619771994

00:23:44.070 --> 00:23:45.630 randomization until treatment failure.

NOTE Confidence: 0.795475042142857

00:23:48.090 --> 00:23:49.428 146 patients have been enrolled as

NOTE Confidence: 0.795475042142857

00:23:49.428 --> 00:23:51.189 of this day to cut with the data.

NOTE Confidence: 0.795475042142857

00:23:51.190 --> 00:23:54.382 Cutoff was March of 2021 and as shown here,

NOTE Confidence: 0.795475042142857

00:23:54.382 --> 00:23:55.922 these were older patients with

NOTE Confidence: 0.795475042142857

00:23:55.922 --> 00:23:58.046 a median age of 75 to 76 years,

NOTE Confidence: 0.795475042142857

00:23:58.050 --> 00:24:00.666 a third with Anika performance status of two.

NOTE Confidence: 0.795475042142857

00:24:00.670 --> 00:24:03.400 Also about 1/4 of patients had

NOTE Confidence: 0.795475042142857

00:24:03.400 --> 00:24:06.468 defined poor risk disease.

NOTE Confidence: 0.795475042142857

00:24:06.470 --> 00:24:07.438 In looking at responses,

NOTE Confidence: 0.795475042142857

00:24:07.438 --> 00:24:09.210 which was not the primary end point,

NOTE Confidence: 0.795475042142857

00:24:09.210 --> 00:24:11.045 there was a statistically significant

NOTE Confidence: 0.795475042142857

00:24:11.045 --> 00:24:13.962 difference in CR as well as composite CRH

NOTE Confidence: 0.795475042142857

00:24:13.962 --> 00:24:16.328 favoring the Asia plus I've Sydney more,

NOTE Confidence: 0.795475042142857

00:24:16.330 --> 00:24:19.290 which namely demonstrated a 53% rate of CRC,

NOTE Confidence: 0.795475042142857

00:24:19.290 --> 00:24:21.450 RH, and half of these patients

NOTE Confidence: 0.795475042142857

00:24:21.450 --> 00:24:23.396 experienced a mutational clearance

NOTE Confidence: 0.795475042142857

00:24:23.396 --> 00:24:25.416 which is increasingly becoming.

NOTE Confidence: 0.795475042142857

00:24:25.420 --> 00:24:27.310 Is being recognized as a predictor

NOTE Confidence: 0.795475042142857

00:24:27.310 --> 00:24:29.455 of a durability of response and

NOTE Confidence: 0.795475042142857

00:24:29.455 --> 00:24:31.495 improvement in event based outcomes

NOTE Confidence: 0.795475042142857

00:24:31.500 --> 00:24:33.666 in the intent to treat population

NOTE Confidence: 0.795475042142857

00:24:33.666 --> 00:24:36.439 in line with the better rates of

NOTE Confidence: 0.795475042142857

00:24:36.439 --> 00:24:38.519 response and deep response by.

NOTE Confidence: 0.795475042142857

00:24:38.520 --> 00:24:40.501 There was a better EFS in the

NOTE Confidence: 0.795475042142857

00:24:40.501 --> 00:24:42.209 Asia plus Ivy Sydney farm.

NOTE Confidence: 0.795475042142857

00:24:42.210 --> 00:24:43.872 This is also translated into better

NOTE Confidence: 0.795475042142857

00:24:43.872 --> 00:24:45.960 OS for that for that arm as well.

NOTE Confidence: 0.795475042142857

00:24:45.960 --> 00:24:47.560 Quite striking at 24 months

NOTE Confidence: 0.795475042142857

00:24:47.560 --> 00:24:48.840 compared with eight months.

NOTE Confidence: 0.795475042142857

00:24:48.840 --> 00:24:50.646 As you can see here for patients

NOTE Confidence: 0.795475042142857

00:24:50.646 --> 00:24:52.369 just getting as alone and this

NOTE Confidence: 0.795475042142857

00:24:52.369 --> 00:24:54.145 is generally what we expect for

NOTE Confidence: 0.795475042142857

00:24:54.145 --> 00:24:55.899 patients getting a zoumana therapy.

NOTE Confidence: 0.795475042142857

00:24:55.900 --> 00:24:58.447 Did it come at the cost of more toxicity?

NOTE Confidence: 0.795475042142857

00:24:58.450 --> 00:25:00.426 Not really in looking at human logic talks,

NOTE Confidence: 0.795475042142857

00:25:00.430 --> 00:25:02.248 but perhaps a little more neutropenia.

NOTE Confidence: 0.795475042142857

00:25:02.250 --> 00:25:05.298 Pina Nonheme talks was also about the same,

NOTE Confidence: 0.795475042142857

00:25:05.300 --> 00:25:07.628 but the frequency of all grade

NOTE Confidence: 0.795475042142857

00:25:07.628 --> 00:25:09.259 differentiation syndrome, but concerned with.

NOTE Confidence: 0.795475042142857

00:25:09.259 --> 00:25:10.108 Ibis Sydney Pomona.

NOTE Confidence: 0.795475042142857

00:25:10.110 --> 00:25:11.610 Couple other targeted agents

NOTE Confidence: 0.795475042142857

00:25:11.610 --> 00:25:13.110 as assessed by investigators,

NOTE Confidence: 0.795475042142857

00:25:13.110 --> 00:25:15.630 was about 14% in the combo arm,

NOTE Confidence: 0.795475042142857

00:25:15.630 --> 00:25:17.586 compared to 8%.

NOTE Confidence: 0.795475042142857

00:25:17.586 --> 00:25:20.822 Think 70% on the monotherapy arm,

NOTE Confidence: 0.795475042142857

00:25:20.822 --> 00:25:22.754 although grade 3 differentiation

NOTE Confidence: 0.795475042142857

00:25:22.754 --> 00:25:24.768 syndrome was only about 4%.

NOTE Confidence: 0.795475042142857

00:25:24.770 --> 00:25:26.290 However, in both arms,

NOTE Confidence: 0.795475042142857

00:25:26.290 --> 00:25:27.810 so not terribly different.

NOTE Confidence: 0.795475042142857

00:25:27.810 --> 00:25:29.386 And looking on the right here you can

NOTE Confidence: 0.795475042142857

00:25:29.386 --> 00:25:30.700 see these are patient reported outcomes

NOTE Confidence: 0.795475042142857

00:25:30.700 --> 00:25:32.200 and measurements of quality of life.

NOTE Confidence: 0.795475042142857

00:25:32.200 --> 00:25:34.202 You can see that Ivo plus Asia

NOTE Confidence: 0.795475042142857

00:25:34.202 --> 00:25:36.527 appear to be a bit more favorable,

NOTE Confidence: 0.795475042142857

00:25:36.530 --> 00:25:39.840 so in some there wasn't.

NOTE Confidence: 0.795475042142857

00:25:39.840 --> 00:25:41.736 Recommendation that further enrollment

NOTE Confidence: 0.795475042142857

00:25:41.736 --> 00:25:44.106 be prematurely discontinued given the

NOTE Confidence: 0.795475042142857

00:25:44.106 --> 00:25:46.475 evidence of a benefit for the combination.

NOTE Confidence: 0.795475042142857

00:25:46.480 --> 00:25:48.531 So I would say, how does this

NOTE Confidence: 0.795475042142857

00:25:48.531 --> 00:25:49.970 translate into clinical practice?

NOTE Confidence: 0.795475042142857

00:25:49.970 --> 00:25:50.478 In short,

NOTE Confidence: 0.795475042142857

00:25:50.478 --> 00:25:52.510 as yet it remains to be determined for

NOTE Confidence: 0.795475042142857

00:25:52.570 --> 00:25:54.640 the patient with ID terminated disease,

NOTE Confidence: 0.795475042142857

00:25:54.640 --> 00:25:57.146 whether he or she is best served

NOTE Confidence: 0.795475042142857

00:25:57.146 --> 00:25:59.929 with a so plus van or a soap.

NOTE Confidence: 0.795475042142857

00:25:59.930 --> 00:26:01.178 I am personally aware of any

NOTE Confidence: 0.795475042142857

00:26:01.178 --> 00:26:02.330 randomized trial at the moment,

NOTE Confidence: 0.795475042142857

00:26:02.330 --> 00:26:06.038 but suspect that is a that is coming soon.

NOTE Confidence: 0.795475042142857

00:26:06.040 --> 00:26:07.645 Sticking with the same theme

NOTE Confidence: 0.795475042142857

00:26:07.645 --> 00:26:08.929 for frontline randomized trials,

NOTE Confidence: 0.795475042142857

00:26:08.930 --> 00:26:11.456 we should discuss the LACEWING trial,

NOTE Confidence: 0.795475042142857

00:26:11.460 --> 00:26:13.200 which was just presented by Eunice

NOTE Confidence: 0.795475042142857

00:26:13.200 --> 00:26:15.607 Wang at the meeting and this is a

NOTE Confidence: 0.795475042142857

00:26:15.607 --> 00:26:17.087 trial that randomized patients with

NOTE Confidence: 0.795475042142857

00:26:17.087 --> 00:26:19.472 newly diagnosed AML and who were

NOTE Confidence: 0.795475042142857

00:26:19.472 --> 00:26:21.248 inappropriate to receive intensive

NOTE Confidence: 0.795475042142857

00:26:21.248 --> 00:26:24.290 therapy to either get a Cerezo plus

NOTE Confidence: 0.795475042142857

00:26:24.290 --> 00:26:26.168 gilteritinib which is a footer

NOTE Confidence: 0.795475042142857

00:26:26.168 --> 00:26:27.636 inhibitor that demonstrated efficacy

NOTE Confidence: 0.795475042142857

00:26:27.636 --> 00:26:29.804 and safety and patients with ribs

NOTE Confidence: 0.795475042142857

00:26:29.804 --> 00:26:31.868 refractory for the mutated disease and

NOTE Confidence: 0.795475042142857

00:26:31.930 --> 00:26:34.016 what's known as the atom whole trial.

NOTE Confidence: 0.795475042142857

00:26:34.020 --> 00:26:34.276 Similarly,

NOTE Confidence: 0.795475042142857

00:26:34.276 --> 00:26:35.556 this trial was launched before

NOTE Confidence: 0.795475042142857

00:26:35.556 --> 00:26:36.970 the results of the alley A.

NOTE Confidence: 0.795475042142857

00:26:36.970 --> 00:26:38.585 Were known the primary endpoint

NOTE Confidence: 0.795475042142857

00:26:38.585 --> 00:26:40.200 of this trial was overall

NOTE Confidence: 0.839955340909091

00:26:40.260 --> 00:26:42.462 survival, so not FS and not or

NOTE Confidence: 0.839955340909091

00:26:42.462 --> 00:26:44.642 more of a response based endpoint.

NOTE Confidence: 0.839955340909091

00:26:44.642 --> 00:26:47.306 Patients were originally randomized 1 to

NOTE Confidence: 0.839955340909091

00:26:47.306 --> 00:26:50.428 one to one either get filter written at

NOTE Confidence: 0.839955340909091

00:26:50.428 --> 00:26:52.710 monotherapy built plus as a or as alone.

NOTE Confidence: 0.839955340909091

00:26:52.710 --> 00:26:54.551 But due to the website it as

NOTE Confidence: 0.839955340909091

00:26:54.551 --> 00:26:56.259 being a preferred therapy change,

NOTE Confidence: 0.839955340909091

00:26:56.260 --> 00:26:59.108 it was modified to randomize patients 2 to

NOTE Confidence: 0.839955340909091

00:26:59.108 --> 00:27:02.668 one to get either guiltless ASA oracea alone.

NOTE Confidence: 0.839955340909091

00:27:02.670 --> 00:27:04.812 Baseline characteristics are shown here and

NOTE Confidence: 0.839955340909091

00:27:04.812 --> 00:27:07.128 demonstrate that this was as expected and.

NOTE Confidence: 0.839955340909091

00:27:07.130 --> 00:27:08.774 Older population with meaning ages 77

NOTE Confidence: 0.839955340909091

00:27:08.774 --> 00:27:10.842 years and also a good proportion with

NOTE Confidence: 0.839955340909091

00:27:10.842 --> 00:27:12.672 any card performance status of two

NOTE Confidence: 0.839955340909091

00:27:12.672 --> 00:27:14.578 plus with perhaps some imbalance in

NOTE Confidence: 0.839955340909091

00:27:14.578 --> 00:27:16.572 favor of the Asian monotherapy arm.

NOTE Confidence: 0.839955340909091

00:27:16.572 --> 00:27:19.542 As expected, there were about 80% IT

NOTE Confidence: 0.839955340909091

00:27:19.542 --> 00:27:21.414 mutations and similar rates of it.

NOTE Confidence: 0.839955340909091

00:27:21.420 --> 00:27:23.828 High disease without at least from my eyes.

NOTE Confidence: 0.839955340909091

00:27:23.830 --> 00:27:24.910 Clear imbalances.

NOTE Confidence: 0.688259697142857

00:27:27.260 --> 00:27:29.269 It's pretty much up for this slide

NOTE Confidence: 0.688259697142857

00:27:29.270 --> 00:27:31.760 with regards to responses CR rates,

NOTE Confidence: 0.688259697142857

00:27:31.760 --> 00:27:32.856 not the primary endpoint,

NOTE Confidence: 0.688259697142857

00:27:32.856 --> 00:27:34.500 which is OS like I mentioned,

NOTE Confidence: 0.688259697142857

00:27:34.500 --> 00:27:35.860 we're somewhere between arms,

NOTE Confidence: 0.688259697142857

00:27:35.860 --> 00:27:38.148 but the rates of CRI and CRP which

NOTE Confidence: 0.688259697142857

00:27:38.148 --> 00:27:39.921 are less than CR response is still

NOTE Confidence: 0.688259697142857

00:27:39.921 --> 00:27:41.536 to be clinically meaningful were

NOTE Confidence: 0.688259697142857

00:27:41.536 --> 00:27:43.433 higher in the combination are nearly

NOTE Confidence: 0.688259697142857

00:27:43.433 --> 00:27:45.071 three times actually for a composite

NOTE Confidence: 0.688259697142857

00:27:45.071 --> 00:27:47.990 C area of about 58% for the combo

NOTE Confidence: 0.688259697142857

00:27:47.990 --> 00:27:50.370 and the 26% for as a monotherapy.

NOTE Confidence: 0.879116239523809

00:27:52.490 --> 00:27:53.880 However, it it's pretty clear

NOTE Confidence: 0.879116239523809

00:27:53.880 --> 00:27:55.646 from this KM curve that overall

NOTE Confidence: 0.879116239523809

00:27:55.646 --> 00:27:57.246 survival was not different between

NOTE Confidence: 0.879116239523809

00:27:57.246 --> 00:27:58.950 arms at about nine months.

NOTE Confidence: 0.879116239523809

00:27:58.950 --> 00:28:00.090 It should be noted, however,

NOTE Confidence: 0.879116239523809

00:28:00.090 --> 00:28:01.938 and this was discussed at the

NOTE Confidence: 0.879116239523809

00:28:01.938 --> 00:28:04.063 meeting and I believe it that this

NOTE Confidence: 0.879116239523809

00:28:04.063 --> 00:28:06.322 may be explained by a couple things.

NOTE Confidence: 0.879116239523809

00:28:06.322 --> 00:28:07.858 Subsequent email therapy was

NOTE Confidence: 0.879116239523809

00:28:07.858 --> 00:28:09.895 received by 20% of patients on

NOTE Confidence: 0.879116239523809

00:28:09.895 --> 00:28:11.960 guilt ASA and just shaved half of

NOTE Confidence: 0.879116239523809

00:28:12.031 --> 00:28:14.245 patients on the ASA monotherapy arm,

NOTE Confidence: 0.879116239523809

00:28:14.250 --> 00:28:15.918 meaning time to that next therapy

NOTE Confidence: 0.879116239523809

00:28:15.918 --> 00:28:17.700 was a bit longer in the ASA.

NOTE Confidence: 0.879116239523809

00:28:17.700 --> 00:28:19.100 Sorry, the combination arm.

NOTE Confidence: 0.879116239523809

00:28:19.100 --> 00:28:21.770 It was like 8 versus 5 months.

NOTE Confidence: 0.879116239523809

00:28:21.770 --> 00:28:23.318 So this might have influenced OS

NOTE Confidence: 0.879116239523809

00:28:23.318 --> 00:28:25.055 in addition to the imbalance and

NOTE Confidence: 0.879116239523809

00:28:25.055 --> 00:28:26.685 performance status that I showed

NOTE Confidence: 0.879116239523809

00:28:26.685 --> 00:28:28.912 you earlier on the right here.

NOTE Confidence: 0.879116239523809

00:28:28.912 --> 00:28:30.877 Looking at unplanned subgroup analysis,

NOTE Confidence: 0.879116239523809

00:28:30.880 --> 00:28:32.140 improved overall survival with guilt

NOTE Confidence: 0.879116239523809

00:28:32.140 --> 00:28:34.159 as it was really not observed in any.

NOTE Confidence: 0.879116239523809

00:28:34.160 --> 00:28:36.008 Although some trans were noted for

NOTE Confidence: 0.879116239523809

00:28:36.008 --> 00:28:37.972 patients that were more fit and

NOTE Confidence: 0.879116239523809

00:28:37.972 --> 00:28:41.044 also here with Highet delic ratio,

NOTE Confidence: 0.879116239523809

00:28:41.050 --> 00:28:43.024 I didn't show any adverse event data

NOTE Confidence: 0.879116239523809

00:28:43.024 --> 00:28:44.934 here because they were largely similar

NOTE Confidence: 0.879116239523809

00:28:44.934 --> 00:28:47.279 between arms including grade 3 plus events.

NOTE Confidence: 0.879116239523809

00:28:47.280 --> 00:28:48.651 So in some,

NOTE Confidence: 0.879116239523809

00:28:48.651 --> 00:28:50.479 although a negative trial

NOTE Confidence: 0.879116239523809

00:28:50.479 --> 00:28:52.090 still an informative 1.

NOTE Confidence: 0.879116239523809

00:28:52.090 --> 00:28:53.114 Supporting the contention that

NOTE Confidence: 0.879116239523809

00:28:53.114 --> 00:28:55.265 a zevan as based on the alley a

NOTE Confidence: 0.879116239523809

00:28:55.265 --> 00:28:56.665 may be the preferred combination

NOTE Confidence: 0.879116239523809

00:28:56.665 --> 00:28:58.253 for older patients who were

NOTE Confidence: 0.879116239523809

00:28:58.253 --> 00:28:59.641 inappropriate to receive intensive

NOTE Confidence: 0.879116239523809

00:28:59.641 --> 00:29:01.029 therapy with mutated disease.

NOTE Confidence: 0.879116239523809

00:29:01.030 --> 00:29:03.460 At the moment, I guess I can always change.

NOTE Confidence: 0.723182602173913

00:29:05.800 --> 00:29:07.856 Last year I had reviewed the data for

NOTE Confidence: 0.723182602173913

00:29:07.856 --> 00:29:09.999 Asia and McGraw map which is an anti

NOTE Confidence: 0.723182602173913

00:29:09.999 --> 00:29:12.058 CD 47 antibody that blocks the quote.

NOTE Confidence: 0.723182602173913

00:29:12.060 --> 00:29:15.015 Don't eat these signal on

NOTE Confidence: 0.723182602173913

00:29:15.015 --> 00:29:16.788 macrophages and specifically.

NOTE Confidence: 0.723182602173913

00:29:16.790 --> 00:29:18.250 Pretty robust efficacy for patients

NOTE Confidence: 0.723182602173913

00:29:18.250 --> 00:29:20.385 that have both P fitted mutated disease

NOTE Confidence: 0.723182602173913

00:29:20.385 --> 00:29:21.910 and wild type disease. Actually,

NOTE Confidence: 0.723182602173913

00:29:21.910 --> 00:29:23.800 for the pilot for the mutated cohort,

NOTE Confidence: 0.723182602173913

00:29:23.800 --> 00:29:25.606 I just over 12 months would be

NOTE Confidence: 0.723182602173913

00:29:25.606 --> 00:29:27.145 the longest meeting OS reported

NOTE Confidence: 0.723182602173913

00:29:27.145 --> 00:29:28.557 for that particular subgroup.

NOTE Confidence: 0.723182602173913

00:29:28.560 --> 00:29:29.764 But like everything else,

NOTE Confidence: 0.723182602173913

00:29:29.764 --> 00:29:32.315 this has to be combined with a zven, right?

NOTE Confidence: 0.723182602173913

00:29:32.315 --> 00:29:34.675 But I will say there are a number

NOTE Confidence: 0.723182602173913

00:29:34.675 --> 00:29:37.052 of preclinical studies which do

NOTE Confidence: 0.723182602173913

00:29:37.052 --> 00:29:39.567 support synergy for this combination,

NOTE Confidence: 0.723182602173913

00:29:39.570 --> 00:29:42.746 so this leads to the trial,

NOTE Confidence: 0.723182602173913

00:29:42.746 --> 00:29:45.566 which was a phase 1B2 trials divide with

NOTE Confidence: 0.723182602173913

00:29:45.566 --> 00:29:47.240 the triplet and patients with both.

NOTE Confidence: 0.723182602173913

00:29:47.240 --> 00:29:48.348 Newly diagnosed disease but

NOTE Confidence: 0.723182602173913

00:29:48.348 --> 00:29:49.456 restricted to P footage.

NOTE Confidence: 0.723182602173913

00:29:49.460 --> 00:29:51.959 Mutated disease as well as factory disease.

NOTE Confidence: 0.723182602173913

00:29:51.960 --> 00:29:53.348 Regardless of Peachtree status,

NOTE Confidence: 0.723182602173913

00:29:53.348 --> 00:29:55.430 the latter being the only cohort

NOTE Confidence: 0.723182602173913

00:29:55.491 --> 00:29:57.249 for the phase one portion and

NOTE Confidence: 0.723182602173913

00:29:57.249 --> 00:29:58.732 the primary endpoint for this

NOTE Confidence: 0.723182602173913

00:29:58.732 --> 00:30:00.388 trial was a composite rate of.

NOTE Confidence: 0.893622421428571

00:30:02.770 --> 00:30:04.975 Here are some baseline characteristics

NOTE Confidence: 0.893622421428571

00:30:04.975 --> 00:30:07.020 to date. I should mention that.

NOTE Confidence: 0.898801785

00:30:09.640 --> 00:30:12.020 Skip that part so.

NOTE Confidence: 0.898801785

00:30:12.020 --> 00:30:14.554 It's basically nothing out of the ordinary.

NOTE Confidence: 0.898801785

00:30:14.560 --> 00:30:16.520 In line with what I mentioned as how

NOTE Confidence: 0.898801785

00:30:16.520 --> 00:30:18.439 the kind of codes were divided up.

NOTE Confidence: 0.898801785

00:30:18.440 --> 00:30:19.720 You could see that you know the ages,

NOTE Confidence: 0.898801785

00:30:19.720 --> 00:30:21.880 maybe a bit younger in the mutated cohorts

NOTE Confidence: 0.898801785

00:30:21.880 --> 00:30:24.157 and the rips or factories specifically,

NOTE Confidence: 0.898801785

00:30:24.160 --> 00:30:25.573 then naive cohorts,

NOTE Confidence: 0.898801785

00:30:25.573 --> 00:30:27.457 as you would imagine.

NOTE Confidence: 0.898801785

00:30:27.460 --> 00:30:28.612 But other than that,

NOTE Confidence: 0.898801785

00:30:28.612 --> 00:30:30.340 no major surprises from a baseline

NOTE Confidence: 0.898801785

00:30:30.397 --> 00:30:32.525 characteristics standpoint and looking well.

NOTE Confidence: 0.898801785

00:30:32.525 --> 00:30:34.055 Just go over some safety data.

NOTE Confidence: 0.898801785

00:30:34.060 --> 00:30:36.668 No DLT's were observed in the Phase 1B

NOTE Confidence: 0.898801785

00:30:36.668 --> 00:30:39.080 portion and the RP 2 randomized phase.

NOTE Confidence: 0.898801785

00:30:39.080 --> 00:30:40.856 Two dose recommended phase two dose

NOTE Confidence: 0.898801785

00:30:40.856 --> 00:30:42.422 was established at 30 milligrams

NOTE Confidence: 0.898801785

00:30:42.422 --> 00:30:44.170 per kick with about a two week

NOTE Confidence: 0.898801785

00:30:44.170 --> 00:30:45.755 kind of priming dose ramp up and

NOTE Confidence: 0.898801785

00:30:45.755 --> 00:30:47.093 then eventually gets a bit easier

NOTE Confidence: 0.898801785

00:30:47.093 --> 00:30:48.697 for the patient every two weeks.

NOTE Confidence: 0.898801785

00:30:48.700 --> 00:30:50.528 Cycle 3 going forward.

NOTE Confidence: 0.898801785

00:30:50.528 --> 00:30:53.270 So getting to some efficacy data.

NOTE Confidence: 0.898801785

00:30:53.270 --> 00:30:54.422 Global findings first.

NOTE Confidence: 0.898801785

00:30:54.422 --> 00:30:56.726 The rate of CR being based

NOTE Confidence: 0.898801785

00:30:56.726 --> 00:30:58.449 on 14 patients with.

NOTE Confidence: 0.898801785

00:30:58.450 --> 00:31:01.429 TP50 mutated disease with 64% double what you

NOTE Confidence: 0.898801785

00:31:01.429 --> 00:31:04.200 would expect with with with a sub N alone,

NOTE Confidence: 0.898801785

00:31:04.200 --> 00:31:05.125 and this has been attributed

NOTE Confidence: 0.898801785

00:31:05.125 --> 00:31:06.410 to at least at the meeting.

NOTE Confidence: 0.898801785

00:31:06.410 --> 00:31:08.276 A quick depth of response with

NOTE Confidence: 0.898801785

00:31:08.276 --> 00:31:10.196 more than half being negative by

NOTE Confidence: 0.898801785

00:31:10.196 --> 00:31:12.331 flow and a first response in less

NOTE Confidence: 0.898801785

00:31:12.331 --> 00:31:14.346 than a month without really any.

NOTE Confidence: 0.898801785

00:31:14.350 --> 00:31:15.130 As you can see here,

NOTE Confidence: 0.898801785

00:31:15.130 --> 00:31:16.817 any early mortality and what I would

NOTE Confidence: 0.898801785

00:31:16.817 --> 00:31:18.329 consider to be a reasonable time

NOTE Confidence: 0.898801785

00:31:18.329 --> 00:31:20.051 to blood count recovery felt to be

NOTE Confidence: 0.898801785

00:31:20.100 --> 00:31:21.520 meaningful and really landing with

NOTE Confidence: 0.898801785

00:31:21.520 --> 00:31:25.250 the definition of what we call CRH.

NOTE Confidence: 0.898801785

00:31:25.250 --> 00:31:27.355 Frontline treatment for wild type

NOTE Confidence: 0.898801785

00:31:27.355 --> 00:31:29.460 patients was even more impressive

NOTE Confidence: 0.898801785

00:31:29.529 --> 00:31:30.849 with a CR CRA of 90%.

NOTE Confidence: 0.898801785

00:31:30.850 --> 00:31:31.882 Conversely, and this is,

NOTE Confidence: 0.898801785

00:31:31.882 --> 00:31:33.180 you know, one of the downsides.

NOTE Confidence: 0.898801785

00:31:33.180 --> 00:31:34.350 This doesn't appear to be a

NOTE Confidence: 0.898801785

00:31:34.397 --> 00:31:35.481 meaningful option for patients

NOTE Confidence: 0.898801785

00:31:35.481 --> 00:31:37.107 who've already been failed by vanetta

NOTE Confidence: 0.898801785

00:31:37.152 --> 00:31:38.430 klax based regimen with the CRA.

NOTE Confidence: 0.898801785

00:31:38.430 --> 00:31:40.498 As you can see here, based on 15 patients,

NOTE Confidence: 0.898801785

00:31:40.498 --> 00:31:43.147 but still zero and only 20% rate of CRI

NOTE Confidence: 0.898801785

00:31:43.147 --> 00:31:45.450 and at the bottom here you can see a 20%.

NOTE Confidence: 0.898801785

00:31:45.450 --> 00:31:46.776 It gets phone numbers but 20%

NOTE Confidence: 0.898801785

00:31:46.780 --> 00:31:49.110 rate of pearly mortality here.

NOTE Confidence: 0.898801785

00:31:49.110 --> 00:31:50.742 Look at this plot that was

NOTE Confidence: 0.898801785

00:31:50.742 --> 00:31:51.830 presented at the meeting.

NOTE Confidence: 0.898801785

00:31:51.830 --> 00:31:53.747 Much of what the last slide kind of showed,

NOTE Confidence: 0.898801785

00:31:53.750 --> 00:31:55.880 but also including data demonstrating that.

NOTE Confidence: 0.898801785

00:31:55.880 --> 00:31:57.680 There was 100% six month OS so short

NOTE Confidence: 0.898801785

00:31:57.680 --> 00:31:59.657 follow up as you could see here as well.

NOTE Confidence: 0.898801785

00:31:59.660 --> 00:32:02.418 For patients that had mutated disease and

NOTE Confidence: 0.898801785

00:32:02.418 --> 00:32:05.756 five of the 14 that were able to get to.

NOTE Confidence: 0.898801785

00:32:05.760 --> 00:32:06.656 Some form of response.

NOTE Confidence: 0.898801785

00:32:06.656 --> 00:32:08.000 We're able to get the transplants

NOTE Confidence: 0.898801785

00:32:08.049 --> 00:32:09.246 about 35% of course.

NOTE Confidence: 0.898801785

00:32:09.246 --> 00:32:10.574 Again short follow up,

NOTE Confidence: 0.898801785

00:32:10.580 --> 00:32:12.120 so maybe more will get the transplant.

NOTE Confidence: 0.898801785

00:32:12.120 --> 00:32:13.928 We'll get a better sense of the median

NOTE Confidence: 0.898801785

00:32:13.928 --> 00:32:15.952 OS and see how it stacks up to 12

NOTE Confidence: 0.898801785

00:32:15.952 --> 00:32:17.667 months noted for the Asian Macro Delta

NOTE Confidence: 0.898801785

00:32:17.667 --> 00:32:21.640 data that I presented to you last year.

NOTE Confidence: 0.898801785

00:32:21.640 --> 00:32:23.488 Frequent I share some more toxicity

NOTE Confidence: 0.898801785

00:32:23.488 --> 00:32:25.726 data frequente, ease of all grades.

NOTE Confidence: 0.898801785

00:32:25.726 --> 00:32:26.656 Hypokalemia, hypophosphatemia,

NOTE Confidence: 0.898801785

00:32:26.656 --> 00:32:29.286 hyperbilirubinemia, about half of patients,

NOTE Confidence: 0.898801785

00:32:29.290 --> 00:32:30.124 and some otherwise.

NOTE Confidence: 0.898801785

00:32:30.124 --> 00:32:31.514 He talks you would expect

NOTE Confidence: 0.898801785

00:32:31.514 --> 00:32:32.809 with as event itself,

NOTE Confidence: 0.898801785

00:32:32.810 --> 00:32:34.590 not necessarily mad or attributable.

NOTE Confidence: 0.898801785

00:32:34.590 --> 00:32:38.629 Among 17 patients that were newly diagnosed,

NOTE Confidence: 0.898801785

00:32:38.630 --> 00:32:41.174 and thus TP50 mutated,

NOTE Confidence: 0.898801785

00:32:41.174 --> 00:32:43.254 the median drop was just about

NOTE Confidence: 0.898801785

00:32:43.254 --> 00:32:44.460 1 gram per deciliter this after

NOTE Confidence: 0.552926056153846

00:32:44.507 --> 00:32:45.098 the first dose,

NOTE Confidence: 0.552926056153846

00:32:45.100 --> 00:32:47.095 and even lesser after the second dose.

NOTE Confidence: 0.552926056153846

00:32:47.100 --> 00:32:48.040 So with close monitoring,

NOTE Confidence: 0.552926056153846

00:32:48.040 --> 00:32:49.770 this anemia was manageable and the anemia,

NOTE Confidence: 0.552926056153846

00:32:49.770 --> 00:32:51.636 which just to give a refresher.

NOTE Confidence: 0.552926056153846

00:32:51.640 --> 00:32:53.740 There is some on target hemolytic anemia,

NOTE Confidence: 0.552926056153846

00:32:53.740 --> 00:32:56.120 just that you know was a bit

NOTE Confidence: 0.552926056153846

00:32:56.120 --> 00:32:58.119 troublesome early on in the trial,

NOTE Confidence: 0.552926056153846

00:32:58.120 --> 00:32:59.480 but appears to be manageable

NOTE Confidence: 0.552926056153846

00:32:59.480 --> 00:33:00.840 with you know no SAS,

NOTE Confidence: 0.552926056153846

00:33:00.840 --> 00:33:02.448 no interruptions or discontinuations

NOTE Confidence: 0.552926056153846

00:33:02.448 --> 00:33:04.458 due to this anemia specifically,

NOTE Confidence: 0.552926056153846

00:33:04.460 --> 00:33:06.302 so this is promising and position

NOTE Confidence: 0.552926056153846

00:33:06.302 --> 00:33:08.400 to possibly be a new standard.

NOTE Confidence: 0.552926056153846

00:33:08.400 --> 00:33:09.600 I mean maybe a little ambitious,

NOTE Confidence: 0.552926056153846

00:33:09.600 --> 00:33:11.292 but for frontline treatment

NOTE Confidence: 0.552926056153846

00:33:11.292 --> 00:33:12.972 both for TP 53 mutated disease

NOTE Confidence: 0.552926056153846

00:33:12.972 --> 00:33:14.012 and even wild type disease.

NOTE Confidence: 0.552926056153846

00:33:14.020 --> 00:33:15.958 But of course need more data

NOTE Confidence: 0.552926056153846

00:33:15.958 --> 00:33:18.588 and more follow up and of course

NOTE Confidence: 0.552926056153846

00:33:18.588 --> 00:33:20.688 randomized trials to confirm this

NOTE Confidence: 0.552926056153846

00:33:20.688 --> 00:33:22.839 added benefit they are underway.

NOTE Confidence: 0.552926056153846

00:33:22.840 --> 00:33:24.968 One last combination and this one is

NOTE Confidence: 0.552926056153846

00:33:24.968 --> 00:33:26.495 one that's restricted to patients

NOTE Confidence: 0.552926056153846

00:33:26.495 --> 00:33:28.163 with RIPS or factory disease and

NOTE Confidence: 0.552926056153846

00:33:28.163 --> 00:33:30.259 one that may have some promise for

NOTE Confidence: 0.552926056153846

00:33:30.259 --> 00:33:31.352 patients with molecular subgroups

NOTE Confidence: 0.552926056153846

00:33:31.352 --> 00:33:32.936 that of interest and maybe patients

NOTE Confidence: 0.552926056153846

00:33:32.936 --> 00:33:34.633 who have been failed by better clocks

NOTE Confidence: 0.552926056153846

00:33:34.633 --> 00:33:36.038 today to critical area of need

NOTE Confidence: 0.552926056153846

00:33:36.038 --> 00:33:37.340 after patients are failed by then,

NOTE Confidence: 0.552926056153846

00:33:37.340 --> 00:33:39.790 it's essentially.

NOTE Confidence: 0.552926056153846

00:33:39.790 --> 00:33:41.235 A black hole Blackstone ever

NOTE Confidence: 0.552926056153846

00:33:41.235 --> 00:33:42.680 metaphor you want to use.

NOTE Confidence: 0.552926056153846

00:33:42.680 --> 00:33:43.720 This is another combination

NOTE Confidence: 0.552926056153846

00:33:43.720 --> 00:33:45.020 that adds to as event,

NOTE Confidence: 0.552926056153846

00:33:45.020 --> 00:33:46.920 but for which there is

NOTE Confidence: 0.552926056153846

00:33:46.920 --> 00:33:48.060 sound clinical rationale.

NOTE Confidence: 0.552926056153846

00:33:48.060 --> 00:33:50.310 This is a therapy that targets CD 123,

NOTE Confidence: 0.552926056153846

00:33:50.310 --> 00:33:52.410 which is the alpha subunit of the

NOTE Confidence: 0.552926056153846

00:33:52.410 --> 00:33:54.902 aisle 3 receptor and is overexpressed

NOTE Confidence: 0.552926056153846

00:33:54.902 --> 00:33:57.033 on leukemic blasts Immunogen 632.

NOTE Confidence: 0.552926056153846

00:33:57.033 --> 00:33:59.994 It's a CD123 targeting ADC comprised of

NOTE Confidence: 0.552926056153846

00:33:59.994 --> 00:34:03.136 a high affinity anti CD 123 antibody

NOTE Confidence: 0.552926056153846

00:34:03.136 --> 00:34:08.078 coupled to a novel DNA alkylating payload.

NOTE Confidence: 0.552926056153846

00:34:08.080 --> 00:34:08.493 Goodsell,

NOTE Confidence: 0.552926056153846

00:34:08.493 --> 00:34:10.558 Linedata Goodyear in PDX modeling

NOTE Confidence: 0.552926056153846

00:34:10.558 --> 00:34:12.623 or experiments good synergy between

NOTE Confidence: 0.552926056153846

00:34:12.623 --> 00:34:14.717 Immunogen 632 in Asia and Dwarven,

NOTE Confidence: 0.552926056153846

00:34:14.720 --> 00:34:17.155 including being able to overcome

NOTE Confidence: 0.552926056153846

00:34:17.155 --> 00:34:18.616 a certain resistance.

NOTE Confidence: 0.552926056153846

00:34:18.620 --> 00:34:20.654 So For these reasons, this is a phase one.

NOTE Confidence: 0.552926056153846

00:34:20.660 --> 00:34:22.466 Two trial of that product combined with

NOTE Confidence: 0.552926056153846

00:34:22.466 --> 00:34:25.280 a 7 and patients with as you'd have guessed,

NOTE Confidence: 0.552926056153846

00:34:25.280 --> 00:34:28.822 CD one or three positive AML to date.

NOTE Confidence: 0.552926056153846

00:34:28.822 --> 00:34:30.226 The triple combo escalation

NOTE Confidence: 0.552926056153846

00:34:30.226 --> 00:34:32.200 is consists of five cohorts,

NOTE Confidence: 0.552926056153846

00:34:32.200 --> 00:34:34.475 4 with the investigational product

NOTE Confidence: 0.552926056153846

00:34:34.475 --> 00:34:36.776 dosed on day, seven of each cycle,

NOTE Confidence: 0.552926056153846

00:34:36.776 --> 00:34:38.180 and one cohort where it's dosed

NOTE Confidence: 0.552926056153846

00:34:38.225 --> 00:34:38.989 on the first day.

NOTE Confidence: 0.552926056153846

00:34:38.990 --> 00:34:40.341 Each cycle make it a bit more

NOTE Confidence: 0.552926056153846

00:34:40.341 --> 00:34:41.952 convenient for the patient at the

NOTE Confidence: 0.552926056153846

00:34:41.952 --> 00:34:43.707 time of this analysis presented.

NOTE Confidence: 0.552926056153846

00:34:43.710 --> 00:34:45.520 Obviously at the last meeting,

NOTE Confidence: 0.552926056153846

00:34:45.520 --> 00:34:47.670 35 patients have been enrolled

NOTE Confidence: 0.552926056153846

00:34:47.670 --> 00:34:48.955 based on characteristics are shown

NOTE Confidence: 0.552926056153846

00:34:48.955 --> 00:34:50.690 here in meeting age was about 65,

NOTE Confidence: 0.552926056153846

00:34:50.690 --> 00:34:52.380 so it was somewhat younger

NOTE Confidence: 0.552926056153846

00:34:52.380 --> 00:34:54.416 population with median 2 lines or

NOTE Confidence: 0.552926056153846

00:34:54.416 --> 00:34:55.846 prior therapy up to three,

NOTE Confidence: 0.552926056153846

00:34:55.850 --> 00:34:58.570 so not relatively terribly pretreated,

NOTE Confidence: 0.552926056153846

00:34:58.570 --> 00:35:00.454 but half of patients did receive

NOTE Confidence: 0.552926056153846

00:35:00.454 --> 00:35:02.129 prior medical acts important to know

NOTE Confidence: 0.552926056153846

00:35:02.130 --> 00:35:03.710 the talks profile was manageable,

NOTE Confidence: 0.552926056153846

00:35:03.710 --> 00:35:06.030 and this inherently goes factory

NOTE Confidence: 0.552926056153846

00:35:06.030 --> 00:35:07.422 population with multiplier

NOTE Confidence: 0.552926056153846

00:35:07.422 --> 00:35:09.650 therapies become an S were.

NOTE Confidence: 0.552926056153846

00:35:09.650 --> 00:35:10.970 Infusion related reactions.

NOTE Confidence: 0.552926056153846

00:35:10.970 --> 00:35:13.084 About 1/3 of patients with only two

NOTE Confidence: 0.552926056153846

00:35:13.084 --> 00:35:14.954 percent being grade 3 and otherwise

NOTE Confidence: 0.552926056153846

00:35:14.954 --> 00:35:17.400 things you would expect with a Savannah loan.

NOTE Confidence: 0.552926056153846

00:35:17.400 --> 00:35:20.676 One patient in the day one cohort

NOTE Confidence: 0.552926056153846

00:35:20.680 --> 00:35:22.696 had to discontinue because of an

NOTE Confidence: 0.552926056153846

00:35:22.696 --> 00:35:24.300 infusion reaction was considered DLT,

NOTE Confidence: 0.552926056153846

00:35:24.300 --> 00:35:27.150 but early mortality defined it at the

NOTE Confidence: 0.552926056153846

00:35:27.150 --> 00:35:28.709 bottom here 30 days with zero percent.

NOTE Confidence: 0.552926056153846

00:35:28.710 --> 00:35:32.777 So my last slide among the 29

NOTE Confidence: 0.552926056153846

00:35:32.777 --> 00:35:34.910 percent 29 patients who are valuable

NOTE Confidence: 0.552926056153846

00:35:34.910 --> 00:35:36.460 efficacy was seen across kind

NOTE Confidence: 0.699811161538462

00:35:36.517 --> 00:35:38.544 of all cohorts, doses and schedules.

NOTE Confidence: 0.699811161538462

00:35:38.544 --> 00:35:40.583 The response rate was 55%.

NOTE Confidence: 0.699811161538462

00:35:40.583 --> 00:35:43.404 And looking at the composite remission rate,

NOTE Confidence: 0.699811161538462

00:35:43.410 --> 00:35:44.910 it's about 30%, you know,

NOTE Confidence: 0.699811161538462

00:35:44.910 --> 00:35:48.200 with maybe higher rates in the higher

NOTE Confidence: 0.699811161538462

00:35:48.200 --> 00:35:50.594 dose cohorts of no patients prior

NOTE Confidence: 0.699811161538462

00:35:50.594 --> 00:35:52.992 van had good Angeliki make activity

NOTE Confidence: 0.699811161538462

00:35:52.992 --> 00:35:55.626 as seen here on the right, waterfall

NOTE Confidence: 0.699811161538462

00:35:55.626 --> 00:35:58.818 plot and overall response rate of 40%.

NOTE Confidence: 0.699811161538462

00:35:58.820 --> 00:36:00.252 Other subsets of note

NOTE Confidence: 0.699811161538462

00:36:00.252 --> 00:36:01.326 flipper mutated disease.

NOTE Confidence: 0.699811161538462

00:36:01.330 --> 00:36:01.951 Even more striking.

NOTE Confidence: 0.699811161538462

00:36:01.951 --> 00:36:02.986 I'll be at 9 patients,

NOTE Confidence: 0.699811161538462

00:36:02.990 --> 00:36:04.886 but 80% rate of composite emission.

NOTE Confidence: 0.699811161538462

00:36:04.890 --> 00:36:07.256 So in some encouraging in some molecular

NOTE Confidence: 0.699811161538462

00:36:07.256 --> 00:36:09.339 subsets and then treated patients,

NOTE Confidence: 0.699811161538462

00:36:09.340 --> 00:36:09.968 but certainly.

NOTE Confidence: 0.699811161538462

00:36:09.968 --> 00:36:11.852 Like the other studies I presented

NOTE Confidence: 0.699811161538462

00:36:11.852 --> 00:36:13.665 more data to assure these values

NOTE Confidence: 0.699811161538462

00:36:13.665 --> 00:36:15.357 don't regress to the mean like

NOTE Confidence: 0.699811161538462

00:36:15.415 --> 00:36:17.600 unfortunately many other similar studies.

NOTE Confidence: 0.699811161538462

00:36:17.600 --> 00:36:18.480 That's my last slide.

NOTE Confidence: 0.699811161538462

00:36:18.480 --> 00:36:19.800 There are a few more presentations

NOTE Confidence: 0.699811161538462

00:36:19.844 --> 00:36:21.380 from match that I wish I could discuss,

NOTE Confidence: 0.699811161538462

00:36:21.380 --> 00:36:22.832 but last only 15 minutes and

NOTE Confidence: 0.699811161538462

00:36:22.832 --> 00:36:24.539 I'm sure I'm over that already,

NOTE Confidence: 0.699811161538462

00:36:24.540 --> 00:36:27.277 so I apologize to Doctor Podolsky and

NOTE Confidence: 0.699811161538462

00:36:27.280 --> 00:36:28.464 look forward to your questions at the end.

NOTE Confidence: 0.835940033333333

00:36:31.910 --> 00:36:33.680 Can you unshare? Sure can.

NOTE Confidence: 0.6455393

00:36:34.800 --> 00:36:40.340 Go. Still cannot share the screen.

NOTE Confidence: 0.6455393

00:36:40.340 --> 00:36:43.362 Right here we go. Thank you alright,

NOTE Confidence: 0.6455393

00:36:43.362 --> 00:36:46.176 so let me find my presentation here.

NOTE Confidence: 0.603578516

00:36:53.310 --> 00:36:55.470 Sorry about this technical difficulty.

NOTE Confidence: 0.77977299375

00:37:17.160 --> 00:37:20.168 Here we go. Alright, here's my view OK?

NOTE Confidence: 0.959218

00:37:23.950 --> 00:37:26.514 Yes, OK, so this is my disclosures,

NOTE Confidence: 0.959218

00:37:26.514 --> 00:37:29.070 so I'm going to go onto the outline.

NOTE Confidence: 0.959218

00:37:29.070 --> 00:37:31.590 So I'm going to present four studies

NOTE Confidence: 0.959218

00:37:31.590 --> 00:37:36.279 which I selected based on disease.

NOTE Confidence: 0.959218

00:37:36.280 --> 00:37:38.476 Talk about devera,

NOTE Confidence: 0.959218

00:37:38.476 --> 00:37:40.826 myelofibrosis and one other

NOTE Confidence: 0.959218

00:37:40.826 --> 00:37:42.598 condition which is infrequent.

NOTE Confidence: 0.959218

00:37:42.600 --> 00:37:45.185 Myeloid lymphoid neoplasm is in

NOTE Confidence: 0.959218

00:37:45.185 --> 00:37:47.627 Affilia and FGFR 1 rearrangement,

NOTE Confidence: 0.959218

00:37:47.627 --> 00:37:51.400 so the first study I would like to

NOTE Confidence: 0.959218

00:37:51.400 --> 00:37:54.186 talk about is the study which is.

NOTE Confidence: 0.959218

00:37:54.190 --> 00:37:58.720 Lookout Trust restaurant type or PTG 300

NOTE Confidence: 0.959218

00:37:58.720 --> 00:38:01.485 and its control of human grade levels

NOTE Confidence: 0.959218

00:38:01.485 --> 00:38:04.597 in patients with polycythemia Vera.

NOTE Confidence: 0.959218

00:38:04.600 --> 00:38:08.884 So the rationale for the study is.

NOTE Confidence: 0.959218

00:38:08.890 --> 00:38:12.509 Which is looking at Hillside and medic.

NOTE Confidence: 0.959218

00:38:12.510 --> 00:38:16.662 Right is the fact that in patients with

NOTE Confidence: 0.959218

00:38:16.662 --> 00:38:18.510 polycythemia Vera iron is necessary

NOTE Confidence: 0.959218

00:38:18.510 --> 00:38:20.850 to make red blood cells in the marrow,

NOTE Confidence: 0.959218

00:38:20.850 --> 00:38:22.180 which is affected by Jack.

NOTE Confidence: 0.959218

00:38:22.180 --> 00:38:25.700 Two V 617 FM PM.

NOTE Confidence: 0.959218

00:38:25.700 --> 00:38:27.710 So as you can see on the left,

NOTE Confidence: 0.959218

00:38:27.710 --> 00:38:30.420 ferroportin is the main transporter

NOTE Confidence: 0.959218

00:38:30.420 --> 00:38:33.130 of the iron from outside,

NOTE Confidence: 0.959218

00:38:33.130 --> 00:38:35.476 from inside the macrophage to the

NOTE Confidence: 0.959218

00:38:35.476 --> 00:38:37.324 circulation and then delivered by

NOTE Confidence: 0.959218

00:38:37.324 --> 00:38:39.009 transparent to the bone marrow

NOTE Confidence: 0.959218

00:38:39.009 --> 00:38:40.958 which is utilized to make excessive

NOTE Confidence: 0.959218

00:38:40.958 --> 00:38:43.009 amounts of red blood cells by Jack.

NOTE Confidence: 0.959218

00:38:43.010 --> 00:38:45.980 2 mutated. Red blood cell precursors.

NOTE Confidence: 0.959218

00:38:45.980 --> 00:38:49.286 So the hepcidin as well as

NOTE Confidence: 0.959218

00:38:49.286 --> 00:38:51.490 restricted which is hepcidin.

NOTE Confidence: 0.959218

00:38:51.490 --> 00:38:54.484 Medical shut down the gates ferroportin

NOTE Confidence: 0.959218

00:38:54.484 --> 00:38:57.519 and decreases the amount of iron

NOTE Confidence: 0.959218

00:38:57.519 --> 00:38:59.904 which is available for transparent

NOTE Confidence: 0.959218

00:38:59.904 --> 00:39:01.996 to transport to the bone marrow

NOTE Confidence: 0.959218

00:39:01.996 --> 00:39:04.070 so it's kind of shutting down the

NOTE Confidence: 0.959218

00:39:04.070 --> 00:39:05.900 door but perhaps not the window.

NOTE Confidence: 0.959218

00:39:05.900 --> 00:39:08.259 A little bit of line is available

NOTE Confidence: 0.959218

00:39:08.259 --> 00:39:10.623 and the idea is that there is no

NOTE Confidence: 0.959218

00:39:10.623 --> 00:39:12.469 iron deficiency state which is

NOTE Confidence: 0.959218

00:39:12.469 --> 00:39:14.297 otherwise created by phlebotomies

NOTE Confidence: 0.959218

00:39:14.297 --> 00:39:15.668 by therapeutic phlebotomies.

NOTE Confidence: 0.959218

00:39:15.670 --> 00:39:17.770 Leading to decreased quality of life of

NOTE Confidence: 0.959218

00:39:17.770 --> 00:39:20.040 this patients due to tissue and efficiency.

NOTE Confidence: 0.959218

00:39:20.040 --> 00:39:23.352 So this is a phase two trial over spare

NOTE Confidence: 0.959218

00:39:23.352 --> 00:39:26.577 type in patients requiring phlebotomy.

NOTE Confidence: 0.959218

00:39:26.580 --> 00:39:28.605 Patients with PD diagnosis based

NOTE Confidence: 0.959218

00:39:28.605 --> 00:39:31.360 on 2016 W criteria were included.

NOTE Confidence: 0.959218

00:39:31.360 --> 00:39:33.532 At least three phlebotomies in the

NOTE Confidence: 0.959218

00:39:33.532 --> 00:39:35.490 last six months were necessary.

NOTE Confidence: 0.959218

00:39:35.490 --> 00:39:38.535 Patients were treated with or without sector.

NOTE Confidence: 0.959218

00:39:38.540 --> 00:39:40.108 Reductive therapy and therapy,

NOTE Confidence: 0.959218

00:39:40.108 --> 00:39:42.935 so the primary endpoint was proportion of

NOTE Confidence: 0.959218

00:39:42.935 --> 00:39:45.015 patients in randomized withdrawal period.

NOTE Confidence: 0.959218

00:39:45.020 --> 00:39:46.490 Who schematic rate is maintained.

NOTE Confidence: 0.959218

00:39:46.490 --> 00:39:48.770 Without the need for phlebotomy,

NOTE Confidence: 0.959218

00:39:48.770 --> 00:39:50.905 the secondary endpoints is the

NOTE Confidence: 0.959218

00:39:50.905 --> 00:39:52.613 response of 29 weeks.

NOTE Confidence: 0.959218

00:39:52.620 --> 00:39:53.716 Absence of liberty eligibility,

NOTE Confidence: 0.959218

00:39:53.716 --> 00:39:55.360 and that's what I'm going to

NOTE Confidence: 0.959218

00:39:55.412 --> 00:39:56.189 talk about today,

NOTE Confidence: 0.959218

00:39:56.190 --> 00:39:58.326 as well as total symptom score

NOTE Confidence: 0.959218

00:39:58.330 --> 00:40:00.870 for those patients who are

NOTE Confidence: 0.959218

00:40:00.870 --> 00:40:02.902 receiving treatment register type.

NOTE Confidence: 0.959218

00:40:02.910 --> 00:40:05.129 The idea is that symptoms will get

NOTE Confidence: 0.959218

00:40:05.129 --> 00:40:07.065 better while they're receiving this

NOTE Confidence: 0.959218

00:40:07.065 --> 00:40:09.133 treatment because planning deficiency state,

NOTE Confidence: 0.959218

00:40:09.133 --> 00:40:11.419 which is otherwise present in patients

NOTE Confidence: 0.959218

00:40:11.419 --> 00:40:13.430 treated with therapeutic phlebotomies,

NOTE Confidence: 0.959218

00:40:13.430 --> 00:40:15.344 will be gone,

NOTE Confidence: 0.959218

00:40:15.344 --> 00:40:17.258 so the study.

NOTE Confidence: 0.959218

00:40:17.260 --> 00:40:18.568 As the three parts,

NOTE Confidence: 0.959218

00:40:18.568 --> 00:40:20.530 the first one is those findings

NOTE Confidence: 0.959218

00:40:20.600 --> 00:40:21.820 part that 28 weeks,

NOTE Confidence: 0.959218

00:40:21.820 --> 00:40:23.812 then there is blinded withdrawal and

NOTE Confidence: 0.959218

00:40:23.812 --> 00:40:26.019 then open label part is part three,

NOTE Confidence: 0.959218

00:40:26.020 --> 00:40:29.020 so we're talking about 63 patients

NOTE Confidence: 0.959218

00:40:29.020 --> 00:40:30.510 currently enrolled enrollment

NOTE Confidence: 0.959218

00:40:30.510 --> 00:40:33.353 between October 2019 and May 2021,

NOTE Confidence: 0.959218

00:40:33.353 --> 00:40:36.104 and patients were treated up to 18

NOTE Confidence: 0.959218

00:40:36.104 --> 00:40:38.259 months between 8:00 and 92 weeks.

NOTE Confidence: 0.959218

00:40:38.260 --> 00:40:41.811 So you can see here that initial

NOTE Confidence: 0.959218

00:40:41.811 --> 00:40:44.866 period is describing six months

NOTE Confidence: 0.959218

00:40:44.866 --> 00:40:47.286 preceding the first dose of the drug.

NOTE Confidence: 0.959218

00:40:47.290 --> 00:40:47.599 Yeah,

NOTE Confidence: 0.959218

00:40:47.599 --> 00:40:49.144 and patients are getting phlebotomy

NOTE Confidence: 0.959218

00:40:49.144 --> 00:40:51.901 is that by you can see this by red

NOTE Confidence: 0.959218

00:40:51.901 --> 00:40:53.361 triangles right after those there

NOTE Confidence: 0.7634323625

00:40:53.370 --> 00:40:55.940 are very few red triangles,

NOTE Confidence: 0.7634323625

00:40:55.940 --> 00:40:57.363 so this is going to be for optimization.

NOTE Confidence: 0.7634323625

00:40:57.363 --> 00:40:58.928 That's what we looking for.

NOTE Confidence: 0.78128789

00:41:01.360 --> 00:41:04.728 84% of patients did not require 14%

NOTE Confidence: 0.78128789

00:41:04.728 --> 00:41:07.876 required one and only 2% required 2

NOTE Confidence: 0.78128789

00:41:07.876 --> 00:41:11.950 phlebotomists so very significant we self

NOTE Confidence: 0.78128789

00:41:11.950 --> 00:41:14.426 eliminating phlebotomies in almost all

NOTE Confidence: 0.78128789

00:41:14.426 --> 00:41:17.840 of the patients within the 1st 28 weeks.

NOTE Confidence: 0.78128789

00:41:17.840 --> 00:41:20.052 Treatment, so this was actually true for

NOTE Confidence: 0.78128789

00:41:20.052 --> 00:41:22.252 both patients who received such a reductive

NOTE Confidence: 0.78128789

00:41:22.252 --> 00:41:24.380 therapy and who didn't on the left.

NOTE Confidence: 0.78128789

00:41:24.380 --> 00:41:26.702 31 patients who didn't require center

NOTE Confidence: 0.78128789

00:41:26.702 --> 00:41:29.170 adaptive therapy on the right 30 put

NOTE Confidence: 0.78128789

00:41:29.170 --> 00:41:32.010 in two patients who did so from the

NOTE Confidence: 0.78128789

00:41:32.010 --> 00:41:36.199 standpoint of assessment of symptoms.

NOTE Confidence: 0.78128789

00:41:36.200 --> 00:41:38.594 Scoring system was used weekly and

NOTE Confidence: 0.78128789

00:41:38.594 --> 00:41:41.899 you can see on the left at baseline

NOTE Confidence: 0.78128789

00:41:41.900 --> 00:41:44.742 the score as well as the score

NOTE Confidence: 0.78128789

00:41:44.742 --> 00:41:46.846 after 2020 weeks of therapy.

NOTE Confidence: 0.78128789

00:41:46.846 --> 00:41:49.390 So there is significant reduction of

NOTE Confidence: 0.78128789

00:41:49.471 --> 00:41:52.117 treatment out of symptoms with this

NOTE Confidence: 0.78128789

00:41:52.117 --> 00:41:54.548 treatment and specifically 1/3 of patients

NOTE Confidence: 0.78128789

00:41:54.548 --> 00:41:57.094 reported at least 40% reduction of

NOTE Confidence: 0.78128789

00:41:57.094 --> 00:42:01.186 symptoms based on MPN soft TSS at 28 weeks.

NOTE Confidence: 0.78128789

00:42:01.186 --> 00:42:04.139 So it is the drug is effective at the

NOTE Confidence: 0.78128789

00:42:04.139 --> 00:42:06.429 eliminating the need of phlebotomy.

NOTE Confidence: 0.78128789

00:42:06.430 --> 00:42:08.842 This is a continuous injection which

NOTE Confidence: 0.78128789

00:42:08.842 --> 00:42:10.970 patients self inject once a week.

NOTE Confidence: 0.78128789

00:42:10.970 --> 00:42:13.232 So from the standpoint Bruce of

NOTE Confidence: 0.78128789

00:42:13.232 --> 00:42:14.363 X to summarize,

NOTE Confidence: 0.78128789

00:42:14.370 --> 00:42:17.425 basically the main side effect

NOTE Confidence: 0.78128789

00:42:17.425 --> 00:42:19.258 was injection reaction.

NOTE Confidence: 0.78128789

00:42:19.260 --> 00:42:22.172 20% of patients and it was transient

NOTE Confidence: 0.78128789

00:42:22.172 --> 00:42:25.589 and did not require discontinuation.

NOTE Confidence: 0.78128789

00:42:25.590 --> 00:42:26.476 In summary,

NOTE Confidence: 0.78128789

00:42:26.476 --> 00:42:31.722 research type war that PTG 300 is hepcidin,

NOTE Confidence: 0.78128789

00:42:31.722 --> 00:42:33.482 mimetic subcutaneously injected

NOTE Confidence: 0.78128789

00:42:33.482 --> 00:42:34.820 for PV patients,

NOTE Confidence: 0.78128789

00:42:34.820 --> 00:42:38.024 leading to elimination of therapeutic

NOTE Confidence: 0.78128789

00:42:38.024 --> 00:42:40.652 phlebotomy needs of majority of patients

NOTE Confidence: 0.78128789

00:42:40.652 --> 00:42:42.929 within the 1st 28 weeks of treatment.

NOTE Confidence: 0.78128789

00:42:42.930 --> 00:42:43.417 Also,

NOTE Confidence: 0.78128789

00:42:43.417 --> 00:42:44.878 reversing iron deficiency,

NOTE Confidence: 0.78128789

00:42:44.878 --> 00:42:47.800 which was evident by increasing MCV

NOTE Confidence: 0.78128789

00:42:47.873 --> 00:42:50.905 MHC and 13 of those patients that was

NOTE Confidence: 0.78128789

00:42:50.905 --> 00:42:53.390 positive impact on PV related symptoms,

NOTE Confidence: 0.78128789

00:42:53.390 --> 00:42:56.048 perhaps because of.

NOTE Confidence: 0.78128789

00:42:56.050 --> 00:42:58.240 Negating some of the iron deficiency

NOTE Confidence: 0.78128789

00:42:58.240 --> 00:42:59.700 related to therapeutic phlebotomies,

NOTE Confidence: 0.78128789

00:42:59.700 --> 00:43:02.598 it was safe and well tolerated without

NOTE Confidence: 0.78128789

00:43:02.598 --> 00:43:05.360 grade 3-4 adverse events and we are

NOTE Confidence: 0.78128789

00:43:05.360 --> 00:43:07.818 planning to open phase three randomized

NOTE Confidence: 0.78128789

00:43:07.818 --> 00:43:11.003 control study at Yale for this patients.

NOTE Confidence: 0.78128789

00:43:11.010 --> 00:43:13.846 So the second study is for my

NOTE Confidence: 0.78128789

00:43:13.846 --> 00:43:15.906 love fibrosis patients and it's

NOTE Confidence: 0.78128789

00:43:15.906 --> 00:43:17.578 gone collaborative wanna therapy

NOTE Confidence: 0.78128789

00:43:17.578 --> 00:43:19.250 for patients with myelofibrosis?

NOTE Confidence: 0.78128789

00:43:19.250 --> 00:43:22.148 This is update of ongoing study.

NOTE Confidence: 0.78128789

00:43:22.150 --> 00:43:26.975 I presented this study last year so

NOTE Confidence: 0.78128789

00:43:26.975 --> 00:43:30.095 it uses it utilizes this knowledge

NOTE Confidence: 0.78128789

00:43:30.095 --> 00:43:33.630 that promo domain and extra terminal

NOTE Confidence: 0.78128789

00:43:33.630 --> 00:43:36.650 domain proteins promote myelofibrosis.

NOTE Confidence: 0.78128789

00:43:36.650 --> 00:43:39.569 You can see the activation of NF

NOTE Confidence: 0.78128789

00:43:39.569 --> 00:43:42.558 Kappa B targeted genes leading to

NOTE Confidence: 0.78128789

00:43:42.558 --> 00:43:44.169 increased inflammatory response.

NOTE Confidence: 0.78128789

00:43:44.170 --> 00:43:44.675 Aberrant,

NOTE Confidence: 0.78128789

00:43:44.675 --> 00:43:46.695 or through a differentiation

NOTE Confidence: 0.78128789

00:43:46.695 --> 00:43:48.210 and aberrant megakaryocytic

NOTE Confidence: 0.78128789

00:43:48.210 --> 00:43:49.251 differentiation manifestations.

NOTE Confidence: 0.78128789

00:43:49.251 --> 00:43:51.906 So far my love fibrosis,

NOTE Confidence: 0.78128789

00:43:51.910 --> 00:43:54.250 inflammatory response causes systemic

NOTE Confidence: 0.78128789

00:43:54.250 --> 00:43:56.945 symptoms as well as cytopenias,

NOTE Confidence: 0.78128789

00:43:56.945 --> 00:43:58.720 including an email from both.

NOTE Confidence: 0.78128789

00:43:58.720 --> 00:44:00.656 Cytopenia conceit can be seen in my life.

NOTE Confidence: 0.78128789

00:44:00.660 --> 00:44:02.432 I prove this difference,

NOTE Confidence: 0.78128789

00:44:02.432 --> 00:44:04.660 so collaboration is the subject of

NOTE Confidence: 0.78128789

00:44:04.660 --> 00:44:07.450 this study, also known as CPI 0610,

NOTE Confidence: 0.78128789

00:44:07.450 --> 00:44:10.498 which is a first in class selective oral,

NOTE Confidence: 0.78128789

00:44:10.500 --> 00:44:12.135 small local inhibitor,

NOTE Confidence: 0.78128789

00:44:12.135 --> 00:44:13.770 bit bad proteins.

NOTE Confidence: 0.78128789

00:44:13.770 --> 00:44:15.966 Got it modifies the expression of

NOTE Confidence: 0.78128789

00:44:15.966 --> 00:44:19.218 genes and Bolton Kappa B signaling.

NOTE Confidence: 0.78128789

00:44:19.218 --> 00:44:21.314 Decreasing the cytokines.

NOTE Confidence: 0.78128789

00:44:21.314 --> 00:44:23.306 Also promoting erythrocyte

NOTE Confidence: 0.78128789

00:44:23.306 --> 00:44:25.298 differentiation and normalizing

NOTE Confidence: 0.78128789

00:44:25.298 --> 00:44:26.626 megakaryocytic differentiation.

NOTE Confidence: 0.78128789

00:44:26.630 --> 00:44:30.039 So that's the background for this study.

NOTE Confidence: 0.78128789

00:44:30.040 --> 00:44:31.830 The study is currently ongoing.

NOTE Confidence: 0.78128789

00:44:31.830 --> 00:44:33.048 It's manifest trial,

NOTE Confidence: 0.78128789

00:44:33.048 --> 00:44:36.430 global study and at this pace to trial.

NOTE Confidence: 0.78128789

00:44:36.430 --> 00:44:39.850 So there are three arms and the arm.

NOTE Confidence: 0.78128789

00:44:39.850 --> 00:44:42.734 I'm going to focus on this

NOTE Confidence: 0.78128789

00:44:42.734 --> 00:44:44.350 patients who are receiving.

NOTE Confidence: 0.78128789

00:44:44.350 --> 00:44:45.934 A collaborative and second

NOTE Confidence: 0.78128789

00:44:45.934 --> 00:44:47.914 line so they were previously

NOTE Confidence: 0.78128789

00:44:47.914 --> 00:44:49.567 treated with rock solid nib

NOTE Confidence: 0.844425436363636

00:44:49.570 --> 00:44:52.122 or were not able to take Luke Slim

NOTE Confidence: 0.844425436363636

00:44:52.122 --> 00:44:54.434 for some reason so the dosing is

NOTE Confidence: 0.844425436363636

00:44:54.434 --> 00:44:56.841 it's an oral drug so this is given

NOTE Confidence: 0.844425436363636

00:44:56.841 --> 00:44:59.297 to its one one week off schedule and

NOTE Confidence: 0.844425436363636

00:44:59.368 --> 00:45:01.685 there are two cohorts in this arm.

NOTE Confidence: 0.844425436363636

00:45:01.690 --> 00:45:03.190 One part of the study,

NOTE Confidence: 0.844425436363636

00:45:03.190 --> 00:45:05.549 one of them is transfusion dependent cohort,

NOTE Confidence: 0.844425436363636

00:45:05.550 --> 00:45:08.378 36 out of 60 patients accrued and

NOTE Confidence: 0.844425436363636

00:45:08.378 --> 00:45:10.374 there's ongoing enrollment and the

NOTE Confidence: 0.844425436363636

00:45:10.374 --> 00:45:12.498 2nd cohort cohort one be finished.

NOTE Confidence: 0.844425436363636

00:45:12.500 --> 00:45:14.980 Enrollment 50 patients. So the.

NOTE Confidence: 0.844425436363636

00:45:14.980 --> 00:45:16.472 Primary endpoint for transfusion

NOTE Confidence: 0.844425436363636

00:45:16.472 --> 00:45:18.337 Dependent Court court is transfusion,

NOTE Confidence: 0.844425436363636

00:45:18.340 --> 00:45:21.917 independence for patients and one cohort 1B.

NOTE Confidence: 0.844425436363636

00:45:21.920 --> 00:45:25.820 It's it's splenic volume response,

NOTE Confidence: 0.844425436363636

00:45:25.820 --> 00:45:27.476 35% reduction spleen volume.

NOTE Confidence: 0.844425436363636

00:45:27.476 --> 00:45:29.546 So the patients were enrolled

NOTE Confidence: 0.844425436363636

00:45:29.546 --> 00:45:31.799 were either Ching knowledgeable,

NOTE Confidence: 0.844425436363636

00:45:31.800 --> 00:45:32.667 jacked to intolerant,

NOTE Confidence: 0.844425436363636

00:45:32.667 --> 00:45:34.401 and the biggest group is jacked

NOTE Confidence: 0.844425436363636

00:45:34.401 --> 00:45:36.299 to refractory resistant patients.

NOTE Confidence: 0.844425436363636

00:45:36.300 --> 00:45:38.722 56% this is a group of patients

NOTE Confidence: 0.844425436363636

00:45:38.722 --> 00:45:39.760 with poor outcomes.

NOTE Confidence: 0.844425436363636

00:45:39.760 --> 00:45:42.280 Median survival is about 14 months,

NOTE Confidence: 0.844425436363636

00:45:42.280 --> 00:45:45.976 so the SDR 35 response at week 20.

NOTE Confidence: 0.844425436363636

00:45:45.980 --> 00:45:48.038 War was a primary endpoint for

NOTE Confidence: 0.844425436363636

00:45:48.038 --> 00:45:50.363 group 1D which is non transfusion

NOTE Confidence: 0.844425436363636

00:45:50.363 --> 00:45:52.944 dependent cohort and it was 18%.

NOTE Confidence: 0.844425436363636

00:45:52.944 --> 00:45:54.864 Most of the patients had

NOTE Confidence: 0.844425436363636

00:45:54.864 --> 00:45:56.016 some splenic response,

NOTE Confidence: 0.844425436363636

00:45:56.020 --> 00:45:58.810 18% had reduction by 35%.

NOTE Confidence: 0.844425436363636

00:45:58.810 --> 00:46:04.659 So the symptom reduction by 50% at

NOTE Confidence: 0.844425436363636

00:46:04.659 --> 00:46:07.291 the end of the 24 week period was

NOTE Confidence: 0.844425436363636

00:46:07.291 --> 00:46:09.504 observed in 20% among all study

NOTE Confidence: 0.844425436363636

00:46:09.504 --> 00:46:11.168 participants transfusion dependent and

NOTE Confidence: 0.844425436363636

00:46:11.168 --> 00:46:13.349 not transfusion dependent participants.

NOTE Confidence: 0.844425436363636

00:46:13.350 --> 00:46:16.602 Finally the group 1B.

NOTE Confidence: 0.844425436363636

00:46:16.602 --> 00:46:19.238 Primary endpoint the transfusion

NOTE Confidence: 0.844425436363636

00:46:19.238 --> 00:46:21.254 dependence converting to transfusion

NOTE Confidence: 0.844425436363636

00:46:21.254 --> 00:46:23.564 independence occurred in 16% of

NOTE Confidence: 0.844425436363636

00:46:23.564 --> 00:46:25.549 patients overall in the whole

NOTE Confidence: 0.844425436363636

00:46:25.549 --> 00:46:27.398 population there was observed

NOTE Confidence: 0.844425436363636

00:46:27.398 --> 00:46:29.738 improvement in hemoglobin levels.

NOTE Confidence: 0.844425436363636

00:46:29.740 --> 00:46:31.756 As you can see on the right hand side

NOTE Confidence: 0.844425436363636

00:46:31.756 --> 00:46:34.169 and among transfusion independent patients,

NOTE Confidence: 0.844425436363636

00:46:34.170 --> 00:46:36.170 38% had improved hemoglobin

NOTE Confidence: 0.844425436363636

00:46:36.170 --> 00:46:38.530 level by 1.5 grams per deciliter.

NOTE Confidence: 0.844425436363636

00:46:38.530 --> 00:46:41.754 At the end of the 2424 week period.

NOTE Confidence: 0.844425436363636

00:46:41.754 --> 00:46:44.365 So there are some exploratory

NOTE Confidence: 0.844425436363636

00:46:44.365 --> 00:46:46.090 endpoints including evolutional.

NOTE Confidence: 0.844425436363636

00:46:46.090 --> 00:46:48.390 Fibrosis in the marrow,

NOTE Confidence: 0.844425436363636

00:46:48.390 --> 00:46:50.995 and about quarter of patients

NOTE Confidence: 0.844425436363636

00:46:50.995 --> 00:46:52.037 had improvement,

NOTE Confidence: 0.844425436363636

00:46:52.040 --> 00:46:54.250 including about 6.7% of patients

NOTE Confidence: 0.844425436363636

00:46:54.250 --> 00:46:56.904 who had improvement by two grades

NOTE Confidence: 0.844425436363636

00:46:56.904 --> 00:46:59.088 of Milo fibrosis in the .0.

NOTE Confidence: 0.844425436363636

00:46:59.090 --> 00:47:01.078 Improvement in fibrosis correlated

NOTE Confidence: 0.844425436363636

00:47:01.078 --> 00:47:03.563 with improvement in hemoglobin levels,

NOTE Confidence: 0.844425436363636

00:47:03.570 --> 00:47:06.336 so the side effects are summarized

NOTE Confidence: 0.844425436363636

00:47:06.336 --> 00:47:07.719 on this slide.

NOTE Confidence: 0.844425436363636

00:47:07.720 --> 00:47:09.850 For the sake of time,

NOTE Confidence: 0.844425436363636

00:47:09.850 --> 00:47:12.406 19% of patients reported adverse events

NOTE Confidence: 0.844425436363636

00:47:12.406 --> 00:47:15.230 which led 2 collaborative discontinuation.

NOTE Confidence: 0.844425436363636

00:47:15.230 --> 00:47:17.519 Most of the side effects were great.

NOTE Confidence: 0.844425436363636

00:47:17.520 --> 00:47:19.029 One and two.

NOTE Confidence: 0.844425436363636

00:47:19.029 --> 00:47:20.538 So, in conclusion,

NOTE Confidence: 0.844425436363636

00:47:20.540 --> 00:47:23.666 this is manifest on one looking

NOTE Confidence: 0.844425436363636

00:47:23.666 --> 00:47:26.196 at 64 patients planned enrollment,

NOTE Confidence: 0.844425436363636

00:47:26.200 --> 00:47:27.036 110 patients,

NOTE Confidence: 0.844425436363636

00:47:27.036 --> 00:47:29.544 there was a decent reduction of

NOTE Confidence: 0.844425436363636

00:47:29.544 --> 00:47:32.432 the spleen volume among transfusion

NOTE Confidence: 0.844425436363636

00:47:32.432 --> 00:47:33.746 dependent patients,

NOTE Confidence: 0.844425436363636

00:47:33.750 --> 00:47:36.319 and there was an improvement in hemoglobin,

NOTE Confidence: 0.844425436363636

00:47:36.320 --> 00:47:38.375 including among patients who are

NOTE Confidence: 0.844425436363636

00:47:38.375 --> 00:47:40.912 transfusion dependent and the 16% of

NOTE Confidence: 0.844425436363636

00:47:40.912 --> 00:47:42.696 them became transfusion independent.

NOTE Confidence: 0.844425436363636

00:47:42.700 --> 00:47:43.985 Marrow fibrosis and I didn't

NOTE Confidence: 0.844425436363636

00:47:43.985 --> 00:47:44.756 present this data.

NOTE Confidence: 0.844425436363636

00:47:44.760 --> 00:47:47.340 Plasma cytokines decrease suggested

NOTE Confidence: 0.844425436363636

00:47:47.340 --> 00:47:51.560 potential disease modification by

NOTE Confidence: 0.844425436363636

00:47:51.560 --> 00:47:53.780 majority of the most common treatment.

NOTE Confidence: 0.844425436363636

00:47:53.780 --> 00:47:55.850 Emergent adverse events were low grade

NOTE Confidence: 0.844425436363636

00:47:55.850 --> 00:47:58.453 and we are planning to participate in

NOTE Confidence: 0.844425436363636

00:47:58.453 --> 00:48:00.944 manifest 2 study randomized phase.

NOTE Confidence: 0.844425436363636

00:48:00.944 --> 00:48:01.996 Three study,

NOTE Confidence: 0.844425436363636

00:48:02.000 --> 00:48:03.590 double blinded between

NOTE Confidence: 0.553255013571428

00:48:05.840 --> 00:48:07.933 CPI 0610 and looks lit new versus

NOTE Confidence: 0.553255013571428

00:48:07.933 --> 00:48:09.827 placebo and looks lit nip at Yale.

NOTE Confidence: 0.553255013571428

00:48:09.830 --> 00:48:13.410 So the next step is and this is

NOTE Confidence: 0.553255013571428

00:48:13.410 --> 00:48:16.169 about the symbol of the drug which

NOTE Confidence: 0.553255013571428

00:48:16.169 --> 00:48:18.478 was recently approved for patients

NOTE Confidence: 0.553255013571428

00:48:18.478 --> 00:48:21.306 with CML as a third line treatment.

NOTE Confidence: 0.553255013571428

00:48:21.310 --> 00:48:24.495 People who were enrolled in the study

NOTE Confidence: 0.553255013571428

00:48:24.500 --> 00:48:27.923 received at least two TCR's and the

NOTE Confidence: 0.553255013571428

00:48:27.923 --> 00:48:30.865 presentation I'm focusing on today is

NOTE Confidence: 0.553255013571428

00:48:30.865 --> 00:48:33.643 update of what was previously presented.

NOTE Confidence: 0.553255013571428

00:48:33.650 --> 00:48:37.551 So this is the drug which is in

NOTE Confidence: 0.553255013571428

00:48:37.551 --> 00:48:40.848 which hits BCR ABL on core protein.

NOTE Confidence: 0.553255013571428

00:48:40.850 --> 00:48:42.719 Activity specifically targeting

NOTE Confidence: 0.553255013571428

00:48:42.719 --> 00:48:44.588 able marstall pocket.

NOTE Confidence: 0.553255013571428

00:48:44.590 --> 00:48:47.718 It's a different way of inhibiting BCR ABL,

NOTE Confidence: 0.553255013571428

00:48:47.720 --> 00:48:49.600 as you can see, even with key for one point,

NOTE Confidence: 0.553255013571428

00:48:49.600 --> 00:48:50.264 9 mutation.

NOTE Confidence: 0.553255013571428

00:48:50.264 --> 00:48:51.924 Weighty people get this changed,

NOTE Confidence: 0.553255013571428

00:48:51.930 --> 00:48:55.742 and regular guys cannot attach a synonym,

NOTE Confidence: 0.553255013571428

00:48:55.742 --> 00:48:58.105 was able to inhibit people

NOTE Confidence: 0.553255013571428

00:48:58.105 --> 00:49:00.790 one kinase activity.

NOTE Confidence: 0.553255013571428

00:49:00.790 --> 00:49:04.168 Study is a phase three trial

NOTE Confidence: 0.553255013571428

00:49:04.168 --> 00:49:05.857 which randomizes patients.

NOTE Confidence: 0.553255013571428

00:49:05.860 --> 00:49:07.762 Between pursuit net 500 milligrams once

NOTE Confidence: 0.553255013571428

00:49:07.762 --> 00:49:11.040 a day and a 740 milligrams twice a day.

NOTE Confidence: 0.553255013571428

00:49:11.040 --> 00:49:11.814 Once again,

NOTE Confidence: 0.553255013571428

00:49:11.814 --> 00:49:14.136 there's a patients who were previously

NOTE Confidence: 0.553255013571428

00:49:14.136 --> 00:49:16.364 treated for chronic phase CML with

NOTE Confidence: 0.553255013571428

00:49:16.364 --> 00:49:20.000 at least two different keys and the

NOTE Confidence: 0.553255013571428

00:49:20.000 --> 00:49:23.992 initial presentation at previous ASH

NOTE Confidence: 0.553255013571428

00:49:23.992 --> 00:49:26.847 meeting looked at primary endpoint,

NOTE Confidence: 0.553255013571428

00:49:26.850 --> 00:49:29.355 which is major molecular response

NOTE Confidence: 0.553255013571428

00:49:29.355 --> 00:49:30.858 at 24 weeks.

NOTE Confidence: 0.553255013571428

00:49:30.860 --> 00:49:33.002 This presentation updates

NOTE Confidence: 0.553255013571428

00:49:33.002 --> 00:49:35.618 the results by expanding.

NOTE Confidence: 0.553255013571428

00:49:35.618 --> 00:49:37.994 Observation period for additional

NOTE Confidence: 0.553255013571428

00:49:37.994 --> 00:49:39.776 7 1/2 months.

NOTE Confidence: 0.553255013571428

00:49:39.780 --> 00:49:42.155 So basically in 19.2 months

NOTE Confidence: 0.553255013571428

00:49:42.155 --> 00:49:43.580 from randomization period.

NOTE Confidence: 0.553255013571428

00:49:43.580 --> 00:49:47.780 So the key secondary endpoint is Mr

NOTE Confidence: 0.553255013571428

00:49:47.780 --> 00:49:49.916 rated 96 weeks is not presented yet,

NOTE Confidence: 0.553255013571428

00:49:49.920 --> 00:49:52.950 so this is the first.

NOTE Confidence: 0.553255013571428

00:49:52.950 --> 00:49:55.670 Presentation in 20 Dash 2020,

NOTE Confidence: 0.553255013571428

00:49:55.670 --> 00:49:58.310 which was also the data was

NOTE Confidence: 0.553255013571428

00:49:58.310 --> 00:50:00.070 also published in Blood.

NOTE Confidence: 0.553255013571428

00:50:00.070 --> 00:50:00.774 Last year,

NOTE Confidence: 0.553255013571428

00:50:00.774 --> 00:50:03.238 so the synonym was better than pursuit

NOTE Confidence: 0.553255013571428

00:50:03.238 --> 00:50:05.987 nip from the standard primary endpoint,

NOTE Confidence: 0.553255013571428

00:50:05.990 --> 00:50:07.702 which is major molecular

NOTE Confidence: 0.553255013571428

00:50:07.702 --> 00:50:10.527 response at 24 weeks by 12.2%.

NOTE Confidence: 0.553255013571428

00:50:10.527 --> 00:50:14.589 So the updated 48 week results

NOTE Confidence: 0.553255013571428

00:50:14.589 --> 00:50:17.742 continue to show the higher

NOTE Confidence: 0.553255013571428

00:50:17.742 --> 00:50:19.986 major molecular response rate.

NOTE Confidence: 0.553255013571428

00:50:19.990 --> 00:50:23.552 So basically at one year is 29.3% which

NOTE Confidence: 0.553255013571428

00:50:23.552 --> 00:50:26.009 is 16% higher than with pursuit nip.

NOTE Confidence: 0.553255013571428

00:50:26.010 --> 00:50:28.080 Also the reduction of desirable

NOTE Confidence: 0.553255013571428

00:50:28.080 --> 00:50:30.150 transcript to less than one.

NOTE Confidence: 0.553255013571428

00:50:30.150 --> 00:50:32.136 Or something blood is seen more

NOTE Confidence: 0.553255013571428

00:50:32.136 --> 00:50:34.241 frequently in a semi warm 42%

NOTE Confidence: 0.553255013571428

00:50:34.241 --> 00:50:36.546 versus 19% more than double.

NOTE Confidence: 0.553255013571428

00:50:36.550 --> 00:50:38.979 So the deep responses are also better

NOTE Confidence: 0.553255013571428

00:50:38.979 --> 00:50:41.751 in a synonym as you can see on our

NOTE Confidence: 0.553255013571428

00:50:41.751 --> 00:50:44.960 4.57 point 6 versus 1.3% and Mr.

NOTE Confidence: 0.553255013571428

00:50:44.960 --> 00:50:49.265 410.8 versus 3.9% when compared to episode.

NOTE Confidence: 0.553255013571428

00:50:49.270 --> 00:50:52.720 So we're all adverse events that

NOTE Confidence: 0.553255013571428

00:50:52.720 --> 00:50:55.550 were less common in patients

NOTE Confidence: 0.553255013571428

00:50:55.550 --> 00:50:58.850 with severe then with mood dip.

NOTE Confidence: 0.553255013571428

00:50:58.850 --> 00:51:00.006 So nevertheless pretty much

NOTE Confidence: 0.553255013571428

00:51:00.006 --> 00:51:01.740 everyone had some kind of adversity.

NOTE Confidence: 0.553255013571428

00:51:01.740 --> 00:51:04.710 But adverse events leading to

NOTE Confidence: 0.553255013571428

00:51:04.710 --> 00:51:07.253 discontinuation again less frequent in

NOTE Confidence: 0.553255013571428

00:51:07.253 --> 00:51:09.894 a similar treating patients treated patients,

NOTE Confidence: 0.553255013571428

00:51:09.894 --> 00:51:12.672 so this is the most common all

NOTE Confidence: 0.553255013571428

00:51:12.672 --> 00:51:14.032 great adverse events as seen

NOTE Confidence: 0.553255013571428

00:51:14.032 --> 00:51:15.682 in more than 20% of patients.

NOTE Confidence: 0.553255013571428

00:51:15.682 --> 00:51:17.930 You can see that a synonym is better

NOTE Confidence: 0.553255013571428

00:51:17.990 --> 00:51:20.130 than other than cytopenia switch.

NOTE Confidence: 0.553255013571428

00:51:20.130 --> 00:51:21.965 I seen more frequently among patients

NOTE Confidence: 0.553255013571428

00:51:21.965 --> 00:51:23.920 who are treated with a similar,

NOTE Confidence: 0.553255013571428

00:51:23.920 --> 00:51:25.888 but this was transient fact at

NOTE Confidence: 0.553255013571428

00:51:25.888 --> 00:51:27.200 the beginning of treatment,

NOTE Confidence: 0.553255013571428

00:51:27.200 --> 00:51:29.282 usually related to the disease itself

NOTE Confidence: 0.553255013571428

00:51:29.282 --> 00:51:32.384 rather than to the treatment so.

NOTE Confidence: 0.553255013571428

00:51:32.384 --> 00:51:36.720 Adverse arterial occlusive events

NOTE Confidence: 0.553255013571428

00:51:36.720 --> 00:51:38.298 that were comparable in both groups,

NOTE Confidence: 0.553255013571428

00:51:38.300 --> 00:51:40.208 but it is challenging to say

NOTE Confidence: 0.553255013571428

00:51:40.210 --> 00:51:41.914 what would happen to the certain

NOTE Confidence: 0.553255013571428

00:51:41.914 --> 00:51:43.364 patients because they were observed

NOTE Confidence: 0.553255013571428

00:51:43.364 --> 00:51:45.177 a lot less than a similar patient.

NOTE Confidence: 0.789190589090909

00:51:45.180 --> 00:51:47.644 So, in conclusion, this is the first

NOTE Confidence: 0.789190589090909

00:51:47.644 --> 00:51:50.016 control study comparing tiki for resistant,

NOTE Confidence: 0.789190589090909

00:51:50.016 --> 00:51:51.540 intolerant patients using

NOTE Confidence: 0.789190589090909

00:51:51.540 --> 00:51:54.080 first and class specific drug,

NOTE Confidence: 0.789190589090909

00:51:54.080 --> 00:51:55.588 which is specifically targeting

NOTE Confidence: 0.789190589090909

00:51:55.588 --> 00:51:57.096 able one restoril pocket.

NOTE Confidence: 0.789190589090909

00:51:57.100 --> 00:51:59.348 Superior efficacy was demonstrated

NOTE Confidence: 0.789190589090909

00:51:59.348 --> 00:52:01.932 for synonym against BOSUTINIB, and.

NOTE Confidence: 0.789190589090909

00:52:01.932 --> 00:52:03.592 More patients remain the treatment

NOTE Confidence: 0.789190589090909

00:52:03.592 --> 00:52:05.928 at the end of 48 week period,

NOTE Confidence: 0.789190589090909

00:52:05.930 --> 00:52:07.748 so it has favorable safety profile.

NOTE Confidence: 0.789190589090909

00:52:07.750 --> 00:52:10.020 Now this is the drug which is available as a

NOTE Confidence: 0.789190589090909

00:52:10.080 --> 00:52:12.408 standard of care option for our CML patients,

NOTE Confidence: 0.789190589090909

00:52:12.410 --> 00:52:14.546 particularly with resistant with

NOTE Confidence: 0.789190589090909

00:52:14.546 --> 00:52:17.216 resistance and influence to two

NOTE Confidence: 0.789190589090909

00:52:17.216 --> 00:52:22.039 TK eyes or more so finally, the.

NOTE Confidence: 0.789190589090909

00:52:22.040 --> 00:52:24.808 They got me up for patients with the

NOTE Confidence: 0.789190589090909

00:52:24.808 --> 00:52:27.380 nominee and rearrangement of GFR one.

NOTE Confidence: 0.789190589090909

00:52:27.380 --> 00:52:29.484 So just to map that this is one

NOTE Confidence: 0.789190589090909

00:52:29.484 --> 00:52:31.540 of the myeloid malignancies.

NOTE Confidence: 0.789190589090909

00:52:31.540 --> 00:52:32.950 We spoke about MPN's pH

NOTE Confidence: 0.789190589090909

00:52:32.950 --> 00:52:34.360 positive and negative so far,

NOTE Confidence: 0.789190589090909

00:52:34.360 --> 00:52:36.154 but this is the myeloid lymphoid

NOTE Confidence: 0.789190589090909

00:52:36.154 --> 00:52:38.619 neoplasm with is an affiliate affiliates.

NOTE Confidence: 0.789190589090909

00:52:38.620 --> 00:52:40.978 Hallmark feature of this group of

NOTE Confidence: 0.789190589090909

00:52:40.978 --> 00:52:42.157 malignancies myeloid malignancies.

NOTE Confidence: 0.789190589090909

00:52:42.160 --> 00:52:44.048 I'm going to focus on this particular one,

NOTE Confidence: 0.789190589090909

00:52:44.048 --> 00:52:45.280 which is, I mean,

NOTE Confidence: 0.789190589090909

00:52:45.280 --> 00:52:46.939 all of them are not very common,

NOTE Confidence: 0.789190589090909

00:52:46.940 --> 00:52:48.964 but nevertheless it's an

NOTE Confidence: 0.789190589090909

00:52:48.964 --> 00:52:51.195 interesting disease which is.

NOTE Confidence: 0.789190589090909

00:52:51.195 --> 00:52:54.450 I'm due to translocation of eight P.

NOTE Confidence: 0.789190589090909

00:52:54.450 --> 00:52:56.334 11 leading to constitutive

NOTE Confidence: 0.789190589090909

00:52:56.334 --> 00:52:57.747 activation of FGFR,

NOTE Confidence: 0.789190589090909

00:52:57.750 --> 00:52:59.950 one that's 16 known partners.

NOTE Confidence: 0.789190589090909

00:52:59.950 --> 00:53:01.650 Chronic phase of this disease

NOTE Confidence: 0.789190589090909

00:53:01.650 --> 00:53:03.507 may present as MPNMDS or MDSMPN.

NOTE Confidence: 0.789190589090909

00:53:03.507 --> 00:53:05.181 That's why it is important to

NOTE Confidence: 0.789190589090909

00:53:05.181 --> 00:53:07.100 check if patient has is an

NOTE Confidence: 0.789190589090909

00:53:07.100 --> 00:53:08.364 affiliate for this rearrangement,

NOTE Confidence: 0.789190589090909

00:53:08.370 --> 00:53:10.668 usually treated with hydroxyurea and keys,

NOTE Confidence: 0.789190589090909

00:53:10.670 --> 00:53:12.545 including non selective

NOTE Confidence: 0.789190589090909

00:53:12.545 --> 00:53:15.045 ponatinib and might historian.

NOTE Confidence: 0.789190589090909

00:53:15.050 --> 00:53:16.946 50% of patients are in blast phase after

NOTE Confidence: 0.789190589090909

00:53:16.946 --> 00:53:18.738 12 months and meeting all survival

NOTE Confidence: 0.789190589090909

00:53:18.738 --> 00:53:20.323 and unfortunately only nine months

NOTE Confidence: 0.789190589090909

00:53:20.323 --> 00:53:22.117 without stem cell transplant one term.

NOTE Confidence: 0.789190589090909

00:53:22.120 --> 00:53:24.120 Oceans are possible with transplants.

NOTE Confidence: 0.789190589090909

00:53:24.120 --> 00:53:26.958 Las Vegas may present as a

NOTE Confidence: 0.789190589090909

00:53:26.960 --> 00:53:28.540 MLTOB cell and mix phenotype.

NOTE Confidence: 0.789190589090909

00:53:28.540 --> 00:53:30.825 Acute leukemia once again important

NOTE Confidence: 0.789190589090909

00:53:30.825 --> 00:53:34.056 test to do to select this patients

NOTE Confidence: 0.789190589090909

00:53:34.056 --> 00:53:36.608 and there is treatment with

NOTE Confidence: 0.789190589090909

00:53:36.608 --> 00:53:38.174 specific induction chemotherapy,

NOTE Confidence: 0.789190589090909

00:53:38.180 --> 00:53:40.108 perhaps with the tiki with one year survival,

NOTE Confidence: 0.789190589090909

00:53:40.110 --> 00:53:41.232 one with 30%.

NOTE Confidence: 0.789190589090909

00:53:41.232 --> 00:53:43.476 Those who achieve CR will abduction,

NOTE Confidence: 0.789190589090909

00:53:43.480 --> 00:53:45.780 Kima have superior survival obviously,

NOTE Confidence: 0.789190589090909

00:53:45.780 --> 00:53:47.355 and long term remissions are

NOTE Confidence: 0.789190589090909

00:53:47.355 --> 00:53:48.615 reported with transplanted patients.

NOTE Confidence: 0.789190589090909

00:53:48.620 --> 00:53:52.130 So this disease is rare.

NOTE Confidence: 0.789190589090909

00:53:52.130 --> 00:53:54.210 And also not very good to have because

NOTE Confidence: 0.789190589090909

00:53:54.210 --> 00:53:55.840 of lack of specific treatments

NOTE Confidence: 0.789190589090909

00:53:55.840 --> 00:53:57.940 as well as poor outcomes with

NOTE Confidence: 0.789190589090909

00:53:57.940 --> 00:53:59.779 available therapy at perhaps other

NOTE Confidence: 0.789190589090909

00:53:59.779 --> 00:54:01.559 than transplant which is available

NOTE Confidence: 0.789190589090909

00:54:01.559 --> 00:54:03.800 for limited number of patients.

NOTE Confidence: 0.789190589090909

00:54:03.800 --> 00:54:06.112 So is this drug which is currently

NOTE Confidence: 0.789190589090909

00:54:06.112 --> 00:54:09.080 approved by FDA as well as in some

NOTE Confidence: 0.789190589090909

00:54:09.080 --> 00:54:11.170 other countries for patients with

NOTE Confidence: 0.789190589090909

00:54:11.170 --> 00:54:12.659 cholangiocarcinoma previously treated

NOTE Confidence: 0.789190589090909

00:54:12.659 --> 00:54:15.041 and respected locally advanced it

NOTE Confidence: 0.789190589090909

00:54:15.041 --> 00:54:17.267 was FGFR 2 fusion and rearrangements.

NOTE Confidence: 0.789190589090909

00:54:17.270 --> 00:54:19.944 The drug inhibits FGFR 1/3 and that

NOTE Confidence: 0.789190589090909

00:54:19.944 --> 00:54:22.930 led to its study in this flight.

NOTE Confidence: 0.789190589090909

00:54:22.930 --> 00:54:24.678 Two or three trial.

NOTE Confidence: 0.789190589090909

00:54:24.678 --> 00:54:28.070 So this is a swimmer sport showing

NOTE Confidence: 0.789190589090909

00:54:28.070 --> 00:54:29.658 ongoing responses for majority

NOTE Confidence: 0.789190589090909

00:54:29.658 --> 00:54:31.643 of patients with chronic phase.

NOTE Confidence: 0.789190589090909

00:54:31.650 --> 00:54:34.467 There are 18 of them and then there is.

NOTE Confidence: 0.789190589090909

00:54:34.470 --> 00:54:37.550 This is the 13 patients with blast phase.

NOTE Confidence: 0.789190589090909

00:54:37.550 --> 00:54:39.302 Unfortunately less responses here.

NOTE Confidence: 0.789190589090909

00:54:39.302 --> 00:54:41.054 A lot of patients,

NOTE Confidence: 0.789190589090909

00:54:41.060 --> 00:54:43.251 especially in the black box who died

NOTE Confidence: 0.789190589090909

00:54:43.251 --> 00:54:45.349 from this disease in the blast based.

NOTE Confidence: 0.789190589090909

00:54:45.350 --> 00:54:45.736 Nevertheless,

NOTE Confidence: 0.789190589090909

00:54:45.736 --> 00:54:48.052 some were breached to allogeneic stem

NOTE Confidence: 0.789190589090909

00:54:48.052 --> 00:54:51.788 cell transplant. So in conclusion.

NOTE Confidence: 0.789190589090909

00:54:51.790 --> 00:54:54.136 Is the first therapy to demonstrate

NOTE Confidence: 0.789190589090909

00:54:54.136 --> 00:54:56.435 durable and high rates of CR&CCYR

NOTE Confidence: 0.789190589090909

00:54:56.435 --> 00:54:59.060 in this group of patients.

NOTE Confidence: 0.75995287875

00:54:59.060 --> 00:55:00.848 Previously, these patients were

NOTE Confidence: 0.75995287875

00:55:00.848 --> 00:55:02.636 treated with other treatments.

NOTE Confidence: 0.75995287875

00:55:02.640 --> 00:55:04.336 Majority of them progressed,

NOTE Confidence: 0.75995287875

00:55:04.336 --> 00:55:06.032 including intensive chemotherapy and

NOTE Confidence: 0.75995287875

00:55:06.032 --> 00:55:07.710 chemotherapeutic stem cell transplant.

NOTE Confidence: 0.75995287875

00:55:07.710 --> 00:55:09.792 Kaplan Meier median duration of CR

NOTE Confidence: 0.75995287875

00:55:09.792 --> 00:55:11.861 and overall response have not been

NOTE Confidence: 0.75995287875

00:55:11.861 --> 00:55:13.890 reached in those treated with Pamela

NOTE Confidence: 0.75995287875

00:55:13.890 --> 00:55:15.266 Gardner clinical and cytogenetic.

NOTE Confidence: 0.75995287875

00:55:15.270 --> 00:55:16.910 Responses were less frequent in

NOTE Confidence: 0.75995287875

00:55:16.910 --> 00:55:18.550 and durable and blood space,

NOTE Confidence: 0.75995287875

00:55:18.550 --> 00:55:19.770 but nevertheless some patients

NOTE Confidence: 0.75995287875

00:55:19.770 --> 00:55:21.295 were able to breach too.

NOTE Confidence: 0.75995287875

00:55:21.300 --> 00:55:23.060 Collagen in stem cell transplant.

NOTE Confidence: 0.75995287875

00:55:23.060 --> 00:55:25.202 See if there were no surprises and

NOTE Confidence: 0.75995287875

00:55:25.202 --> 00:55:27.254 safety profiles and die of this

NOTE Confidence: 0.75995287875

00:55:27.254 --> 00:55:28.682 treatment consistent with Jeff

NOTE Confidence: 0.75995287875

00:55:28.682 --> 00:55:30.929 Gordon condition and this may be a

NOTE Confidence: 0.75995287875

00:55:30.929 --> 00:55:32.597 good option for long term treatment

NOTE Confidence: 0.75995287875

00:55:32.600 --> 00:55:35.474 for patients with Melanie with FGFR

NOTE Confidence: 0.75995287875

00:55:35.474 --> 00:55:37.390 rearrangement ineligible for transplant

NOTE Confidence: 0.75995287875

00:55:37.455 --> 00:55:39.815 or facilitate bridging tool transplant.

NOTE Confidence: 0.75995287875

00:55:39.815 --> 00:55:42.630 Thank you.

NOTE Confidence: 0.6592189925

00:55:42.630 --> 00:55:43.730 Thank you Doctor Badasci

NOTE Confidence: 0.6592189925

00:55:43.730 --> 00:55:44.830 thank you Doctor Cialis.

NOTE Confidence: 0.6592189925

00:55:44.830 --> 00:55:49.410 Great comprehensive presentations and.

NOTE Confidence: 0.6592189925

00:55:49.410 --> 00:55:51.138 We are going to take a few questions

NOTE Confidence: 0.6592189925

00:55:51.138 --> 00:55:52.590 from the audience if any has,

NOTE Confidence: 0.6592189925

00:55:52.590 --> 00:55:54.844 so please feel free if you want

NOTE Confidence: 0.6592189925

00:55:54.844 --> 00:55:57.343 to type your question or if you

NOTE Confidence: 0.6592189925

00:55:57.343 --> 00:55:59.572 want to ask directly, you can.

NOTE Confidence: 0.6592189925

00:55:59.572 --> 00:56:01.802 I think Lenny can mute you

NOTE Confidence: 0.6592189925

00:56:01.802 --> 00:56:03.908 and you can ask the question.

NOTE Confidence: 0.6592189925

00:56:03.910 --> 00:56:06.478 I'm gonna actually start one question

NOTE Confidence: 0.6592189925

00:56:06.478 --> 00:56:09.192 for Doctor Sheraz where we are waiting

NOTE Confidence: 0.6592189925

00:56:09.192 --> 00:56:11.678 so Rory treatment of AML historical.

NOTE Confidence: 0.661338957

00:56:14.370 --> 00:56:19.730 7 + 3 or really not much aside from that,

NOTE Confidence: 0.661338957

00:56:19.730 --> 00:56:21.627 so can you walk us through your

NOTE Confidence: 0.661338957

00:56:21.627 --> 00:56:23.222 thinking of the different options

NOTE Confidence: 0.661338957

00:56:23.222 --> 00:56:25.370 for a patient that potentially could

NOTE Confidence: 0.661338957

00:56:25.370 --> 00:56:27.709 be seen in any of the care centers.

NOTE Confidence: 0.661338957

00:56:27.710 --> 00:56:32.534 74 year old male. Walks with a cane,

NOTE Confidence: 0.661338957

00:56:32.534 --> 00:56:34.489 but otherwise in good shape.

NOTE Confidence: 0.661338957

00:56:34.490 --> 00:56:37.270 Who comes with acute myeloid

NOTE Confidence: 0.661338957

00:56:37.270 --> 00:56:38.670 leukemia outpatient?

NOTE Confidence: 0.60001224

00:56:41.180 --> 00:56:43.714 And the patient has a flip 3

NOTE Confidence: 0.60001224

00:56:43.714 --> 00:56:45.976 mutation and mutation which we can

NOTE Confidence: 0.60001224

00:56:45.976 --> 00:56:47.896 see certainly in some patients.

NOTE Confidence: 0.60001224

00:56:47.900 --> 00:56:50.720 So how do you work through the

NOTE Confidence: 0.60001224

00:56:50.720 --> 00:56:52.020 different treatment options as you

NOTE Confidence: 0.60001224

00:56:52.020 --> 00:56:53.918 consider what to do with this patient?

NOTE Confidence: 0.851500112857143

00:56:55.970 --> 00:56:57.962 Well, I could think my practices

NOTE Confidence: 0.851500112857143

00:56:57.962 --> 00:57:00.111 is fairly evidence based with some

NOTE Confidence: 0.851500112857143

00:57:00.111 --> 00:57:01.620 rare exceptions, and you know,

NOTE Confidence: 0.851500112857143

00:57:01.620 --> 00:57:03.770 I'd say this is a double edged sword.

NOTE Confidence: 0.851500112857143

00:57:03.770 --> 00:57:05.402 I mean, it's very fortunate that the field

NOTE Confidence: 0.851500112857143

00:57:05.402 --> 00:57:07.078 is moving very quickly with novel agents,

NOTE Confidence: 0.851500112857143

00:57:07.080 --> 00:57:08.373 novel combinations with.

NOTE Confidence: 0.851500112857143

00:57:08.373 --> 00:57:10.528 You know a recent preference

NOTE Confidence: 0.851500112857143

00:57:10.528 --> 00:57:11.900 for randomized trials,

NOTE Confidence: 0.851500112857143

00:57:11.900 --> 00:57:13.788 but by the time a trial is launched,

NOTE Confidence: 0.851500112857143

00:57:13.790 --> 00:57:14.666 let alone completed,

NOTE Confidence: 0.851500112857143

00:57:14.666 --> 00:57:15.834 maybe the reference standard,

NOTE Confidence: 0.851500112857143

00:57:15.840 --> 00:57:18.863 the comparator arm is obsolete, so.

NOTE Confidence: 0.851500112857143

00:57:18.863 --> 00:57:19.952 At the moment,

NOTE Confidence: 0.851500112857143

00:57:19.952 --> 00:57:22.490 you know a 74 year old is,

NOTE Confidence: 0.851500112857143

00:57:22.490 --> 00:57:24.650 you know, age isn't all ages,

NOTE Confidence: 0.851500112857143

00:57:24.650 --> 00:57:26.205 more of an imperfect surrogate

NOTE Confidence: 0.851500112857143

00:57:26.205 --> 00:57:27.449 for other patient specific

NOTE Confidence: 0.851500112857143

00:57:27.449 --> 00:57:28.909 factors like end organ reserve.

NOTE Confidence: 0.851500112857143

00:57:28.910 --> 00:57:31.526 And I'd say maybe I put a bit

NOTE Confidence: 0.851500112857143

00:57:31.526 --> 00:57:33.649 more emphasis on the disease

NOTE Confidence: 0.851500112857143

00:57:33.649 --> 00:57:35.969 biology and with two troubling

NOTE Confidence: 0.851500112857143

00:57:35.969 --> 00:57:38.054 mutations and intensive therapy

NOTE Confidence: 0.851500112857143

00:57:38.054 --> 00:57:39.668 appropriate eligible candidate.

NOTE Confidence: 0.851500112857143

00:57:39.670 --> 00:57:40.192 I mean,

NOTE Confidence: 0.851500112857143

00:57:40.192 --> 00:57:42.280 I would probably say this is a patient

NOTE Confidence: 0.851500112857143

00:57:42.343 --> 00:57:44.455 that probably would be treated with

NOTE Confidence: 0.851500112857143

00:57:44.455 --> 00:57:46.267 an intensive backbone plus midostaurin

NOTE Confidence: 0.851500112857143

00:57:46.267 --> 00:57:49.840 you didn't give me a fits it high or.

NOTE Confidence: 0.851500112857143

00:57:49.840 --> 00:57:51.513 But I think we can all agree

NOTE Confidence: 0.851500112857143

00:57:51.513 --> 00:57:53.249 this is probably a patient best

NOTE Confidence: 0.851500112857143

00:57:53.249 --> 00:57:54.844 served with that triplet regimen.

NOTE Confidence: 0.851500112857143

00:57:54.850 --> 00:57:56.370 You know at the patient was not intensive,

NOTE Confidence: 0.851500112857143

00:57:56.370 --> 00:57:57.728 they would be eligible in the clinic.

NOTE Confidence: 0.851500112857143

00:57:57.730 --> 00:57:59.110 You know, you know,

NOTE Confidence: 0.851500112857143

00:57:59.110 --> 00:58:00.490 eyes in the beholder.

NOTE Confidence: 0.851500112857143

00:58:00.490 --> 00:58:02.260 Then it's a it's dealers choice.

NOTE Confidence: 0.851500112857143

00:58:02.260 --> 00:58:03.940 As event is probably still appropriate

NOTE Confidence: 0.851500112857143

00:58:03.940 --> 00:58:05.810 just based on the Lacewing data,

NOTE Confidence: 0.851500112857143

00:58:05.810 --> 00:58:07.898 you know that Eunice Wang had

NOTE Confidence: 0.851500112857143

00:58:07.898 --> 00:58:10.785 presented and until we have a

NOTE Confidence: 0.851500112857143

00:58:10.785 --> 00:58:13.320 randomized trial looking at sequencing.

NOTE Confidence: 0.851500112857143

00:58:13.320 --> 00:58:14.064 Just flip three.

NOTE Confidence: 0.851500112857143

00:58:14.064 --> 00:58:15.800 I think the question is still unanswered,

NOTE Confidence: 0.851500112857143

00:58:15.800 --> 00:58:17.000 but it's hard to stray from

NOTE Confidence: 0.851500112857143

00:58:17.000 --> 00:58:18.066 what we know from the belly.

NOTE Confidence: 0.851500112857143

00:58:18.066 --> 00:58:19.770 I think as of them still be the

NOTE Confidence: 0.851500112857143

00:58:19.824 --> 00:58:21.637 standard if the patient is need to

NOTE Confidence: 0.851500112857143

00:58:21.637 --> 00:58:23.043 not be intensive therapy appropriate

NOTE Confidence: 0.851500112857143

00:58:23.043 --> 00:58:25.066 and maybe in the next couple of

NOTE Confidence: 0.851500112857143

00:58:25.066 --> 00:58:26.600 years you might have a randomized

NOTE Confidence: 0.851500112857143

00:58:26.600 --> 00:58:28.402 trial that looks at that and maybe

NOTE Confidence: 0.851500112857143

00:58:28.402 --> 00:58:30.173 a seven could be superior to even

NOTE Confidence: 0.851500112857143

00:58:30.173 --> 00:58:31.339 classical intensive therapy,

NOTE Confidence: 0.851500112857143

00:58:31.340 --> 00:58:32.894 but at the moment that's the

NOTE Confidence: 0.851500112857143

00:58:32.894 --> 00:58:33.930 dichotomy I would say.

NOTE Confidence: 0.758994072

00:58:36.740 --> 00:58:38.805 Perfect so clearly a lot of options

NOTE Confidence: 0.758994072

00:58:38.805 --> 00:58:40.394 for this patient. This patient

NOTE Confidence: 0.758994072

00:58:40.394 --> 00:58:42.506 could go with his even potentially.

NOTE Confidence: 0.758994072

00:58:42.510 --> 00:58:46.714 Some patients can still do IDH 2 monotherapy

NOTE Confidence: 0.758994072

00:58:46.714 --> 00:58:51.520 could be aids with IDH 2 inhibitor could be.

NOTE Confidence: 0.758994072

00:58:51.520 --> 00:58:53.945 10 + 3 could be 7 + 3 with middle story and

NOTE Confidence: 0.758994072

00:58:53.945 --> 00:58:56.157 you still could consider transparent or not.

NOTE Confidence: 0.758994072

00:58:56.160 --> 00:58:57.918 So clearly many many different options.

NOTE Confidence: 0.758994072

00:58:57.920 --> 00:58:59.140 And clearly the best option

NOTE Confidence: 0.758994072

00:58:59.140 --> 00:59:00.360 is always a clinical trial,

NOTE Confidence: 0.758994072

00:59:00.360 --> 00:59:01.676 which we always encourage.

NOTE Confidence: 0.758994072

00:59:01.676 --> 00:59:04.648 So I'm pretty sure you know in the care

NOTE Confidence: 0.758994072

00:59:04.648 --> 00:59:06.825 centers these patients are seen all the

NOTE Confidence: 0.758994072

00:59:06.888 --> 00:59:09.424 time and I encourage people even if the

NOTE Confidence: 0.758994072

00:59:09.424 --> 00:59:11.482 patient does not want to come to the

NOTE Confidence: 0.758994072

00:59:11.482 --> 00:59:13.784 main campus or cannot travel to call

NOTE Confidence: 0.758994072

00:59:13.784 --> 00:59:16.980 one of us and go through some of the

NOTE Confidence: 0.758994072

00:59:16.980 --> 00:59:21.430 potential options that we have Nikolai.

NOTE Confidence: 0.758994072

00:59:21.430 --> 00:59:23.908 So fibrosis things are also clearly changing

NOTE Confidence: 0.758994072

00:59:23.908 --> 00:59:26.194 issue that some of the clinical trials

NOTE Confidence: 0.758994072

00:59:26.194 --> 00:59:29.008 that are in progress but currently 4.

NOTE Confidence: 0.758994072

00:59:29.010 --> 00:59:29.586 Doctors in.

NOTE Confidence: 0.758994072

00:59:29.586 --> 00:59:30.162 In practice,

NOTE Confidence: 0.758994072

00:59:30.162 --> 00:59:32.706 one of the most common I think tough

NOTE Confidence: 0.758994072

00:59:32.706 --> 00:59:34.586 situations is patients with myelofibrosis

NOTE Confidence: 0.758994072

00:59:34.586 --> 00:59:38.566 who are on rock solid and anemic.

NOTE Confidence: 0.758994072

00:59:38.566 --> 00:59:40.710 So the patient basically

NOTE Confidence: 0.758994072

00:59:40.710 --> 00:59:42.318 has controlled spleen.

NOTE Confidence: 0.758994072

00:59:42.320 --> 00:59:43.835 They are not having constitutional

NOTE Confidence: 0.758994072

00:59:43.835 --> 00:59:45.350 symptoms but they are needing

NOTE Confidence: 0.758994072

00:59:45.350 --> 00:59:49.200 transfusions and they are on.

NOTE Confidence: 0.758994072

00:59:49.200 --> 00:59:53.238 Let's say 20 milligram P opyd.

NOTE Confidence: 0.758994072

00:59:53.240 --> 00:59:57.120 Now we have a drug approved that we

NOTE Confidence: 0.758994072

00:59:57.120 --> 00:59:59.500 have a drug nib and there's another

NOTE Confidence: 0.758994072

00:59:59.500 --> 01:00:02.259 drug in front of the FDA molet nib.

NOTE Confidence: 0.758994072

01:00:02.260 --> 01:00:04.028 And you know a bunch of other things,

NOTE Confidence: 0.758994072

01:00:04.030 --> 01:00:09.240 he says androgens and potentially.

NOTE Confidence: 0.758994072

01:00:09.240 --> 01:00:10.808 So how do you think about these

NOTE Confidence: 0.758994072

01:00:10.808 --> 01:00:12.051 different options as you approach

NOTE Confidence: 0.758994072

01:00:12.051 --> 01:00:13.087 your patient like this?

NOTE Confidence: 0.5364392455

01:00:13.580 --> 01:00:15.200 So from the standpoint

NOTE Confidence: 0.5364392455

01:00:15.200 --> 01:00:16.820 of FDA approved therapy,

NOTE Confidence: 0.5364392455

01:00:16.820 --> 01:00:19.074 we have right now for awhile and

NOTE Confidence: 0.5364392455

01:00:19.074 --> 01:00:21.001 looks like name is obviously

NOTE Confidence: 0.5364392455

01:00:21.001 --> 01:00:23.089 dominating the market since 2011,

NOTE Confidence: 0.5364392455

01:00:23.089 --> 01:00:25.182 so I think that was approved for

NOTE Confidence: 0.5364392455

01:00:25.182 --> 01:00:27.130 similar group of patients from 2019

NOTE Confidence: 0.5364392455

01:00:27.130 --> 01:00:29.062 and usually considered as a second

NOTE Confidence: 0.5364392455

01:00:29.125 --> 01:00:31.065 line for those patients who are

NOTE Confidence: 0.5364392455

01:00:31.065 --> 01:00:33.375 not satisfied with that rock solid.

NOTE Confidence: 0.5364392455

01:00:33.380 --> 01:00:35.680 Networx limp is not working

NOTE Confidence: 0.5364392455

01:00:35.680 --> 01:00:37.415 anymore with variable results,

NOTE Confidence: 0.5364392455

01:00:37.415 --> 01:00:39.965 So what we have approval is.

NOTE Confidence: 0.5364392455

01:00:39.970 --> 01:00:41.860 A grid Neb out on the 1st of March

NOTE Confidence: 0.5364392455

01:00:41.860 --> 01:00:43.428 was FDA approved for patients

NOTE Confidence: 0.5364392455

01:00:43.428 --> 01:00:45.403 who have low platelet count so

NOTE Confidence: 0.5364392455

01:00:45.403 --> 01:00:47.118 called cited piknic Milo fibrosis

NOTE Confidence: 0.5364392455

01:00:47.118 --> 01:00:49.454 and perhaps this drug can be used

NOTE Confidence: 0.5364392455

01:00:49.454 --> 01:00:51.260 not only for patients who have

NOTE Confidence: 0.5364392455

01:00:51.260 --> 01:00:52.928 platelet count less than 50 so,

NOTE Confidence: 0.5364392455

01:00:52.930 --> 01:00:55.821 but maybe between 50 and 100 because

NOTE Confidence: 0.5364392455

01:00:55.821 --> 01:00:57.694 effective dose sometimes is not

NOTE Confidence: 0.5364392455

01:00:57.694 --> 01:00:59.782 feasible for this group of patients.

NOTE Confidence: 0.5364392455

01:00:59.790 --> 01:01:02.954 So none of these drugs address anemia

NOTE Confidence: 0.5364392455

01:01:02.954 --> 01:01:05.210 sore from momentum study which was

NOTE Confidence: 0.5364392455

01:01:05.210 --> 01:01:07.631 just presented that you know the data

NOTE Confidence: 0.5364392455

01:01:07.631 --> 01:01:09.296 was presented as a company release,

NOTE Confidence: 0.5364392455

01:01:09.296 --> 01:01:10.661 so there's no publication about

NOTE Confidence: 0.5364392455

01:01:10.661 --> 01:01:12.219 that at the end of January.

NOTE Confidence: 0.5364392455

01:01:12.220 --> 01:01:15.712 So this drug is geared towards

NOTE Confidence: 0.5364392455

01:01:15.712 --> 01:01:17.754 patients with anemia,

NOTE Confidence: 0.5364392455

01:01:17.754 --> 01:01:21.389 who are progressing after sliding.

NOTE Confidence: 0.5364392455

01:01:21.390 --> 01:01:23.330 Now this was a randomized

NOTE Confidence: 0.5364392455

01:01:23.330 --> 01:01:24.494 study against Danazol,

NOTE Confidence: 0.5364392455

01:01:24.500 --> 01:01:26.250 which you argue may not be the

NOTE Confidence: 0.5364392455

01:01:26.250 --> 01:01:27.000 best randomization strategy.

NOTE Confidence: 0.5364392455

01:01:27.000 --> 01:01:28.578 So there is some improvement in

NOTE Confidence: 0.5364392455

01:01:28.578 --> 01:01:29.960 patients who have anemia there,

NOTE Confidence: 0.5364392455

01:01:29.960 --> 01:01:31.619 but the drug is for symptom control,

NOTE Confidence: 0.5364392455

01:01:31.620 --> 01:01:33.060 more just for anemia.

NOTE Confidence: 0.5364392455

01:01:33.060 --> 01:01:34.940 Fix the patient you were talking

NOTE Confidence: 0.5364392455

01:01:34.940 --> 01:01:36.156 about at the beginning.

NOTE Confidence: 0.5364392455

01:01:36.160 --> 01:01:38.338 Looks solid, treated, patient with anemia.

NOTE Confidence: 0.5364392455

01:01:38.340 --> 01:01:40.564 There is a there is a study called

NOTE Confidence: 0.5364392455

01:01:40.564 --> 01:01:42.438 Independents trial looking at luspatercept.

NOTE Confidence: 0.5364392455

01:01:42.440 --> 01:01:44.505 This group of patients we know that

NOTE Confidence: 0.5364392455

01:01:44.505 --> 01:01:46.794 was part of Sept is approved for

NOTE Confidence: 0.5364392455

01:01:46.794 --> 01:01:49.051 MDS with doing Super Blast right so

NOTE Confidence: 0.5364392455

01:01:49.051 --> 01:01:50.926 and perhaps some people can get it

NOTE Confidence: 0.5364392455

01:01:50.926 --> 01:01:52.969 off label to treat these patients,

NOTE Confidence: 0.5364392455

01:01:52.970 --> 01:01:54.314 but I think it is a little premature.

NOTE Confidence: 0.5364392455

01:01:54.320 --> 01:01:55.545 We have to see how this results

NOTE Confidence: 0.5364392455

01:01:55.545 --> 01:01:56.470 are going to bend out.

NOTE Confidence: 0.932323168

01:01:59.450 --> 01:02:00.280 So what would you do

NOTE Confidence: 0.764727925238095

01:02:01.020 --> 01:02:03.148 so you know, for patients who first

NOTE Confidence: 0.764727925238095

01:02:03.148 --> 01:02:05.673 of all don't give up slip to patients

NOTE Confidence: 0.764727925238095

01:02:05.673 --> 01:02:08.024 whose main problem is an email, right?

NOTE Confidence: 0.764727925238095

01:02:08.024 --> 01:02:10.148 So because an email becomes worse,

NOTE Confidence: 0.764727925238095

01:02:10.150 --> 01:02:12.474 is the drug to fix the symptoms,

NOTE Confidence: 0.764727925238095

01:02:12.480 --> 01:02:15.301 and some patients would be happy to

NOTE Confidence: 0.764727925238095

01:02:15.301 --> 01:02:17.390 take crooks because they have bad

NOTE Confidence: 0.764727925238095

01:02:17.390 --> 01:02:18.670 symptoms and receive transfusions

NOTE Confidence: 0.764727925238095

01:02:18.670 --> 01:02:20.110 because their quality of life,

NOTE Confidence: 0.764727925238095

01:02:20.110 --> 01:02:21.832 even though transfusions may be a little

NOTE Confidence: 0.764727925238095

01:02:21.832 --> 01:02:23.590 bit more frequent, becomes better.

NOTE Confidence: 0.764727925238095

01:02:23.590 --> 01:02:27.160 So we can sometimes try to give

NOTE Confidence: 0.764727925238095

01:02:27.160 --> 01:02:29.390 everything like Derby Poitin 150 weekly

NOTE Confidence: 0.764727925238095

01:02:29.390 --> 01:02:31.790 or 300 weekly to those patients.

NOTE Confidence: 0.764727925238095

01:02:31.790 --> 01:02:33.815 In conjunction with within those

NOTE Confidence: 0.764727925238095

01:02:33.815 --> 01:02:34.625 country intuitive.

NOTE Confidence: 0.764727925238095

01:02:34.630 --> 01:02:35.326 Because rooks,

NOTE Confidence: 0.764727925238095

01:02:35.326 --> 01:02:37.018 lithium is Jack stat pathway

NOTE Confidence: 0.764727925238095

01:02:37.018 --> 01:02:38.314 inhibitor and worth reporting

NOTE Confidence: 0.764727925238095

01:02:38.314 --> 01:02:39.610 actually activates that pathway,

NOTE Confidence: 0.764727925238095

01:02:39.610 --> 01:02:41.777 but Bruce Lipton was not there 24/7,

NOTE Confidence: 0.764727925238095

01:02:41.777 --> 01:02:44.766 so we allow some hematopoiesis in between.

NOTE Confidence: 0.764727925238095

01:02:44.770 --> 01:02:47.119 So by doing that and some of the patients

NOTE Confidence: 0.764727925238095

01:02:47.119 --> 01:02:49.410 may have less transfusion requirement,

NOTE Confidence: 0.764727925238095

01:02:49.410 --> 01:02:50.858 so it's either supportive,

NOTE Confidence: 0.764727925238095

01:02:50.858 --> 01:02:53.494 care with transfusions or trying to give

NOTE Confidence: 0.764727925238095

01:02:53.494 --> 01:02:55.810 darbepoetin to those patients who need

NOTE Confidence: 0.764727925238095

01:02:55.810 --> 01:02:59.226 or trying to decrease the looks lit nap,

NOTE Confidence: 0.764727925238095

01:02:59.230 --> 01:03:02.380 which of course is a you know may lead to.

NOTE Confidence: 0.764727925238095

01:03:02.380 --> 01:03:04.462 Reoccurrence of some of the symptoms

NOTE Confidence: 0.764727925238095

01:03:04.462 --> 01:03:05.850 and worsening of symptomatology

NOTE Confidence: 0.764727925238095

01:03:05.901 --> 01:03:06.819 in those patients.

NOTE Confidence: 0.764727925238095

01:03:06.820 --> 01:03:08.344 So no perfect solution to this

NOTE Confidence: 0.764727925238095

01:03:08.344 --> 01:03:09.850 group of patients at this time.

NOTE Confidence: 0.761834914285714

01:03:12.260 --> 01:03:14.626 Would you consider adding danazol also or

NOTE Confidence: 0.746569894052632

01:03:14.900 --> 01:03:17.444 so danazol would be one of the options

NOTE Confidence: 0.746569894052632

01:03:17.444 --> 01:03:19.149 with Retropulsion doesn't work with

NOTE Confidence: 0.746569894052632

01:03:19.149 --> 01:03:21.159 overall response rate of about 20%,

NOTE Confidence: 0.746569894052632

01:03:21.160 --> 01:03:22.980 which may last up to two years.

NOTE Confidence: 0.746569894052632

01:03:22.980 --> 01:03:24.640 Again, monitoring of liver function,

NOTE Confidence: 0.746569894052632

01:03:24.640 --> 01:03:26.362 test PSA and man would be important

NOTE Confidence: 0.746569894052632

01:03:26.362 --> 01:03:27.740 for this group of patients.

NOTE Confidence: 0.746569894052632

01:03:27.740 --> 01:03:29.336 Yes, this is the second line

NOTE Confidence: 0.746569894052632

01:03:29.336 --> 01:03:31.070 option for an email management.

NOTE Confidence: 0.746569894052632

01:03:31.070 --> 01:03:32.660 Can I ask you a question?

NOTE Confidence: 0.746569894052632

01:03:32.660 --> 01:03:33.848 So because we have to move

NOTE Confidence: 0.746569894052632

01:03:33.848 --> 01:03:34.640 to the tumor board.

NOTE Confidence: 0.746569894052632

01:03:34.640 --> 01:03:36.033 I just have this question so if

NOTE Confidence: 0.746569894052632

01:03:36.033 --> 01:03:37.862 there is no clinical trial and your

NOTE Confidence: 0.746569894052632

01:03:37.862 --> 01:03:40.445 patience and your patient with MD's

NOTE Confidence: 0.746569894052632

01:03:40.445 --> 01:03:43.340 high risk MD's didn't respond to HMA,

NOTE Confidence: 0.746569894052632

01:03:43.340 --> 01:03:45.652 would you try to do off label addition

NOTE Confidence: 0.746569894052632

01:03:45.652 --> 01:03:47.477 of donetta clocks two weeks on,

NOTE Confidence: 0.746569894052632

01:03:47.480 --> 01:03:48.716 two weeks off to this patient?

NOTE Confidence: 0.746569894052632

01:03:48.720 --> 01:03:51.393 If you can get it covered by the insurance?

NOTE Confidence: 0.746569894052632

01:03:51.400 --> 01:03:52.710 No clinical trial available.

NOTE Confidence: 0.826749906210526

01:03:55.300 --> 01:03:56.812 Yeah, so that's again like the

NOTE Confidence: 0.826749906210526

01:03:56.812 --> 01:03:58.485 dilemma we have with those patients

NOTE Confidence: 0.826749906210526

01:03:58.485 --> 01:04:00.327 because we don't have anything that's

NOTE Confidence: 0.826749906210526

01:04:00.327 --> 01:04:01.820 FDA approved for those patients,

NOTE Confidence: 0.826749906210526

01:04:01.820 --> 01:04:03.295 so I would consider it.

NOTE Confidence: 0.826749906210526

01:04:03.300 --> 01:04:04.760 However, I would, you know,

NOTE Confidence: 0.826749906210526

01:04:04.760 --> 01:04:07.035 be very clear with the patient about

NOTE Confidence: 0.826749906210526

01:04:07.035 --> 01:04:08.846 the limitations of this being off

NOTE Confidence: 0.826749906210526

01:04:08.846 --> 01:04:11.199 label and we don't have a lot of data.

NOTE Confidence: 0.826749906210526

01:04:11.200 --> 01:04:14.048 I do think it's quite a suppressive regimen,

NOTE Confidence: 0.826749906210526

01:04:14.050 --> 01:04:16.618 so for some patients you have to expect

NOTE Confidence: 0.826749906210526

01:04:16.618 --> 01:04:19.058 that they are going to need to come

NOTE Confidence: 0.826749906210526

01:04:19.058 --> 01:04:21.200 three times a week to the clinic,

NOTE Confidence: 0.826749906210526

01:04:21.200 --> 01:04:23.010 need frequent transitions they will

NOTE Confidence: 0.826749906210526

01:04:23.010 --> 01:04:25.147 need to be on prophylactic antibiotics.

NOTE Confidence: 0.826749906210526

01:04:25.147 --> 01:04:27.763 So I consider it more in the setting

NOTE Confidence: 0.826749906210526

01:04:27.763 --> 01:04:29.635 where I'm thinking about bridging

NOTE Confidence: 0.826749906210526

01:04:29.635 --> 01:04:31.485 the patient to a transplant.

NOTE Confidence: 0.826749906210526

01:04:31.490 --> 01:04:34.166 If the patient does not have

NOTE Confidence: 0.826749906210526

01:04:34.166 --> 01:04:35.504 a transplant option.

NOTE Confidence: 0.826749906210526

01:04:35.510 --> 01:04:36.740 Think about it,

NOTE Confidence: 0.826749906210526

01:04:36.740 --> 01:04:38.295 but not as strongly,

NOTE Confidence: 0.826749906210526

01:04:38.295 --> 01:04:39.920 except in situations where the

NOTE Confidence: 0.826749906210526

01:04:39.920 --> 01:04:41.829 patient is in relatively good shape.

NOTE Confidence: 0.826749906210526

01:04:41.830 --> 01:04:43.958 The problem is that many of those

NOTE Confidence: 0.826749906210526

01:04:43.958 --> 01:04:45.593 patients are very old and they

NOTE Confidence: 0.826749906210526

01:04:45.593 --> 01:04:48.360 have a lot of comorbidities and

NOTE Confidence: 0.826749906210526

01:04:48.360 --> 01:04:51.228 therefore supportive care could be.

NOTE Confidence: 0.826749906210526

01:04:51.228 --> 01:04:54.290 Also, I think appropriate in some patients,

NOTE Confidence: 0.826749906210526

01:04:54.290 --> 01:04:56.242 but just take one last question because I

NOTE Confidence: 0.826749906210526

01:04:56.242 --> 01:04:59.600 see it from doctor to doctor Szeles about.

NOTE Confidence: 0.826749906210526

01:04:59.600 --> 01:05:01.917 Why do you think there was no

NOTE Confidence: 0.826749906210526

01:05:01.917 --> 01:05:03.213 overall survival advantage with

NOTE Confidence: 0.826749906210526

01:05:03.213 --> 01:05:04.755 his guilt compared to.

NOTE Confidence: 0.826749906210526

01:05:04.755 --> 01:05:08.870 5% Neb with guilt in in in the agile.

NOTE Confidence: 0.833299728333333

01:05:11.870 --> 01:05:13.058 I actually answered in the trap,

NOTE Confidence: 0.833299728333333

01:05:13.060 --> 01:05:14.940 but I guess in brief I mean there

NOTE Confidence: 0.833299728333333

01:05:14.940 --> 01:05:16.334 were some imbalances between the

NOTE Confidence: 0.833299728333333

01:05:16.334 --> 01:05:18.182 groups were only talking about the

NOTE Confidence: 0.833299728333333

01:05:18.182 --> 01:05:19.910 you know the Lacewing trial which

NOTE Confidence: 0.833299728333333

01:05:19.910 --> 01:05:21.630 which is the gold ribbon trial.

NOTE Confidence: 0.833299728333333

01:05:21.630 --> 01:05:23.652 More patients on the ASA monotherapy

NOTE Confidence: 0.833299728333333

01:05:23.652 --> 01:05:26.304 arm were able to proceed to subsequent

NOTE Confidence: 0.833299728333333

01:05:26.304 --> 01:05:28.782 therapy which of course could influence

NOTE Confidence: 0.833299728333333

01:05:28.782 --> 01:05:30.650 any OS for that group as well.

NOTE Confidence: 0.833299728333333

01:05:30.650 --> 01:05:31.310 I think it was more.

NOTE Confidence: 0.833299728333333

01:05:31.310 --> 01:05:33.006 I think it was like 40 versus 20%.

NOTE Confidence: 0.833299728333333

01:05:33.010 --> 01:05:35.096 It was almost double and there is

NOTE Confidence: 0.833299728333333

01:05:35.096 --> 01:05:37.173 also about a four month difference

NOTE Confidence: 0.833299728333333

01:05:37.173 --> 01:05:39.033 in time to next therapy.

NOTE Confidence: 0.833299728333333

01:05:39.040 --> 01:05:40.830 So patients who already committed

NOTE Confidence: 0.833299728333333

01:05:40.830 --> 01:05:42.262 so that could probably.

NOTE Confidence: 0.833299728333333

01:05:42.270 --> 01:05:43.620 You know, explain some of that.

NOTE Confidence: 0.833299728333333

01:05:43.620 --> 01:05:44.604 There were also.

NOTE Confidence: 0.833299728333333

01:05:44.604 --> 01:05:46.244 There was also striking imbalance

NOTE Confidence: 0.833299728333333

01:05:46.244 --> 01:05:48.060 in the performance status,

NOTE Confidence: 0.833299728333333

01:05:48.060 --> 01:05:50.100 which is more of a surrogate for frailty,

NOTE Confidence: 0.833299728333333

01:05:50.100 --> 01:05:52.240 which is again debated itself,

NOTE Confidence: 0.833299728333333

01:05:52.240 --> 01:05:54.305 but more patients on the ASIC guilt

NOTE Confidence: 0.833299728333333

01:05:54.305 --> 01:05:55.895 arm were just higher performance

NOTE Confidence: 0.833299728333333

01:05:55.895 --> 01:05:57.809 status you talked to was I

NOTE Confidence: 0.833299728333333

01:05:57.809 --> 01:05:59.710 think I wanna say 30% wallpaper

NOTE Confidence: 0.767530559333333

01:05:59.720 --> 01:06:01.554 so you know I thought the second

NOTE Confidence: 0.767530559333333

01:06:01.554 --> 01:06:03.136 line treatment with guilt in those

NOTE Confidence: 0.767530559333333

01:06:03.136 --> 01:06:04.865 who were treated with ASA you know

NOTE Confidence: 0.767530559333333

01:06:04.918 --> 01:06:06.542 so would be also the main reason

NOTE Confidence: 0.767530559333333

01:06:06.542 --> 01:06:08.728 why there was no at the end of all

NOTE Confidence: 0.767530559333333

01:06:08.728 --> 01:06:09.980 survival difference in this too.

NOTE Confidence: 0.767530559333333

01:06:09.980 --> 01:06:11.040 And they were, you know.

NOTE Confidence: 0.767530559333333

01:06:11.040 --> 01:06:12.390 So it's just very difficult

NOTE Confidence: 0.767530559333333

01:06:12.390 --> 01:06:13.470 to show overall survival.

NOTE Confidence: 0.677973283636364

01:06:15.830 --> 01:06:17.486 Yeah, I think with all of

NOTE Confidence: 0.677973283636364

01:06:17.486 --> 01:06:19.338 these trials I you know, I,

NOTE Confidence: 0.677973283636364

01:06:19.338 --> 01:06:21.546 I think doing this postmortem is,

NOTE Confidence: 0.677973283636364

01:06:21.550 --> 01:06:23.686 you know, a good thinking exercise.

NOTE Confidence: 0.677973283636364

01:06:23.690 --> 01:06:24.747 But at the end of the day,

NOTE Confidence: 0.677973283636364

01:06:24.750 --> 01:06:26.454 all of this should be thought

NOTE Confidence: 0.677973283636364

01:06:26.454 --> 01:06:27.962 before the trial and what we

NOTE Confidence: 0.677973283636364

01:06:27.962 --> 01:06:29.450 have is what we need to go with.

NOTE Confidence: 0.677973283636364

01:06:29.450 --> 01:06:30.727 So thank you so much. Again,

NOTE Confidence: 0.677973283636364

01:06:30.727 --> 01:06:32.869 if anybody has any additional questions,

NOTE Confidence: 0.677973283636364

01:06:32.870 --> 01:06:35.781 feel free to send us an

NOTE Confidence: 0.677973283636364

01:06:35.781 --> 01:06:37.107 email or call any of us.

NOTE Confidence: 0.677973283636364

01:06:37.110 --> 01:06:38.573 Thank you so much and I think

NOTE Confidence: 0.677973283636364

01:06:38.573 --> 01:06:40.300 we have the tumor board. Yes,

NOTE Confidence: 0.71855441

01:06:40.310 --> 01:06:42.998 tumor board please.